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1.

A.

INTRODUCTION

Statement of Problem
One third of North Americans will die of an atherosclerotic dis-

ease.

In comparison, this disease will cause the death of three

quarters of America•s diabetic population.

Diabetes occurs in ten

percent of the U.S. Armed Forces veteran population with more than 90
percent of these veterans having type II (non-insulin dependent or
maturity-onset) diabetes (1).

Atherosclerotic occlusive vascular

disease is the most common complication in diabetes (2-4).

Epidemio-

logical studies have indicated that other risk factors involved in
atherosclerosis include age, sex, race, family history, smoking,
hypertension,

dyslipoproteinemi_~

and obesity (5).

While it may be useful to consider atherosclerosis in the diabetic as a severe form of the disease found in non-diabetics, many
investigators believe this approach to be simplistic.

Many differences

occur between groups of patients in the progression of the disease
manifestations.

Which risk factors make diabetics especially suscept-

ible to atherosclerosis or whether the disease produces its own factors
to increase atheroslcerotic susceptibility are open to debate.
Hypertriglyceridemia and hypercholesterolemia are common problems
of the diabetic.

While drug therapy is, in many cases, ineffective for

lowering and managing triglyceride and cholesterol concentrations, an
effective and safe dietary approach would be advantageous.

The major

concern in treating diabetic, hypertriglyceridemic patients is the
type of dietary therapy to be administered.
1

Since increased hyper-

2

lipemia occurs with increased fat consumption, there has been a growing tendency to limit fat intake in diabetic patients.

This results

in diets that are composed of higher amounts of carbohydrate and
protein relative to fat.

This trend in diabetic care has received

official sanction from the American Diabetes Association•s Committee
on Food and Nutrition (6}.

It is now recommended that most diabetics

should consume a diet containing up to 50 or 60% carbohydrate.

In a

recent editorial in Diabetologia, Reaven (102) is skeptical about the
effects of high carbohydrate diets.

He observes that the beneficial

effects of high carbohydrate diets on diabetic patients are modest at
best.
The effects of a high carbohydrate diet on the diabetic population were first studied by Himsworth (7}.

One advantage claimed for

the use of a high carbohydrate diet was the enhancement of insulin
sensitivity.

In a series of studies in normal patients, he demon-

strated that the plasma glucose response to the oral glucose load
improved when dietary carbohydrate was increased.

In similar studies

with both insulin-dependent and non-dependent diabetics, Himsworth (8)
was able to show a sensitive and insensitive population to high
carbohydrate intake.

Insensitive patients showed no increase in

insulin sensitivity and a significant deterioration in glucose tolerance.

Brunzell and Anderson (9-10) performed similar experiments and

found an improvement of 8-11% in blood glucose levels when carbohydrate was increased from 45 percent to 78-85 percent of total caloric
intake.
In recent years, sources of carbohydrate have changed.

The
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current level of simple sugars supplied by the diet is about 200
g/person/day; of this, 62 percent is composed of the refined sugar
sucrose (11).

Many industrialized food preparations and processed

beverages contain sucrose, accounting for more than two-thirds of the
refined sugar consumed (11).

Beverage products now comprise the

single largest industrialized usage of refined sugar while the next
largest use is in cereal and bakery products.

These three food sources

now account for about one-sixth the per capita consumption of refined
sugar.

Much of this sucrose is hidden sugar, either used in the baking

process or in enhancing the sweetness of foods.

Therefore, consumers

(including diabetics) are unaware of their total sucrose consumption.
As early as 1950,

worker~

with the Kemper Rice Diet reported that

although high carbohydrate diets increase glucose tolerance and lowered
serum cholesterol levels, there was also a sizeable increase in neutral
fats (triglycerides) (12).

Waddell and Fallon (13) examined the pos-

sibility that diets of high sugar content accelerate hepatic triglyceride synthesis by increasing the capacity for fatty acid esterification in rats.

Rats fed diets containing 75 percent glucose or fructose
increased their capacity for triglyceride formation from [ 13 c] glycerol
(14).

An initial increase occurred when both sugars were administered,

but a sustained increase in serum triglyceride could only be accomplished with a high fructose intake.

When serum triglyceride removal-

was inhibited by administration of Triton WR-1339, both diets increased labelled glycerol incorporation and increased triglyceride levels.
They concluded that the difference in triglyceride levels between
fructose and glucose diets may be attributed to a smaller increase in
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hepatic production of triglyceride when rats were given glucose.
These investigators speculated that another factor involved was the
rate of serum triglyceride removal.

Bierman and Hamlin (14) studied

the effects of low-fat, high carbohydrate diets in diabetic patients.
The liquid diets were administered with rice supplements and contained
15 percent protein, 85 percent carbohydrate and virtually no fat.
Their results demonstrated that insulin-treated diabetics exhibited a
hyperlipemic response to isocaloric substitution of carbohydrate for
fat.

Several studies, however, tend to refute these observations.

Kiem and Anderson (15) studied the effects of a high-carbohydrate,
high-fiber diet on hyperglycemic diabetic men.

Their finding showed

that solid diets containing 75 percent of calories as carbohydrate resulted in a significant improvement in glucose tolerance and lowered
the average fasting serum triglyceride levels.
The use of carbohydrate induction as a viable theory for hypertriglyceridemia was questioned from its inception.

Antonis and Bersohn

(16) reported that subjects, given an isocaloric high-carbohydrate diet,
showed a rise in fasting triglycerides in the first few weeks, but the
abnormally increased levels tended to recede to the prediet level after
3 weeks.

If carbohydrate-induced lipemia was a physiological fact,

then populations which consume high-carbohydrate diets would tend to
have chronically elevated triglyceride levels.

Several investigators

have demonstrated that this is not the case (17-21).
In contrast, MacDonald and Braithwaite (22) in 1964, and Kuo and
Bassett (23) in 1965, studied the effects of the disaccharide sucrose
on hyperlipemia.

Both groups found the consumption of low fat diets,
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containing 500 g of sucrose as compared to corn starch, resulted in
increased serum lipids.

Fatty-acid patterns in adipose tissue were

also affected by the high carbohydrate intake.

Mann and co-workers

were able to reduce fasting serum triglyceride levels by an average of
22 percent through voluntary sucrose restriction (24,25).

The inter-

pretation of the results was clouded by the effect of weight loss in
most hypertriglyceridemic individuals.

Thus, the effect of sucrose

might be calorie-induced rather than sugar-induced lipemia.
Evidence continued to mount that increased sucrose consumption
produced virtually all the clinical symptoms of diabetes.

Cohen, et al.

demonstrated that feeding high sucrose diets to human volunteers resulted in impaired glucose toleranc,e, hyperlipemia, and impaired insulin
activity (26).

In his experiments, he also found the feeding of sucrose

to rats produced diabetes, renal arteriosclerosis and diabetic retinal
angiopathy.

Studies in which sucrose-restricted diets were administer-

ed, tended to confirm the effect of sucrose on hyperlipemia with no
significant correlation made between changes in triglyceride levels
and weight (27-28).

Since sucrose is a disaccharide, studies were

undertaken to determine if sucrose or its monosaccharide components,
glucose and fructose, could be responsible for the hyperlipemic effect.
MacDonald (29) gave patients fat-free liquid diets of sucrose, starch,
or glucose-maltose.

He found a decrease in serum lipids on the glucose-

maltose regime, whereas with the sucrose-starch diet, the lipid level
remained constant.

Since previous fat-free diets had been shown to

lower lipid levels, these findings suggested that the absence of fat in
the diet was compensated for by the formation of lipids from carbohy-
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drate when the starch-sucrose diet was consumed.

Further evidence to

support this possibility was the altered fatty acid pattern observed in
patients on the starch-sucrose diet.

The increased oleic acid content

observed was consistent with the conversion of carbohydrate to fat.
MacDonald (30) investigated the effects of glucose and fructose diets on
blood lipid levels concluding that the fructose component of the diet
gives rise to responses of lipid metabolism that are different from
those found after consuming glucose.

Triglyceride responses to dietary

glucose appeared to be unaffected by the many factors that affect serum
triglyceride responses to fructose.

However, Akgun and Ertel (31)

demonstrated that fructose and sorbitol meals resulted in lower plasma
glucose and immunoreactive insu)in levels than corresponding amounts of
sucrose in a meal.

This observation was directly in contrast to the

ones made by MacDonald (30).
A direct relationship has been observed between the estimated
magnitude of insulin secretion and the increase in plasma triglycerides produced by carbohydrate-rich diets (32).

Mann and Truswell

(33) found that there was no difference between concentrations of fasting serum lipids when starch replaced glucose, but the concentration of
serum triglycerides was higher after mixed meals containing sucrose.
They also found increased insulin release after meals of complex carbohydrate as compared to sucrose.

They correlated the insulin response

to a significantly smaller degree of lipemia while consuming the starch
diet.

MacDonald (34) found the increase in serum glucose after sucrose

ingestion slightly less than that after glucose ingestion.

Because

sucrose is composed of 50 percent glucose, and all of the fructose
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moiety could not have been interconverted, the elevated glycemic response was surprising.

Their results were explained by

postulati~g

that an equal dose of sucrose would elicit a lower insulin response
than an equal amount of glucose.

They concluded that lipid levels

would fall on high glucose diets because of increased lipoprotein
lipase activation in relation to lipid response (35).

This, however,

was not the case, and the fall in triglyceride in three out of four
experiments was greater with fructose than glucose.

Hayford and Danney

(36) found that elevated plasma insulins usually reflected decreased
triglyceride levels, while Olefsky (37) found a positive relationship
between insulin and hypertriglyceridemia.
was possible the insulin and

t~iglyceride

Hayford (36) felt that it
changes were both secondary

to the dietary changes and were not related to one another.

Since

sucrose was associated with higher triglyceride concentrations, he
could not resolve whether the inverse relationship was a function of
the insulin response, dietary components, or a combination of both.
Most of the experiments performed to evaluate carbohydrate
influence on lipemic responses utilized low fiber liquid diets.

The

investigation of sucrose induced carbohydrate hyperlipemia was further
confused by the report of Albrink and Newman (38) in which the effect
of high and low fiber diets on plasma lipids and insulin were ascertained.

Two very high carbohydrate diets were administered, one with

high fiber content, and one with low fiber.

The glucose response to

both test meals were similar while the insulin response to the low fiber
meal was twice as great as that to the high fiber meal containing equivalent amounts of carbohydrate.

Serum lipids increased when low fiber
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meals were consumed and decreased after high fiber diets.

These results

suggest that carbohydrate-induced hyperlipemia does not occur if the
carbohydrate diet is rich in dietary fiber.

An interesting report was

issued by Beck-Nielsen and Pederson in 1980 (39), examining the effects
of high fructose feeding in normal subjects.

They found high fructose

feeding was associated with a drop in insulin sensitivity, and for the
first time, increased insulin concentrations in certain individuals
was observed.

The high fructose diet resulted in a 30 percent reduction

of insulin binding to monocytes but glucose feeding resulted in no
change.

They concluded that feeding a diet high in fructose can result

in a reduction in the number of high-affinity receptor sites, i.e., a
reduction in total receptor

af~nity

for insulin.

High-sucrose feeding

can result in a 36 percent decrease in specific cell binding fractions
for insulin {40).

When these results are compared to the above, one

can conclude that sucrose, or its monosaccharide component, fructose,
causes an altered insulin sensitivity, at least in part, explained by
altered insulin binding.

The decrease in insulin binding is associated

with reciprocal changes in plasma insulin concentration.

The decrease

in cellular binding of insulin by fructose was attributed to the depression of both cellular levels of cyclic AMP and protein synthesis caused
by the depletion of ATP.
It is also possible to explain the higher insulin levels observed
after sucrose feeding on the basis of adaptive changes of the small
intestine.

Sucrase activity was greater in humans who consumed

isocaloric diets containing sucrose compared to glucose (41).

The

intestinal absorption of glucose and fructose was enhanced after rats
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and baboons had adapted to diets high in sucrose (42-43).

In human

volunteers, a significantly greater secretion of the intestinal hormone,
gastric inhibitory polypeptide (GIP), was found in response to a sucrose
load when compared to a starch load (44).

GIP stimulates insulin secre-

tion of the pancreas in response to oral (but no intravenous) glucose
(45). Thus sucrose feeding could produce adaptive increases in intestinal digestive enzymes and hormones which could be expected to increase
secretion of insulin.

This could be accomplished by increasing the rate

of appearance of the component monosaccharide in the circulation or by a
direct action on insulin secretion.

Eaton and Nye (46) also found a

positive correlation between insulin levels and triglyceride production.
To ascertain if insulin was the direct cause of hyperlipemia in
11

sensitive 11 patients, direct pharmacological inhibition of pancreatic

insulin secretion was used to examine the effect of acute suppression of
insulin on triglyceride concentrations.

Their observations imply, that

in normal weight lipemic subjects, the pancreatic beta cells are in a
chronic state of hypersecretion, characterized by an increased carbohydrate-stimulated insulin secretion associated with increased basal triglyceride concentrations.
Hypertriglyceridemia in diabetics, resulting from increased intake
of carbohydrates, could occur via three mechanisms.

In some patients,

as reported above, a decreased insulin release seems to be characterized
by a decrease in both the secretion and removal of triglyceride-rich
lipoprotein with the defect in removal being greater than the defect in
production.

Even in the absence of exogenous fat, the disparity between

triglyceride rich lipoprotein (VLDL) production and removal is sufficient
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to result in an increase in plasma triglyceride concentrations (47).

A

second mechanism through which carbohydrate induced lipemia can occur
results from resistance to insulin-mediated glucose uptake.

The compen-

satory hyperinsulinemia acts upon the liver to accelerate hepatic triglyceride synthesis and secretion resulting in elevated triglyceride levels
{37).

A third mechanism that could induce hypertriglyceridemia was

proposed by Reaven (48) who studied a non-insulin dependent diabetic
patient population who were insulin resistant, but had normal fasting
and postprandial insulin concentrations.

Because of insulin resistance,

normal insulin levels cannot stimulate proper glucose uptake or inhibit
lipolysis.

These subjects have marked elevations of fasting and post-

prandial glucose and free fatty acids levels.

Thus, the increased

hypertriglyceridemia could occur due to stimulation of the normally insulinized liver by increased circulating FFA concentrations (49).
Other reports have supported the concept of increased triglyceride synthesis causing hypertriglyceridemia in relation to a carbohydrate load (50-52).

However, these reports deal with total blood

triglyceride concentrations and the kinetic behavior of the plasma
triglycerides in these patients is largely unknown.

Reliable data on

the transport and production of plasma triglycerides can be obtained
by labeling

them~

vivo.

It has been shown that a glycerol-labeling

technique (described later) can give useful information on human plasma
triglyceride turnover kinetics (53-56) and has been used to characterize
aspects of plasma triglyceride metabolism in carbohydrate induced
lipemia.

Nikkila and Kekki {57), in a landmark paper, evaluated dia-

betic hypertriglyceridemia and found this syndrome to be characterized
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by a primary stimulation of hepatic triglyceride secretion.

Tobey et al.

(58) found significant relationships between insulin-resistance,
insulin-response, VLDL-TG secretion and plasma TG concentrations in both
normal and hypertriglyceridemic individuals, suggesting that insulin
modulates plasma TG levels in both groups.

However, some additional

abnormality must be present to account for the elevated plasma TG concentrations in hypertriglyceridemic individuals.

Adams and Kissebah

(59) were able to demonstrate that a group of hypertriglyceridemic
patients were hyperinsulinemic and showed increased triglyceride synthesis with increased FFA release.

These patients had an abnormality

in the removal mechanism for plasma triglycerides, a decreased Vmax and
an increased Km when compared t,o other hypertriglyceridemics.

Adams and

Kissebah (59) hypothesized that elevated FFA release due to lipolysis,
because of insulin resistance, could inhibit lipoprotein lipase (the
primary enzyme in plasma lipid removal) and lead to some impairment in
triglyceride clearance.

The primary change could be due to enzyme de-

rangement, deficiency of insulin receptors or an abnormality in circulating insulin.

Huttunen et al. (60) showed the fractional removal rate

of endogenous triglyceride to be positively correlated to lipoprotein
lipase activity.

The mean activity of post heparin plasma lipoprotein

lipase was also significantly lower in subjects with hyperprebetalipoproteinemia.
Persson (61) did a comprehensive study of 249 patients with different types of hyperlipidemia.

His work clearly demonstrated a lower

lipoprotein lipase activity per wet weight adipose tissue in type IV
hyperlipidemic individuals compared to normal subjects.

Brunzell and
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Porte {62) studied untreated diabetic subjects and documented a defect
in triglyceride removal related to lipoprotein lipase activity.

They

suggest an interesting mechanism, in which the increase in Km for the
lipase system could be related to a change in VLDL protein cofactors.
These proteins, designated apoproteins, are structural components of
lipoprotein molecules, which serve as activators for lipoprotein lipase,
or function as recognition proteins which aid in the peripheral removal
of the lipoprotein from the circulation (212-218).

These protein compo-

nents are described later in the text.
An alteration in the lipoprotein cofactors, causing an inefficient removal of triglyceride from VLDL, has long been postulated as a
mechanism for the induction of ;hypertriglyceridemia.

Gabor and Spain

{63) studied the apoprotein composition of VLDL and HDL by gel electrophoresis and found the VLDL of diabetics had an increased proportion of
apo C, particularly apo CIII.

They also demonstrated that diabetics with

increased VLDL and serum triglyceride concentration had decreased ratios
of CII to CIII.

Bar-On and Roheim (64) noted a relative increase in

CIII 1 apoprotein and a decrease in CIII 2 apoprotein in streptozotocin
induced diabetic rats fed high sucrose diets. Varying CIII components
differ only in their amount of sialic acid residues.

Since diabetes has

been correlated to increased concentrations of other serum glycoproteins, it is tempting to speculate that altered C proteins might influence lipoprotein lipase activity (65).

Witzum and Schonfeld (66) gave

carbohydrate-enriched diets to rats to investigate the effect on VLDL
composition and structure.

A rise in triglyceride and cholesterol in

the carbohydrate fed rats and a fall in apo B concentration was

13

observed.

The arginine-rich protein (ARP) 'also fell while apo C rose.

These investigators also studied perfused livers of these animals and
found changes in apoproteins to be parallel to those seen in plasma.
This suggested the action of the diet on the liver was responsible for
the plasma VLDL changes seen (66).

Falko (67) showed that ingestion of

high carbohydrate diets (88 percent total calories) caused apo CII and
apo CIII levels to .increase by 30 percent in VLDL while these same levels
fell in higher density lipoprotein fractions.

Levels of apo C increased

in proportion to VLDL-TG in normal individuals, but increased less in
patients with type IV hyperlipemia.

Falko postulated that short term

feeding of high carbohydrate diets resulted in alterations in the metabolism of lipoproteins in

hype~lipemic

subjects.

Studies conducted by Lambert and Catapano (68, 69) tended to substantiate previous work.

A large population of hypertriglyceridemic

subjects were assessed for apo CII, CIII 1 and CIII 2 levels. Good
correlations were obtained between triglyceride levels and apo CII with
apo CIII 1 increasing with hypertriglyceridemia. Apo CIII 2 followed
the pattern of CII, but to a lesser extent. Definite results concerning
C apoprotein levels were obtained by Matsuoka and Shirai (70).

These

investigators found that patients who had hypertriglyceridemia were deficient in apo CII with maximum hydrolysis of VLDL occurring at 2.5 ug
apo CII/mg triglyceride.

The Km value of the lipoprotein lipase enzyme

for apo CII deficient VLDL was 7.8 mol/L.

When 2.5 ug of apo CII was

added to the medium, the Km decreased to 1 mol/L.

A possible explana-

tion of the affect of apo CII to decrease the Km is that the protein
enhances the interaction between lipoprotein lipase and triglyceride
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within the surface monolayer of the lipoprotein.
studies have also been conducted concerning the effect of
carbohydrate on apo B catabolism {71, 72).

h~gh

Ginsbert (71) found no pro-

duction change in apo B during the normal carbohydrate diet in which 40
to 60 percent of VLDL apo B was converted to LDL.

However, patients on

high carbohydrate diets converted only 16 to 42 percent of VLDL apo B
to LDL.

In most cases direct catabolism of VLDL apo B occurred without

conversion to higher density lipoprotein classes during the high carbohydrate diet with essentially no VLDL apo B converted directly to LDL
apo B.

A fall in LDL-apo B concentrations did not follow the reduced

input from VLDL and was explained by a reduction in the removal rate of
LDL-apo B.

Thus, significant a)terations in the routes of catabolism

of apo B occurred with high carbohydrate diets.

Others have reported

that apo LDL turnover in hyperlipoproteinemic patients did not differ
from the control {73).

Since VLDL and LDL are in a precursor-product

relationship, these results also suggest a defect in VLDL catabolism.
VLDL are usually found to migrate as a single band with pre beta
mobility during electrophoresis (74-76).

Recently, two electrophoretic

populations of VLDL were isolated from human serum {77-79).

The

mobility of the slow subunit has been found to have more beta (LDL)
rather than pre beta characteristics.

The reduced mobility of the slow-

er component was related to a loss of C apoproteins relative to B and E.
This change in protein composition and increase in the ratio of cholesterol esters to triglyceride was remarkably similar to the structure of
remnant VLDL (breakdown products of VLDL lipolysis) (80).

These results

suggest that many individuals who are hyperlipemic could have large
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amounts of the remnant lipoproteins present.

These sVLDL have been

found to cause macrophages to become loaded with massive amounts
cholesteryl esters (81-83).

~f

This effect was attributable to a high

affinity binding site on the macrophage surface that recognizes sVLDL.
The B and E apoproteins, major constituents of sVLDL, interact with this
high affinity receptor.

Similar studies were conducted demonstrating

remnant particle uptake by rat aortic smooth muscle cells (84).

Ali-

quots of VLDL and sVLDL were added to smooth muscle cell cultures and
remnant uptake exceeded that of very low density lipoproteins.

Avid

uptake of remnants by aortic smooth muscle cells might have relevance
to the close association between increased levels of circulating VLDL
remnants and atherosclerosis.

~omologous

studies were performed on cul-

tured human aortic smooth muscle (85) in which regular VLDL uptake was
measured instead of sVLDL.

In humans, VLDL uptake approximated 320 to

1100 ng/100 ug of protein, whereas VLDL uptake by rat aortic muscle
averaged only 5 ng/100 ug.

Humans and rats differ markedly in their

propensity to develop atherosclerosis.

Since man appears to be parti-

cularly prone to accumulate lipid in arterial smooth muscle, these results are consistent with the possibility that these lipoproteins play a
central role in atherogenesis.
An interesting observation has been made by Brown et al (86) concerning the accumulation of cholesterol in macrophages.

LDL could not

be incorporated into the cells unless the epsilon-amino groups of lysine
in the lipoprotein had been removed or chemically modified, giving the
protein an enhanced negative change.

Naturally occurring reactions which

would modify these sites were investigated.

A fascinating observation
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noted was that treatment of LDL with malondialdehyde stimulated cholesterol LDL accumulation in monocytes {87).

The importance of this re-

action derives from the fact that malondialdehyde (MDA) is produced by
platelets as a byproduct of arachidonic acid metabolism during the synthesis of thromboxanes {88).

If liberated in high enough quantities

(for example, regions of thrombosis), it is possible that (MDA) could
modify LDL so that it is taken up by macrophages.

If this is the case,

platelet aggregation and developmental atherosclerosis may be closely
linked.

Platelet hyperactivity has been linked with diabetic maladies

for some years since an increased platelet sensitivity to aggregation
from ADP and epinephrine has been described many times in diabetes
{89-92).

Increased plasma pros,taglandin E levels were found in dia-

betic patients administered aggregating agents, suggesting that an
increase in this biosynthetic pathway is one cause of increased platelet sensitivity (93).
dietary fat (94).

Platelet function also seems to be dependent on

It was found that diets low in saturated and high in

polyunsaturated fats prolonged the aggregation times and decreased
aggregability of platelets in subjects receiving these diets.

Other

studies have shown that arterial thrombus formation is significantly delayed by a high polyunsaturated/saturated fat ratio (95, 96).
Different types of endogenous hyperlipemia can also cause increased platelet function (97).

The mechanism of platelet hypersensitivity

in non-insulin dependent disorders is unknown.

Alterations in platelet

function may be related to an underlying metabolic abnormality in
familial hyperbetalipoproteinemia.

Platelets may incorporate total low-

density lipoproteins or components into their membranes and thus alter
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their surface characteristics.

To substantiate this, Bolton (98) has

isolated lipoprotein fractions that are responsible for changes
electrophoretic mobility of platelets.
enhanced

~

i~

the

Zahavi et al. (99) demonstrated

vivo platelet release reactions and malondialdehyde forma-

tion in patients with hyperlipemia.

The mechanism of the enhanced re-

lease reaction and MDA formation could be related indirectly to elevated
serum lipids.

Besides changes in membrane constituents, changes in the

cholesterol content of platelets can influence the metabolism of arachidonic acid and increase the levels of thromboxane B2 (100). Finally,
in a study measuring the effects of sucrose on insulin levels and
platelet adhesiveness, Szanto (101) found that increased insulin levels
correlated well with increased;platelet adhesiveness.
Therefore, this introduction suggests a general mechanism to explain the relationships between diabetes mellitus, platelet aggregation,
hyperlipoproteinemia and carbohydrate intolerance, all contributing
factors in atherogenesis.

Since the many reports about the effect of

sucrose seem to conflict in the literature, the plan of this study is to
administer both high sucrose and low sucrose diets employing natural
food sources, to diabetic patients over a long term period to ascertain
which atherogenic parameters are affected.
The recent recommendation of the American Diabetes Association
Committee on Food and Nutrition and a greater consumption of processed
foods which have variable but large proportions of added unquantitated
sucrose, necessitates the need to know how hypertriglyceridemic
diabetics respond to graded amounts of sucrose.

2. RELEVANT LITERATURE REVIEW

A. Atherosclerosis Disease Description
Pathologically, the atherosclerotic lesion consists of a plaquelike thickening of the arterial wall.

Moore (103) demonstrated that

atheromata could be induced by placing a catheter into the aorta of
rabbits for different periods of time, indicating that endothelial injury is important in the atherogenic process (112).

The plaque con-

sists of a thickening of proliferating smooth muscle cells surrounded by
large amounts of interstitial substances that include collagen, elastin,
glycosaminoglycans, and fibrin (104-106).

The substance that is most

detrimental to the atheromatous plaque is lipid, chiefly cholesterol.
Compelling evidence has been established which include the following observations:
1.

Atherosclerosis, leading to myocardial infarction, can
be produced in every species studied by increased
cholesterol consumption (105).

2.

Endothelial damage in normal animals will usually produce a benign scar.

However, if blood cholesterol and

triglyceride levels are increased, lipid is deposited in
the lesion and atherosclerosis develops (105).
3.

In the human population, in which mean plasma cholesterol
levels are lower than 160 mg/dl, atherosclerosis is reduced even when other factors, such as diabetes, smoking,
and hypertension exist.

4.

Myocardial infarctions are positively correlated with
18
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serum cholesterol and triglyceride levels (107, 108).
5.

Finally, genetic diseases that cause elevations in
cholesterol concentration usually produce atherosclerosis in early childhood (109).

a.

Cause of the Disease
In nature, injuries to the endothelium occur in a myriad of ways.

Blood flow around irregularities, such as atheromata and branch points,
could cause injury.

Diabetes has also been associated with increased

endothelial damage.

Repeated immunization, such as insulin injection

in insulin-dependent diabetics, could lead to antibody-antigen complexes resulting in vascular injury {110).

Ditzel (111) raised the

question that diabetics may have impaired erythrocyte oxygen transport
and may develop arterial injury by hypoxia.
Platelets do not adhere to normal, healthy endothelium (114), but
platelets interact with the collagen of injured endothelium through the
effects of thromboxane.

Further endothelial damage and the release of

platelet-derived growth factor stimulates smooth muscle proliferation.
The breakdown in the barrier function of the endothelium allows large
amounts of plasma constituents, including lipoproteins, to penetrate the
artery wall.

Proliferating smooth-muscle cells migrate into the inner

layer and remove foreign plasma constituents by endocytosis.

These con-

stituents are hydrolyzed components of lipoproteins that are metabolized
to relatively soluble materials (free fatty acids, amino acids, and
monosaccharides).

The cholesterol and free fatty acids that are ab-

sorbed by the endothelium are esterified and can not be removed by
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simple solubilization.
in the arterial wall.

Thus, cholesterol and triglyceride accumulate
These smooth muscle cells do not possess

r~

ceptor mediated uptake of lipoproteins but a type of scavenger mechanism is in operation (118) and large levels of lipid can be accumulated.
Other constituents of the arterial wall such as glycosaminoglycans have
been shown to trap lipoproteins entering the endothelial space (116,
117).

These findings point to the fact that atherosclerosis is a multi-

faceted disease state in which many of the factors listed above are
additive (107).

B. SUCROSE
a. History
Sucrose, or s-D-fructofuranosyl-a-0-glucopyranoside, is composed
of one molecule of glucose and one molecule of fructose joined by a
glycoside bond.

It is a non-reducing sugar and is stable against boil-

ing with very strong alkali solutions.

However, it is more easily

hydrolyzed by acids than are other common disaccharides.

Sucrose is

synthesized in the green leaves of plants and stored in the fruits and
roots as a source of energy and carbon.

Commercially, sucrose is ob-

tained primarily from sugar beet or sugar cane, accounting for 40 and 60
percent respectively of world sucrose production (131).
Like fat consumption, the amount of sucrose consumed per individual increases with the average income of the country.

In India,

Pakistan, and China, daily consumption averages approximately 15 g of
sucrose per person.

In the U.S., England, and Scandinavia the daily

individual consumption is 150 g of sucrose.

From a nutritional point
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of view, a high sucrose consumption is undesirable since it is a highly
refined product containing no essential nutrients.

Clearly,

howe~er,

humans and animals have a strong preference for its sweet taste.

b. Digestion
Sucrose must be hydrolyzed into its monosaccharide components before absorption in the small intestine.
tion of unhydrolyzed sucrose.

There is no significant absorp-

In animal experiments, sucrose adminis-

tered by injection was quantitatively excreted {140).

Hydrolysis of

sucrose is catalyzed by enzymes in the intestinal brush borders of the
mucosal epithelial cells.
unable to absorb sucrose

Patients with congenital lack of sucrase are
(133-1~5).

Theoretically, the ability of a

subject to absorb a specific disaccharide is dependent on the intestinal activity of the enzyme which hydrolyzes the specific disaccharide.
It is possible that dietary disaccharide stimulates the corresponding
disaccharidase activity by induction.

It is postulated that a regula-

tory gene codes for a repressor protein which binds the operator region.
Glucose and other sugars may bind the repressor so that the operator
gene can synthesize mRNA resulting in increased enzyme production.

This

concept of specific dietary regulation of jejunal disaccharidase activity has been postulated by Rosenweig and Herman (136).

They studied the

effect of isocaloric diets of glucose and sucrose or sucrose and maltose.
Intestinal biopsies were done on each subject after either glucose, sucrose, or maltose consumption.

It was found that the activities of the

disaccharidases were higher with sucrose diets than with glucose and
maltose diets.
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Intestinal absorption processes also respond to dietary sucrose.
Rats that were adapted to sucrose diets demonstrated enhanced absqrption of sucrose and constituent monosaccharides as compared to isocaloric diets of starch (42).

Since disaccharidase activity has been

shown to occur in proximal areas of the small intestine and glucose
absorbed in this part of the intestine has been found to be a more
efficient secretagogue for gastric inhibitory polypeptide (GIP), a more
rapid absorption of glucose after a sucrose load in sucrose adapted individuals might partially explain the enhanced leveled of GIP in these
individuals (138).

GIP is an important stimulator of insulin secretion

and the term enteroinsular axis has been used to describe the influence
of this intestinal hormone on

i~sulin

secretion (139).

The finding that

sucrose is a much more efficient secretagogue for GIP might explain
specific metabolic differences observed in sucrose as compared to glucose ingestion.

Rats fed disaccharides (sucrose rather than monosaccha-

rides) exhibited an increase in hepatic lipogenic activity (140).

Dis-

accharides are hydrolyzed prior to their intestinal absorption and must
have their effect at this level.
from greater GIP stimulation.

The disaccharide effect could result

This stimulation produces hyperinsu-

linism, and signals a pattern of enzyme induction which directs carbohydrate metabolism to lipogenesis.
The idea that high sucrose diets led to an increase in hepatic
fatty acid synthetase was supported by the work of Bruchdorfer and Khan

(141). When the diet contained fructose or sucrose, a high correlation
was found between hepatic synthetase and triglyceride concentration.
The presence of these sugars in the diet could not be related to insulin
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concentration.

In another study of hyperlipemia due to sucrose in-

gestion, it was found that a majority of the triglycerides that were
synthesized came directly from sucrose as the main carbon source (142).
By using [ 14 c] labeled sucrose Chlouverakis was able to demonstrate a
greater [ 14 c] content in triglycerides produced with sucrose feeding
than with comparable glucose or starch feeding.

Sucrose has also been

found to cause greater weight gains in animals than isocaloric amounts
of glucose or starch (143, 144).

In general, these results imply that

the organism metabolizes sucrose more efficiently than glucose.

This

agrees with theoretical calculations demonstrating that smaller amounts
of sucrose are required to produce a unit of metabolizable energy than
glucose (145).

While the effects of sucrose on the liver and the endo-

crine pancreas point to increased lipogenesis, the cause of this hyperlipemia remains to be elucidated.

C. HUMAN TRIGLYCERIDE METABOLISM
a. Exogenous Incorporation
Triglycerides are the principal form in which long chain fatty
acids are stored and transported in the blood.

This is true whether

they arise from intestinal absorption or hepatic secretion.

To be ab-

sorbed, these lipids must first be converted into more polar compounds
by processes that take place primarily in the lumen of the small intestine (119).

The lipids are finely emulsified by the churning action of

the small intestine, then further broken down by the action of pancreatic lipases and solubilized in detergent structures containing high
amounts of free cholesterol and bile salts, called mixed micelles.
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These structures are polar enough to transport lipid across the unstirred water layer that lies on the surface of the intestinal membrane.
Once inside the intestine, these lipids are reesterfied with glycerol
and are transported to the endoplasmic reticulum (148, 149}.

Osmio-

philic particles of the same size, shape and staining properties, called chylomicrons (large lipoproteins of intestinal origin), are assembled
at the endoplasmic reticulum of the mucosal cell with triglyceride added
to the protein core.

These particles first appear in the apical region

of the cell within vesicular and tubular cisternae of smooth surfaced
endoplasmic reticulum.
attached ribosomes.

Thereafter they appear in cisternae with some

The newly-synthesized chylomicrons appear to mi-

grate from the smooth endoplasmjc reticulum to the Golgi apparatus
(supranuclear in intestinal absorptive cells) (120).

The Golgi appara-

tus is a tubular system through which the chylomicrons must pass.

The

particles accumulate in secretory vesicles of the Golgi and appear at
lateral extracellular spaces between absorptive cells.

The lipopro-

teins are subsequently extruded from these vesicles into the lacteals
and course through the lymphatics gaining access to the systemic circulation via the thoracic duct.

This lymphatic route bypasses the liver

and the bulk of the triglyceride is hydrolyzed in several extrahepatic
tissues. After a fat-containing meal, the process of deposition begins
when these chylomicrons enter the circulation and come in contact with
the endothelial surface of adipocyte capillaries.

FFA, and

phosphate is then released and stored in the adipocyte.

La

glycero-
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b. Endogenous Production
Most mammals can convert carbohydrate to fatty acids which can
be deposited as adipose fat.

The central argument concerning enzy-

matic triglyceride production from carbohydrate derived precursors
concerns the role that processing of carbohydrate plays on fatty acid
biosynthesis.

Recent studies over the last two decades have led to a

prodigious effort to uncover the mechanism involved in the physiologic
regulation of fatty acid biosynthesis.

There are two types of control

mechanisms that regulate the complete synthesis of fatty acids by the
de nova pathway.

One is long term control which involves changes in

the content of fatty acid biosynthetic enzymes including acetyl CoA
carboxylase, fatty acid

synthe~ase

complex, citrate lyase, glucose

6-phosphate dehydrogenase and malic enzyme, which are stimulated in the
liver when glucose is fed.

By contrast, the content of these enzymes

in the liver decreases during starvation or in diabetes associated with
insulin deficiency (122-124).

In this way, the cell has large quanti-

ties of these enzymes needed for conversion of carbohydrate into fatty
acid only when carbohydrate and ATP are available.
There is also a short-term control mechanism that acts on acetyl
CoA carboxylase, the rate limiting enzyme in fatty acid synthesis.
involves modulation of the activity of acetyl CoA carboxylase.

It

Citrate

activates the enzyme by causing aggregation, while long chain acyl CoA
inactivates it (125).

Other enzymatic steps may also be important in

the regulation of fatty acid synthesis (126).

For example, pyruvate

dehydrogenase has been implicated as a site of control (127-128).
It was found the intestine secretes triglycerides into mesenteric
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lymph as VLDL sized particles.

Studies by Cenedella et al. {129) demon-

strated that rats fed orotic acid, known to block liver release

o~

lipo-

proteins, developed a sustained entry of triglyceride into the plasma
pool.

The labelled triglyceride was thought to be of intestinal origin

because of the time course involved in the appearance of TG in the
plasma of orotic acid fed animals.

This observation was consistent with

the idea that triglycerides released from the liver gain immediate access to the plasma while those from the intestine must travel through
the lymphatics.

Orotic fed rats formed only ten percent as much circu-

lating triglyceride as control animals.

This, coupled with a consider-

able less rapid triglyceride turnover suggests that the intestines could
produce ten percent of the plasma triglycerides presumably derived from
liver.
The hepatic subcellular pathway of triglyceride secretion shares
many common features with the intestinal pathway.

In the liver,

secretory vesicles near the cell surface fuse with the plasma membrane
resulting in the discharge of VLDL into the Space of Disse.

Recogni-

tion proteins probably exist in membranes of secretory vesicles and in
the plasma membranes which result in fusion of the two.

Reaven

suggested that microtubule protein is essential in maintaining the
structural integrity of Golgi membranes and associated structures (130),
with the use of antimicrotubule agents leading to a disaggregation of
microtubule protein structure.

This disorganization of the Golgi re-

sults in impairment of VLDL (TG) secretion possibly because the membranes of the formed VLDL-containing vacuoles lack a critical component
normally acquired through the Golgi complex.

The liver, the major site
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of fatty acid biosynthesis, then releases these triglyceride laden lipoproteins for subsequent deposition of triglyceride into the

adipo~yte.

This synthetic mechanism is probably the main cause of diet induced
hyperlipemia.

Studies using radiolabeled triglyceride components have

shown that this increased synthesis plays an important role in hyperlipemia (49, 57, 58).

D. THE HUMAN LIPOPROTEINS
I. Introduction
The plasma lipoproteins have become a focus of intense study in
recent years.

This has resulted in part from new technical advances in

electrophoresis for the

separa~ion

of lipoprotein classes (146).

In

1967, Fredrickson published a comprehensive survey of the plasma lipo-

proteins and suggested a method for defining hyperlipoproteinemia on the
basis of five phenotypes (147).

The use of plasma lipoprotein phenotyp-

ing became widespread with clinical interest in these proteins increasing due to accumulating evidence which related elevated levels of plasma
lipoproteins to premature coronary artery disease.

It has become evi-

dent that the classification of different hyperlipemias is, in fact,
based on changes in the subunit structure and distribution of the plasma
lipoproteins.

II. Composition and Identification of Lipoproteins
a. Chylomicrons
Dietary triglycerides are hydrolyzed in the duodenum to free fatty
acids and 2-monoglycerides.

After absorption, triglycerides are resyn-
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thesized and incorporated into the chylomicron particle in the intestinal wall (148-149).

Lymph chylomicrons are heterogenous in size,
0

ranging in diameter from 300 to 5000A.

These particles mainly con-

sist of triglyceride (70-90%) and there is a direct relationship between the size of the chylomicron and triglyceride content.

Chylo-

microns also contain a small fraction of phospholipid (8%) and
cholesterol (5%).

Phosphatidylcholine and sphingomyelin are the major

phospholids present (150).
but variable.

The protein content of chylomicron is small

Kastner (151) found that human chylomicrons isolated from

the thoracic duct contain all of the apoproteins of VLDL.

The approxi-

mate protein composition of chylomicrons is 66 percent apo C, 22 percent
apo B and 12 percent apo A.

A~

interesting point of this study was that

apo A and apo A1 were present in approximately equal quantities in the
chylomicron differing from the ratio of 3:1 found in HDL.

b. VLDL
In man, the very low density lipoprotein (VLDL) particle is the
major transport vehicle for endogenously derived triglyceride (150).
Streja and Kallai (152) found that VLDL molecules are very heterogenous
0

0

with sizes ranging in a continuum of 280A-750A.

It was also observed

that larger lighter VLDL particles were metabolized more rapidly from
the plasma compartment than smaller heavier particles.

The size of the

VLDL particle is related directly to the triglyceride content and indirectly to the phospholipid and protein content.
most abundant lipid component (56 percent) of VLDL.

Triglyceride is the
The average VLDL

lipid content is 19-21 percent phospholipid and 17 percent cholesterol.
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In VLDL the esterified to unesterified cholesterol ratio is approximately 1.

Phosphatidylcholine and sphingomyelin are the predominant

phospholipids.
The protein composition of VLDL has been well characterized
through the use of various isolation techniques.

The percent compo-

sition of soluble and insoluble apoproteins in VLDL remains fairly constant regardless of sex and age of the individual.

However, there are

variations in concentrations of apoproteins in VLDL from one individual to another.

Observed variations in the absolute concentrations of

apolipoprotein in the VLDL subfraction from individual subjects probably
reflects their nutritional and metabolic status.

Lee and Alaupovic

{151) found that an increasing plasma triglyceride level in the postabsorptive state is accompanied by higher levels of apo B and apo C.
Esterification of fatty acids in the endoplasmic reticulum could stimulate apoprotein synthesis (154).

Previous studies by Gustafson (153)

found that the protein moiety is an integral component of the lipoprotein particle providing structural stability for the molecule.

In

the presence of detergent (e.g. sodium dodecyl sulfate) apo VLDL can be
solubilized and fractionated into respective apoproteins.
tains about 55 percent apo B and 45 percent apo A.
apo A are immunologically detectable, but very low.

VLDL con-

Concentrations of
AI and AII peptides

accounted for less than one percent of the total protein.

Other reports

estimate the apo B concentration to comprise 35 percent of total VLDL
apoprotein (154).

Kane and Sata (155) found another apoprotein, apo E,

rich in arginine, which represented approximately 20 percent of the
total apoprotein content.

Apo E was at first confused with apo B,
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giving the relatively high value previously seen for apo B (155).

These

investigators also discovered a previously undetected entity of apo C
having electrophoretic mobility compatible with an increment of one unit
of charge over that of another apo C subgroup.

These authors hypothe-

sized that this moiety was a sialoprotein since neuraminidase treatment resulted in proteins migrating with decreased mobility (similar to
typical apo C subspecies).

c. Low Density Lipoproteins
In the U.S., the average normal fasting adult concentration of low
density lipoprotein (LDL) is 400 mg/dl in males and 340 mg/dl in females.

LDL contains approximate)y 75 percent lipid and 25 percent pro-

tein.

Lipid composition by weight is 50 percent cholesterol esters, 30

percent phospholipids and 10 percent reesterfied cholesterol with 10
percent triglyceride.

Phosphatidylcholine and sphingomyelin account for

65 percent and 25 percent of the total phospholipid respectively with
linoleic acid as the major fatty acid in LDL (150).

LDL particles

appear almost spherical in size and are quite uniform in appearance when
observed by electron microscopy with negative staining techniques (156).
0

Eighty percent of LDL particles are between 210 and 250A in diameter
with molecular weight ranges reported to vary between 2-35 X 10 6 daltons
(159).

Subfractions of LDL have been isolated using density gradient

centrifugation between 1.019 and 1.063 g/L (154, 160).

Although the

molecular weight of the subfractions is different, each LDL particle
contains a constant percentage of protein.

Studies of the density sub-

classes of LDL (LDL 1 and LDL 2 ) demonstrate that there is a constant
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ratio of soluble (apo C, A, E) to insoluble {apo B) protein in both
subclasses (154).

However, marked differences in the apoprotein com-

position of these subclasses have been observed.

In contrast to LOL ,
2
the LOL 1 fraction contains roughly as much apo C (38 percent) as VLOL
and LOL 1 may represent an integral part or continuation of VLOL
metabolism.

All three apo C subclasses were identified in LOL isola-

ted in the 1.006-1.019 density ranges.

The LOL 2 subclasses represent
the only segment of the lipoprotein density spectrum consisting predominantly of apo B.

The soluble apolipoproteins account for only 4-9

percent of the total protein content of LOL 2 • Apo B content of this
subgroup is in agreement with the observed LOL apo B content estimated
by Lees using radial

immunodiff~sion

{161).

functions as a storage depot for cholesterol.

Plasma LOL probably
Extrahepatic tissues can

obtain LOL-cholesterol for membrane synthesis through a receptor
mediated process.

In metabolizing LOL for structural purposes, extra-

hepatic tissues constitute a major site of LOL catabolism.

d. HOL
High density lipoproteins (HOL) are relatively small aggregates of
0

lipids and proteins with diameters ranging from 90 to 120A (156).
Lipids account for about one-half of HOL by weight.

Phospholipids

(42-51 percent), cholesterol (32 percent) and triglyceride (10 percent)
are the main components (150).

Phosphatidylcholine constitutes 70-80

percent and sphingomyelin 12-14 percent of the total phospholipid.
Phosphatidylserine and phosphatidylinositol are minor components.
Linoleic acid is the predominant fatty acid of the esterified
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cholesterol.
Protein moieties of HDL have been identified using DEAE-cellulose
chromatography and consist of two major components (165).

About 90

percent by weight of the protein in HDL is either apo AI or Ail.

AI

accounts for 70 percent and AII about 20 percent of the total protein.
Other peptide components, C and E protein subunits, have been isolated
from (HDL 2 ) subfractions but comprise minor amounts of the total HDL
protein (166). The ratio of apo AI to apo AII varies within each HDL
subfraction.

These peptides are remarkable in that they can function

as detergents capable of solubilizing lipids and cholesterol in large
quantities.

In fact, 1 g of HDL AI can solubilize up to 2.5 g of phos-

pholipid in a disc-like micelle;(167), structures analogous to the
lecithin-cholesterol-bile salt micelles found in bile.

However, bile

salts act as detergents in fat digestion, whereas HDL proteins are the
detergents in plasma (168).
A minor HDL component, HDL 1 , has been isolated between 1.050
and 1.063 g/L (HDL normally are between 1.063-1.21). HDL 1 has electrophoretic and immunochemical properties similar to normal HDL 2
(162). Several HDL subspecies have been identified by analytical and
preparative gel electrofocusing (163-164), but their physiological significance is unknown.

However, the human plasma HDL 2/HDL 3 ratio is
affected by several pathologic and physiologic processes.

e. Pre
A pre

a

a

Lipoprotein
lipoprotein has been observed in human serum with electro-

phoretic mobility and staining characteristics in agarose gel similar to
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albumin (160).

Free fatty acids and a high content of the phospholipid

lysolecithin are present in this fraction (170).

The ability of

~1-

bumin to bind both types of lipids lends support to the theory that
albumin makes up a substantial part of the pre

a

lipoprotein.

The

presence of other phospholipids and neutral lipids suggests that other
apoproteins may be present in pre

a

lipoproteins.

Wille and associates

(171) characterized the protein fractions utilizing immunological
methods.

They found that one single band was found on PAGE electro-

phoresis, but double diffusion experiments disclosed the presence of apo
AI as well.

The total amino acid composition is similar to albumin ex-

cept for higher amounts of glycine, serine and glutamic acid.

Use of

mercaptoethanol to reduce disulfide bonds resulted in two bands on PAGE
where one had been previously observed (172).

One protein had a mole-

cular weight comparable to albumin (67,000) and the other to apo AI
(28,400).

Albumin may attach peptides through disulfide bridges, parti-

cularly at position SH-34 cysteine (173).

Since apo AI does not contain

a cysteine residue, the apo AI molecule might be enclosed within
crevices in the larger albumin molecule (174).
previously been ascribed to a pre

a

A functional role has

lipoprotein in lysolecithin trans-

port (180) and may function as an acceptor for the lysolecithin generated by the lecithin-cholesterol acyltransferase reaction in plasma
(175).

f. Lipoprotein (A)
Lipoprotein A (LpA) exhibits the same properties as LDL, but is
considered an additional lipoprotein class.

It is isolated in the
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1.050-1.120 g/L density range and has a molecular weight of about 5 X
1o6 daltons. LpA exhibits pre-s mobility on agarose gel electrophoresis and has a lipid composition similar to LDL, though its protein
content is completely different (176).

LpA, when delipidated, contains

65 percent apo B, 15 percent albumin and a unique apoprotein called apo
Lp(A) (177).

The occurrence of LpA in the general population may be as

high as 75-85 percent with an average plasma concentration of 14 mg/100
ml.

LpA concentration does not appear to correlate with age, sex, or

lipid concentration, and the functional significance of LpA is not known
(178-179).

E. THE APOPROTEINS
Until about ten years ago, lipoproteins were viewed as isolated
families or species defined either by ultracentrifugation or by electrophoresis.

This basis of classification provided little insight into

causes of lipoprotein abnormalities or the role of the lipoproteins in
lipid transport.

Many processes involved in lipoprotein metabolism are

regulated by enzymes whose activity is influenced by the apoproteins.
It is generally accepted that there are at least seven different apeprotein classes which differ in their primary, secondary, and tertiary
structure.

These proteins also differ in their function and distribu-

tion throughout the lipoprotein spectrum.

(Table 1).

a. Apo A
Chromatography of delipidated apo HDL yields two pure polypeptides
designated apo AI and apo AII, the major apoproteins of HDL (181).

Apo
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AI is a single polypeptide chain of 245 amino acids and has a molecular
weight of 28,331 daltons.

The amino acid content determined by

B~ker

indicated a protein composed primarily of cysteine, cystine, isoleucine and carbohydrate (182).

Glutamine is the carboxyterminal amino

acid and aspartic acid is the amino terminal group.

Heterogeneity has

been observed by Nestruck et al. who found four isoprotein subgroups of
apo AI {183).

They had identical molecular weights and common anti-

genicity with antisera raised against apo AI.

Each form had a similar

amino acid composition except for A IV which contained one isoleucine
residue .Per mole.

All forms of apo AI were LCAT activators except for

AIV which inhibited the enzyme {183).
AI - Alii are considered

~quivalent

polymorphic forms while AIV

is considered a different form of unresolved heterogeneity.

Apo AI has

been isolated from a wide range of animal species, but all types have
similar physiochemical properties (184).

Results from many structural

studies indicate lipid binding properties may be related to the degree
of self-association of the proteins {185-188).

Vitelli and Scanu {189)

have found that the molecular weight of Apo AI can very between 30,000
and 167,000 at protein concentration of 0.2-0.9 mg/ml due to a monomerdimer-tetramer-octamer equilibrium.

A minor apo AI component has been

isolated by Weisgraber et al. that coelectrophoresed with apo AI on SDS
polyacrylamide gel (190).

It was immunogenically similar to apo I

except that it contained two amino acids, cysteine and isoleucine, which
are not found in normal apo AI.

By virtue of its cysteine group, apo AI

is capable of forming disulfide bridges.
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PROPERTIES OF LIPOPROTEINS
Chylomtcrons
MaJOr
Constituents

triglycerides

VLDL

LDL

tr!Qlycendes

cholesterol,
prote1n,
phospholipid

HDL

prote1n,
phospholipid.
cholester o1

Apolipoprotell'\5

B,A,C

B,C,E

8

SIZe(,!.)

>1000

300-800

180-250

100

Oens1ty (g/ml)

<095

0.95-1.006

1.006-1.063

1.063-1.125

Flotation (Sf 1 063)

>400

20-400

0-20

or1g1n

pre-beta

beta

Mobility
Precipitation

Table 1:

HDL 2

t~

A,C,D,E

75
1.125 -1.21

(FL~l35-9

0-3.5
a~ha-1

t

t~

t

Summary of the basic properties for the 5 specific lipoprotein classes listed.
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Apo All is the second most abundant apoprotein of human HDL.

It

consists of two identical polypeptide chains of 77 amino acids which
are linked by a disulfide bridge at cystine-6 (199).

Histidine,

arginine, tryptophan and carbohydrate are absent from apo Ali.

Stone

and Reynolds (188) have calculated that apo All has a dimeric molecular
weight of 34,000.

Gwynne et al. (193) on the other hand, reported the

molecular weight of apo All is dependent on concentration and obtained
an equilibrium constant of 2.8 X 10 4M- 1 for monomer-dimer equilibrium.
Studies from other animals indicate the disulfide bridge is not
crucial for apo 11 to fulfill a lipid carrier role (194-195).

The

interactions between A apoprotejns and lipids have been extensively
studied (196).

Both apo AI and apo All bind phosphatidylcholine to

form protein-phospholipid complexes (197).

When apo Ali is added to a

sonicated mixture of either lecithin or sphingomyelin, 79-90 percent
of the apo AII can be isolated in the HDL density range.

In contrast,

only about ten percent of added apo AI is found in this range.

b. Apo B
Apo B is the least well characterized of the plasma apoproteins.
Similar to integral membrane proteins, apo B is not readily soluble in
aqueous solutions unless high concentrations of detergents are added
(198-200).

Results from solubilization studies have resulted in no

general agreement concerning the number of subunits or the molecular
weight of apo B.

Reported weights range from 8000-275,000 daltons with

the most commonly reported values between 25,000-30,000 daltons (201).
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Apo B has been recently studied and found to have an amino acid composition similar to that of the other apoproteins (201).

The concen-

tration of apo B in normal human plasma is between 70-110 mg/dl and
primarily found in LDL (204-205).

c. Apo C
Fractionation of apo C into its component proteins can be
achieved by ion exchange chromatography or isoelectric focusing (166).
Apo CI is a single polypeptide chain of 57 amino acid residues (206).
The protein contains about 55 percent a-helix which is increased in
the presence of phospholipid (207).
SDS urea gels, certain bands

a~e

Upon fractionating the protein in

produced through carbamylation of the

£-amino groups of lysine with urea.

This carbamylation converts the

positively charged lysine to neutral homocitrulline and results in
greater anodal migration on alkaline polyacrylamide gels (208).

Once

precautions are taken, these artifactual polymorphs disappeared.
Brown et al. (209) reported that all of the apo c•s aggregate to
form high molecular weight species in the absence of dissociating
agents.

In addition to binding and transporting lipid, apo Cacti-

vates lipoprotein lipase and LCAT (210).
Human apo CII contains 79 amino acids and has a calculated
molecular weight of 9110 daltons (211).

In addition to binding lipid,

apo CII is a potent activator of lipoprotein lipase from post-heparin
plasma, adipose tissue and cow's milk (212-218).

The work of Matsuoka

et al. (70) demonstrates that apo CII acts on lipoprotein lipase by enhancing the interaction between lipoprotein lipase and triglyceride
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within the surface monolayer of the lipoprotein particle (70).

His

work with apo CII deficient patients has provided much information concerning enzyme kinetics of the lipoprotein lipase-apo CII reaction.
Phospholipids also appear to be necessary for optimal lipolysis.

In

the absence of lipid, apo CII forms a stable complex with purified milk
lipoprotein lipase (214).

Apo CII contains only 23 percent a-helix

and undergoes self-association at protein concentrations greater than
mg/ml (209).
Apo CIII, the most abundant apo C constituent, contains 79 amino
acids, has a molecular weight of 8764 daltons and is a glycoprotein with
an oligosaccharide attached to threonine at position 74.

The oligosac-

charide contains one residue of ;galactose and galactosamine and 0-3
residues of sialic acid (215).

The complete amino acid sequence has

been determined with amino terminal threonine and carboxy terminal
alanine.

Polymorphism of the protein on polyacrylamide gel electro-

phoresis is caused by differences in sialic acid content (215-216).
Nestruck et al. (217) have shown that sialylation occurs in the Golgi
apparatus of rat liver and the extent of sialylation increases with
residence time of VLDL in the organelle.

While the physiologic function

of apo CIII is uncertain, Brown et al. (218) have found apo CIII is an
inhibitor of lipoprotein lipase.

This is due to binding of apo CIII to

the lipase substrate with resulting prevention of enzyme substrate
interactions.

If apo CIII exceeds 2 percent of the weight of the lipase

substrate, it reduces the hydrolysis of lipoproteins containing sufficient apo CII.

Blood apo C concentrations are not stable

and have been found to be influenced by diet and metabolic status.

A
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decrease in the ratio of apo CII/apo CIII has been observed in the
of hypertriglyceridemia (69).

In addition, high carbohydrate diets re-

sult in alterations in the metabolism of apo CII and apo CIII suggesting the secretion of both apoproteins is increased or their clearance
is delayed {67).

d. Arginine Rich Apoprotein (Apo E)
The arginine rich protein was first isolated by Shore and Shore
(166) from VLDL and HDL.

In normal VLDL, apo E content is approxi-

mately equal to that of apo CI and apo CII and exceeded only by that of
apo Band apo CIII (219).
daltons was obtained by

A molecular weight for apo E of 33,000

sos~polyacrylamide

gel electrophoresis.

Approximately ten percent of the total amino acids are arginine.

Lysine

and alanine are reported to be the amino and carboxy terminal acids respectively (220).
tent (221).

The arginine-rich protein has a high a-helical con-

It is present in several polymorphic forms which can be

separated by either ion exchange chromatography or isoelectric focusing (222-225).

In humans, a diet containing increased cholesterol

causes elevations in plasma apo E levels, some of which are found in
HDL.

HDL containing apo E has been shown to have a greater affinity

than LDL for the LDL receptor (226).

Studies on patients with type III

hyperlipoproteinemia have shown that plasma levels of total apo E are
increased, but that a deficiency exists in one of the isoprotein subunits (227-223).

The deficiency may be seen as a structural mutation

of the isoprotein subunit causing a different migration on two dimensional electrophoretic gels.

Studies by Havel and Chao (228) suggest
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another function of apo E.

In perfused rat livers, treated with

ethynyl estradiol for five days, there was a stimulated uptake of
lamellar complexes of apo E.

Human lipoproteins with apo E, con-

taining all of the major protein isoforms, were comparable to rat
lipoprotein containing apo E, during estrogen stimulated uptake at the
hepatic site.

However, lipoproteins from patients with dysbetalipo-

proteinemia, Type III disease, were characterized by decreased hepatic
uptake.

Havel hypothesized that apo E is an essential component re-

quired for recognition by the hepatic receptor to remove remnant VLDL.
Accumulation of remnant particles is often found in type III hyperlipoproteinemia.

Further proof of the function of apo E was obtained

by Weisgraber and Mahley (229)
plex in VLDL and HDL.

~pon

their discovery of a 46,000 MW com-

This protein was reducible with mercaptoethanol

or dithiothreitol into two chains indicating the presence of disulfide
bonds.

The two subunits were identified as apo E All monomers by

coelectrophoresis and immunochemical activity.

It was found that con-

version of the complex to the E apoprotein resulted in a markedly enhanced binding activity of the lipoprotein, containing the (apo E-AII),
to receptors.

The dimer is thought to block the recognition sites on

apo E for the receptor.

Elevated levels of this dimer complex could be

responsible for decreased uptake of VLDL remnants and HDL by their receptors:

e. Apo D or Thin Line Apoprotein
A protein has been isolated from human HDL and has been referred
to as thin line protein or apo D (223-231).

The name, thin line
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protein, is derived from a characteristic thin precipitin line formed
~po

near the antigen well with either anti-HDL or anti-whole serum.

D

has been found in HDL 3 , LDL and VLDL (232). A preliminary estimate
indicates this protein accounts for 1-2 percent of the total protein
content of normal HDL (233).

The protein is characterized by the

presence of all common amino acids, including half-cystine.

The carboxy

terminal acid is serine, and carbohydrate analysis demonstrates apo D is
a glycoprotein of 22,100 MW (234}.

Carbohydrate moieties present are

glucose, mannose, galactose, glucosamine, and sialic acid (accounting
for 18 percent of the dry weight of apo D).

The lipid moiety contains

cholesterol, cholesterol ester, triglyceride and phospholipid.
phospholipid content is

charact~rized

The

by a relatively high amount of

lysolecithin and sphingomyelin and a relatively low amount of lecithin.
Kastner (235) found that apo D activates LCAT and Olaffsson and
Gustafson (236) have suggested it may be a specific protein carrier for
lysolecithin formed by the action of LCAT on HDL.

Chajek and Fielding

(237} demonstrated that human plasma contains a specific lipoprotein
apoprotein that catalyzes the net transport of cholesteryl esters from
HDL to VLDL and LDL.
D.

The purified protein is identical to that of apo

It is possible that the normal catabolism of VLDL to LDL requires

the presence of both HDL and plasma cholesteryl ester transport protein,
apo D.

F. STRUCTURE OF PLASMA LIPOPROTEINS
Serum lipoproteins are referred to as soluble proteins to specify
their solubility in aqueous media.

Since they are fundamental in lipid
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transport, a knowledge of their structural makeup is necessary to
understand their function.

Scanu (238) reviewed the methods of analy-

sis used to ascertain membrane structure (238).

Some of these methods

include chemical and enzymatic studies, reassembly studies, ultracentrifugation, electron microscopy, Optical Rotatory Dispersion (ORO),
Circular Dichroism (CD), IR, NMR, ESR, X-ray techniques and surface
balance studies.
The ability of plasma apoproteins to interact to form soluble
complexes with phospholipids cannot be explained by amino acid content
or from direct inspection of primary structure.

The overall amino acid

structure is similar to other soluble plasma proteins.

Segrest et al.

(230) built space filling models for apoproteins whose sequences were
known and found a common structural feature in the phospholipid binding
region.

Based on model-building studies and the assumption that an

a-helix is fundamental to the mechanism of phospholipid binding, he
suggested that these regions, referred to as amphipathic helices,
represented the binding sites of apo A and apo C for phospholipid.

Such

helices have both polar and non-polar sites each comprising 180° of the
cylindrical surface.

Such an arrangement fascilitates simultaneous

interaction of the protein with water insoluble lipids and with the
external environment.

Negatively charged amino acid residues (aspartic

and glutamic acids) are clustered toward the middle of the polar face
while positively charged basic side chains (lysine, arginine) are
oriented toward the lateral edges of the interface between the polar and
non~polar

sides.

This topographical arrangement of charged amino acids

led to the suggestion that steric zwitterions are created and electro-
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static attractions between the positively charged choline groups of
the phospholipid with the glutamic acid or aspartic acid side chains
and between the phosphate and the lysine or arginine residues could
occur.

Maleylation of apo Ali abolishes the binding of phosphatidyl-

choline suggesting that lysine plays a role in the binding mechanism
(240).

If such ionic interactions do exist, they are probably less

important than the hydrophobic interactions that are found.
Another possible function of these steric ion pairs is that they
could produce an initial orientation of the apoprotein with respect to
the phospholipid which favors the interaction of these species during
the initial phase of binding.

The steric zwitterions within the helix

are composed of two amino acids: which occur in a 1, 2 or 1, 4 relationship (235).

These 1, 2 and 1, 4 ion pairs are not found in globular

proteins which suggests they are of importance in lipoprotein phospholipid interactions (241).

It has been suggested that these ion pairs

could function to lock a section of the peptide backbone into an
a-helix through preferential hydration of the polar side of the helix.
Sparrow et al. (242) have synthesized a series of model peptides which
would be expected to have characteristics of amphipathic regions (242).
The ability of these synthetic peptides to bind phospholipid was shown
to depend on the degree of hydrophobicity of the non-polar surface of
the helix.

By making a substitution of Try-Trp for Ala-Ala, Sparrow

found it was possible to transform a non-binding peptide into one which
binds lipid more readily (242).
The mass of data on lipid and protein interactions have led to the
development of three separate models for lipoprotein structure.

The
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lipid core model was proposed for VLDL and chylomicrons.

The physio-

chemical problem of keeping a neutral lipid-rich particle in solution
is overcome by putting triglycerides and cholesteryl esters into a
central core while phospholipids and cholesterol are on the surface
(243-245).

Gustafson (246) has calculated that the quantity of pro-

tein, phospholipid, and unesterified cholesterol in VLDL is sufficient to cover the surface of the particle.

Schumaker (247) has

suggested that as triglycerides are removed from the particle by the
action of lipoprotein lipase, there is a concomitant reduction in surface area affected through the removal of cholesterol by the action of

LCAT.
Models of LDL structure are based on small angle X-ray scattering, nuclear magnetic resonance, and neutron scattering techniques
(248-250).

Mateu et al. (248) have concluded, from X-ray scattering,

that there are outer and inner high electron-dense regions separated
by an immediate low-electron-dense region (248).

The LDL model suggest-

ed by this work has a phospholipid bilayer with cholesteryl esters,
cholesterol and triglycerides separating an outer protein shell and an
inner protein core.

However, other investigators using neutron dif-

fraction, demonstrated that the central core is predominantly occupied
by hydrocarbon chains of lipid (250).
the location of

li~id

Finer (249) has used NMR to probe

and protein and has concluded that at least 30

percent of the choline residues are immobile and inaccessible to solvent.

It has been suggested that LDL contains a trilayer structure that

surrounds a central core of protein (249).
To date, the bulk of the experimental data resulted from analysis
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of the HDL lipoproteins.

While the data is diverse, several common

features are shared by the different models proposed (251-253).

The

particle is micellar with the head groups of the phospholipids and
the polar end of cholesterol oriented toward the surface.

The apolar

ends of these molecules are oriented toward the center with the
cholesteryl esters sequestered on the inside of the particle.

The

major point of disagreement between suggested models is the relative
location of the principal apoprotein components and how they interact
with the phospholipids.

Studies by Shen et al. (254) using composi-

tional analysis have shown that a hydrophobic core of cholesterol ester
0

and triglyceride is surrounded by a 20A thick monolayer of cholesterol
and phospholipid closely packed, on the surface of the core.

The curva-

ture of the surface results in large gaps between the polar head groups
of this monolayer.

The unfolded protein fills these gaps and masks the

polar head groups of free cholesterol.

The essential features of this

model are a sharply defined boundary between the hydrophobic core and
the amphipathic layer surrounding it.

This boundary is occupied ex-

clusively by phospholipids and cholesterol and their tight packing does
not allow for the penetration of any other component.

The apoprotein is

located in the same surface layer as the phospholipid head groups with
these two components competing for the same space.

Therefore, Scanu has

speculated that an identical structure for all lipoproteins could be
assumed regardless of size.

G. LIPOPROTEIN SYNTHESIS AND CATABOLISM
The liver and intestine are the major sites of synthesis of the
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plasma lipoproteins.

On a high fat diet, the bulk of triglyceride

fatty acids are derived from chylomicrons synthesized in the
tine.

inte~

Dietary carbohydrates may also be converted to fatty acids in

both liver and adipose tissue.

a. Chylomicron Synthesis
Absorption of dietary fat occurs mainly in the upper small intestine.

Tytgat (255) found that the major site of chylomicron syn-

thesis in man is the jejunal mucosa.

Electron micrographs indicate

that the (SER) is the major cellular organelle involved in the transport of newly synthesized triglyceride and suggest that chylomicron
synthesis is completed there (2,56-257).

Synthesis of chylomicron lipo-

proteins presumably occurs in the ribosomes of the RER (257).

b. VLDL Synthesis
Both the liver and intestine incorporate radioactive amino acids
into the protein moieties of VLDL (258).

But no radioactivity was in-

corporated into apo C proteins when intestinal perfusion systems using
labeled amino acids were employed.

This suggests that apo C proteins

are synthesized in the liver and their occurrence in lymph is due to a
transfer from lipoproteins of hepatic origin.

Intestinal synthesis of

apo B has been observed in rats fed a diet containing orotic acid (259).
The mesenteric lymph of these rats has mean normal levels of apo B,
whereas the plasma contains virtually no apo B.

Orotic acid-fed indivi-

duals accumulate hepatic fat as a result of their inability to mobilize
lipid from the liver (260).

The liver and intestine share many common
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features in the synthesis and excretion of these particles.

Secretion

is influenced by the availability of non-esterified fatty acids of
either endogenous or exogenous origin.

The lipid composition of the

particles is influenced by several factors.

Heimburg and Wilcox (261)

have shown that approximately 50 percent more VLDL triglyceride is
secreted when isolated rat liver is perfused with oleic acid than with
palmitic acid.

VLDL secreted during palmitate infusion are more dense,

contain a higher proportion of cholesterol to phospholipid and have a
lower proportion of triglyceride as compared to rats fed oleic acid.
During the early stages of VLDL synthesis, the Golgi apparatus of
0

hepatocytes contain fat particles of 300-lOOOA in diameter, which have
physical and chemical propertie.s similar to VLDL (262).
Other types of dietary manipulations can also effect the secretion of VLDL.

Dolphian et al. (263) demonstrated that normal hepatic

Golgi and secretory vesicles contain triglyceride-rich lipoproteins
which have none or minimal amounts of apo CII and are deficient in apo
E relative to serum VLDL.

Hepatic fractions from hypercholesterolemic

rats contained cholesteryl ester and apo E-rich triglyceride-depleted
VLDL with size, immunodiffusion characteristics, and apo B to apo E
ratios similar to hypercholesterolemic serum VLDL {263).

He deduced

that diet induced hypercholesterolemia resulted in lipoprotein secretory products which contribute to the plasma pool of abnormal cholesteryl ester and apo E-enriched lipoproteins.

Witzum (66) observed that

liver perfusion of rats on high carbohydrate diets resulted in increased triglyceride secretion.

The VLDL isolated were larger, triglyceride-

enriched, less dense than normal.

Although total VLDL protein rose, the
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amount of VLDL apo B decreased.

Both apo C and apo E levels rose

while apo CIII subfraction levels were altered.

Apo CIII

increa~ed,

1
This suggests the amount of time spent in

while apo CIII 2 decreased.
the Golgi was decreased because of the small amount of protein sialization (reflected in decreased apo CIII 2 levels).
Finally, Zannis and Breslow (264) demonstrated that patients
with Type III hyperlipidemia (Broad Beta Disease) had non-characteristic apo E isoprotein patterns.

They demonstrated a post-transla-

tional modification of apo E by showing that treatment of VLDL with
neuraminidase prior to electrophoresis resulted in a disappearance of
the non-characteristic band.

This indicated that the group of faulty

proteins occurred by sialation pf apo E.

c. Chylomicron Catabolism
Chylomicron catabolism has been found to occur rapidly with a
half life of less than one hour.

Initially, this catabolism involves

triglyceride hydrolysis catalyzed by lipoprotein lipase followed by the
removal of a triglyceride poor remnant by the liver.

Phospholipids are

hydrolyzed by both lipoprotein lipase and lecithin cholesteryl acyl
transferase.

The role of the apoprotein components in chylomicron meta-

bolism has been reported by Havel (271) to consist of net transfer of
apo CII proteins from HDL to chylomicrons and back to HDL.
proteins are transferred at the same time.

Other apo C

The presence of apo err on

the surface of the chylomicron could promote hydrolysis by stabilizing
triglyceride emulsions.

The apo C proteins very likely modulate the

catabolism of triglyceride-rich chylomicrons through this cycling
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mechanism involving HDL.

The chylomicron particle that remains after

hydrolysis forms the remnant particle which is removed by the
(272).

liv~r

This observation is based on studies of the catabolism of

lipoproteins from hepatectomized rats.

Radiolabeled chylomicrons were

injected into these animals and remnant particles enriched with phospholipids and cholesteryl esters were isolated from plasma (273).
Cholesterol taken up by the liver is converted to bile and released
from the liver.

d. VLDL Catabolism
The degradation pathway of VLDL is similar to that of the chylomicrons.

It is believed that

c~ylomicrons

and VLDL share a common

catabolic pathway and their triglycerides are hydrolyzed at extrahepatic tissues by the same lipoprotein lipase system (267).

Labeling

studies with the apo C component of VLDL have shown that these apoproteins rapidly appear in HDL fractions after the addition of LPL (274).
In addition to the radioactivity found in the HDL fraction, transfer of
radioactively labeled proteins was observed in the 1.006-1.019 density
range and then in the low density lipoprotein range.

This would indi-

cate a precursor-product relationship between VLDL and LDL.

Eisenberg

et al. (275) demonstrated that lipolysis induces transfers of apo CII
and apo CIII from VLDL to HDL.

This transfer was proportional to the

extent of triglyceride hydrolysis and similar for the two apoproteins.
Their results suggested that there is no preferential removal of CII or
CIII from VLDL particles.

The redistribution of apo C between VLDL and

HDL during lipolysis may be caused by deletion of core VLDL consti-
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tuents, surface VLDL constituents and changes in mass ratios between
the two lipoprotein classes.

Glangeaud et al. (276} demonstrated that

the presence of HDL is not always an obligatory requirement for the
lipolysis of VLDL to occur.

Their observations showed that in the ab-

sence of albumin or serum, extremely minimal lipolysis occurred and apo

c was

not released.

However, with albumin present, lipolysis occurred

with release of apo C protein.

c,

HDL, though it acted as a pool for apo

was not necessary for lipolysis, and in the absence of HDL the apo C

proteins were isolated in several density regions with different lipid
composition.

Eisenberg (277) had demonstrated this same phenomenon

when he found that surplus surface constituents, phospholipids, apo C,
and cholesterol were freed from the VLDL to form a surface fragment
particle.

In a system devoid of plasma or lipoprotein, he observed a

decrease in the VLDL surface area that was independent of any acceptor
protein.

The remaining VLDL remnants had the same chemical and physical

properties as those which underwent lipolysis.
During the catabolism of VLDL, the loss of surface components converts the lipoprotein into a progressively smaller particle designated
as the intermediate density lipoprotein.

VLDL remnants are taken up

more rapidly than larger VLDL particles by cells in culture (278).

This

partial hydrolysis of the triglyceride-rich lipoprotein appears to be
necessary for efficient cellular uptake.

The LDL receptor recognizes

two apoproteins, apo B and apo E, both of which are contained in the
VLDL remnant (279).

The enhanced reactivity of remnants with cells may

be due to several factors:

1) As larger lipoproteins are converted to

smaller remnants, steric hindrance to their interaction with receptors
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is reduced.

2) The selective retention of apo B and apo E could con-

centrate apo B and E over lipoprotein surfaces.

3) The conformations

of the binding sites of apoproteins could be altered as the surface
area of the lipoprotein is reduced.

Binding sites could also be un-

masked as a consequence of lipid and protein removal (280), a possibility recently investigated by Shelburne and Windler (281-282).

They

studied the effect of different apo C proteins on liver removal of triglyceride emulsions incubated with apo E and found that emulsions containing both CI and CII proteins did not effect the increased hepatic
uptake of either the synthetic emulsion or chylomicron produced apo E
remnants.

However, the CIII protein had a pronounced inhibitory effect

on hepatic uptake which could
sialation.

b~

influenced by the state of apoprotein

It is possible that this glycoprotein is similar to other

sialated glycoproteins that demonstrate a negative correlation between
neuramminic acid content and hepatic receptor affinity (283).

The ob-

servation that at least two apoproteins control hepatic uptake provides
a mechanism for denying the lipoproteins hepatic access until the appropriate peripheral metabolism has occurred.

If CIII were not present,

an ineffectual recycling to the liver might result.
The second step in VLDL metabolism is remnant or intermediate uptake by the parenchymal liver cells (284).

Formation of low density

lipoproteins has been postulated to follow the uptake of IDL by the
liver with a subsequent release of apo B-cholesterol ester-rich
particles.

Man, who has the highest LDL concentration, is the only

species in which almost all VLDL apo B is recovered in LDL (285).
Deckelbaum et al. 286) have shown that in humans, a direct conversion
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of VLDL to LDL can occur solely by the action of extrahepatic lipase.
These particles have many features in common, but are not identical to
normally formed plasma LDL.

This pathway could function as a major

non-hepatic VLDL catabolic route.

Recently, data from the labs of

Janus and Nicoll (287) have demonstrated that in some patients, not all
VLDL is converted to LDL, but that some lipoprotein is degraded directly.

In normal controls, VLDL-B derived LDL-B production was found to

be virtually identical, suggesting that all LDL-B is produced from VLDL.
However, in hyperlipemic individuals, the mean conversion of VLDL to
LDL was only 45 percent, suggesting a direct catabolism of VLDL not
previously observed (287).

Since IDL has been shown to be as potent as

LDL in suppressing receptor mediated HMG CoA, it is not unreasonable to
assume that binding and degradation of IDL to cells might form an integral part of this observed effect (288) (Figure 1).

e. Lipoprotein Lipase
A description of the catabolic events that occur when chylomicrons
or VLDL are broken down would be incomplete without and understanding of
the lipoprotein lipase (LPL) enzyme system.

Recent studies have shown

that the lipase activity released by heparin is actually a combination
of lipoprotein lipase, extra-hepatic triglyceride lipase, hepatic triglyceride lipase, monoglyceride hydrolases, and phospholipases (265).
There are at least two triglyceride lipases related to post-heparin
lipolytic activity which differ in substrate specificity and other
physiochemical properties (265).

Lipoprotein lipase (LPL) has a pH

optimum of 8.0, requires a serum cofactor, and is inhibited by prota-
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mine sulfate.

The lipoprotein lipase component of post heparin lipase

activity (PHLA) is a composite of enzymes from adipose tissue, skeletal
muscle, heart, mammary gland, lungs, and aorta (266).

These enzymes

are assumed to be on the capillary surface since their release occurs
almost immediately following heparin infusion.
In 1955, Korn and Quigley (267) described a serum factor which
activated lipoprotein lipase.

This protein activator, found in VLDL

and chylomicrons is CII (212-218).

Recent studies have shown that apo

CII is the major cofactor in human serum for adipose tissue, skeletal
muscle, and purified plasma LPL.

Apo CII stimulates product formation

and has been found to increase the catalytic rate of LPL.
Matsuoka (268) have found that

~here

Jackson and

is a direct relationship between

the amount of lipoprotein lipase bound to VLDL or chylomicrons, and the
amount of apo CII present. By adding I 125 lipoprotein lipase and HDL
to VLDL they were able to show that as apo CII was transferred to HDL
the amount of lipase bound to VLDL diminished proportionately.
apoproteins activate lipoprotein lipase.

Other

Ekman and Krauss (269-270)

demonstrated that apo AII activated LPL but apo E, apo CI, apo AI, and
apo CIII inhibited LPL.

These investigators hypothesized that inhibi-

tion of the lipolytic processes by high concentrations of these apeproteins in certain disease states may be a contributory factor in the
development of hypertriglyceridemia since the proteins decrease substrate availability to the enzyme active site.
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VLOL-LOL

~THWAYS

Figure 1: Schematic ~epresentation of VLDL-LDL catabolic pathways.

The

VLDL produced in the liver is partially catabolized in the
periphery at the lipoprotein lipase site releasing triglyceride and FFA into the blood and adipocytes.

Apo C protein

is also lost from the VLDL and is scavenged in the plasma by
circulating HDL which acts as a pool for apo C.

After loss

of the apo C, partial surface destabilization of the VLDL, now
called a remnant, occurs.
liver.

These remnants are returned to the

Apoprotein E found on the surface of the remnant is a

recognition marker for the liver cell receptor which binds the
remnant and removes it from the circulation.

The remaining

triglyceride is released to the hepatocyte and a molecule rich
in cholesterol and containing primarily apoprotein B is released into the plasma pool.
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f. LDL-Synthesis and Catabolism
Synthesis of LDL presumably occurs after hepatic lipolysis of
remnant VLDL.

Direct synthesis may also occur in the liver.

As the

size of the VLDL particle diminishes, it becomes an intermediate density lipoprotein.

Excess surface material, mostly phospholipid and

cholesterol, are transferred to HDL.

HDL particles interact with LCAT,

(lecithin cholesterol acyltransferase) which esterifies the excess
cholesterol with fatty acids from the 2-position of lecithin.

The

synthesized cholesteryl ester is transferred back to IDL, apparently
through apo D.

The IDL is then absorbed in the liver sinusoids where

most of the remaining triglyceride is lost and a pure LDL is released
into the circulation.
In humans, LDL is the principal lipoprotein carrier for cholesterol.

Approximately three-fourths of the cholesterol is esterified

and half of the cholesterol esters contain oleic acid.

Low density

lipoprotein receptors were first discovered by Goldstein (289) using
cultured human fibroblasts.

The initial event in cellular LDL metabo-

lism involves the binding of LDL to this receptor.

This binding ex-

hibits saturation kinetics, high affinity and specificity.

In addition,

the process is stimulated by the presence of calcium and severely inhibited by pronase.

LDL binding involves ionic interaction between the

protein component and the surface receptor which appears to be a glycoprotein (290-291).

In order to achieve the physiological effect, the

LDL that is bound to the receptor enters the cells by endocytosis.

A

low affinity uptake can also occur and may represent a non-specific
endocytosis since uptake is proportional to the lipoprotein concentra-
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tion in the system, is not affected by pronase, and shows no apparent
saturation (291).

The degradative process appears to be similar re-

gardless if the LDL is bound to a specific high affinity receptor or
low affinity receptor (291).

Goldstein (289} hypothesized that LDL is

catabolized through the formation of endocytic vesicles called endosomes, which fuse intracellularly with lysosomes.

The protein compo-

nent of LDL is then catabolized to amino acids and the cholesteryl
ester component of LDL is hydrolyzed by a lysosomal acid lipase.

Intra-

cellular accumulation of unesterified cholesterol regulates the activities of two microsomal enzymes.

A reduction in cholesterol synthesis

results from modulation of HMG CoA reductase (3-hydroxy-e-methylglutaryl
coenzyme A reductase) and an increase in cholesterol esterification results from activation of acyl CoA:

cholesteryl acyltransferase (292).

The net effect of the LDL receptor-mediated process is to transfer free
and esterified cholesterol from LDL to the cell altering the fatty acid
composition of cholesteryl esters from polyunsaturated to a more saturated form (293).
The activity of the LDL receptor is regulated by a feedback mechanism.

Brown et al. (290) observed that incubation of fibroblast mono-

layers with LDL progressively reduces the ability of the cells to bind
125
labeled LDL due to a reduction in the number of receptors synthe1
sized (290).

More than 90 percent of the cholesterol produced in the

body comes from the liver or the intestine, even though all non-hepatic
tissues need cholesterol and possess the enzymatic capacity to synthesize it (294}.

Brown (295) proposed that cholesterol synthesis is

suppressed, in vivo, in non-hepatic tissues because these tissues pre-
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ferentially take up and utilize LDL cholesterol through the LDL high
affinity receptor.
Human fibroblasts produce a maximum of 20,000-50,000 receptors
per cell.

Brown (296) characterized the receptor which requires a

divalent cation (either calcium or manganese), is sensitive to different proteases, but resistant to glycosidases.

The receptor recognizes

both apo B and apo E, but not AI or Ali apoproteins.

The receptor is

extremely efficient with high amounts of LDL internalization occurring within 15 minutes due to receptors located in coated pits (297}.
These represent specialized regions of the cell surface that are indented and coated on the cytoplasmic surface with a fuzzy surface
material.

The coated pits take; up only two percent of the cells sur-

face but contain 50 to 80 percent of the receptors.

Pearse (298) ob-

served that the fuzzy coat is composed of a protein of 180,000 MW called clathrin.

The LDL receptor is synthesized in membrane bound poly-

ribosomes, glycosylated in the Golgi apparatus and inserted into the
plasma membrane at random sites (296}.
the receptor has two active sites (296).

The genetic data suggests that
One, the binding site for LDL,

must be on the external membrane surface, and the second, the internalization site, allows the receptor to be recognized as a component of
the coated pits.

Receptors that contain a functional internalization

site migrate laterally and cluster in the coated pits.

Brown (296)

postulated that this clustering occurs as a result of the specific
interaction of the internalization site of the receptor with the coat
protein clathrin.

The receptors escape destruction as LDL endosomes

attach to the liposomes and are likely recycled to the cell surface
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where they again cluster in the coated pit regions (299).
several lines of evidence indicate that the hepatic uptake of
chylomicron and VLDL remnants is mediated by a receptor that resembles
the extrahepatic LDL receptor and recognizes apo E (300).

Both re-

ceptors promote the uptake of lipoproteins by endocytosis, are subject to metabolic regulation and bind apo E-containing lipoproteins
with higher affinity than LDL (300).

But extrahepatic receptors take

up LDL, in vivo, whereas hepatic receptors take up chylomicron remnants.

This may stem from the large size of the remnant particles as

compared to LDL.

Remnants can cross the endothelium of extrahepatic

tissues slowly, if at all.

The rapid hepatic uptake of remnants im-

plies that these particles eros? the endothelium that lines the hepatic
sinusoids either by bulk flow through the fenestrated sinusoidal epio

thelium, which permits passage of particles up to lOOOA in diameter or
by a specific transendothelial transport (301).
Kovanen and Bilheimer (302) have recently discovered that the
liver can also manufacture LDL receptors in response to pharmacological
interventions with colestipol (a bile acid sequestrant) and mevinolin
(a cholesterol synthesis inhibitor).

Colestipol is a bile acid-binding

resin that produces an increased requirement for cholesterol for conversion to bile salts.

Mevinolin is a specific inhibitor of 3 HMG CoA

reductase, the rate limiting enzyme in cholesterol synthesis.

These

two drugs can act synergistically raising the hepatic demand for
cholesterol.

These investigators observed that membranes prepared from

livers of normal animals treated with this drug combination showed an
increase in the number of lipoprotein binding sites.

The resulting
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combination of decreased cholesterol synthesis and increased cholesterol removal led to a 70 percent drop in plasma LDL levels.

This

study raises the possibility that mevinolin and colestipol may have a
useful effect in lowering human plasma LDL-cholesterol levels therapeutically {303).
Chait and Bierman (304) have also discovered that insulin, which
stimulates cholesterol synthesis by enhancing HMG CoA reductase activity, also enhances the degradation of LDL by increasing LDL receptors.
This could have the effect of depositing cholesterol in cells that are
actively synthesizing this compound causing an overabundance and accumulation of cholesterol in these cells.
Another route of removal of LDL from the plasma is by the action
of macrophages and other scavenger cells (305-306).

These cells become

so swollen with cholesterol droplets that they are called foam cells.
The mechanism by which the macrophages take up LDL differs in three important respects from the high affinity receptor system (86).

These are

1) the cellular antigens that activate each pathway; 2) the specificity
of the surface binding sites; and 3) the fate of cholesterol liberated
from the degradated lipoprotein.

The macrophages internalize only

modified lipoproteins and possess at least 3 binding sites for these
proteins.

The first is an acetyl LDL binding site which recognizes an

epsilon amino group of lysine that is acetylated on the surface of the
LDL.

Other receptors recognize and incorporate maleylated LDL and

malondialdehyde LDL into the macrophage (86).
The cholesterol liberated from cellular receptor-mediated uptake
of LDL regulates receptor concentration and de novo cellular synthesis
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of cholesterol so that overaccumulation will not occur.
phage scavenger pathway shows no such regulation.

The macro-

About half the

cholesterol that enters the macrophage through this pathway is excreted in the presence of a substance capable of binding the cholesterol.

Red blood cells, albumin, and in particular, HDL are effec-

. tive in this process.

The other half is re-esterified and stored as

cholesteryl ester droplets which can result in excessive accumulation.

g. HDL Synthesis and Catabolism
HDL precursors appear to originate from two sources: direct
secretion by the liver or intestine of discoidal HDL into plasma or
lymph; and from the surface components of VLDL and chylomicrons.
Studies in the rat have shown that discoidal HDL is produced in perfused rat liver and the small intestine (307-308).
During the transformation of chylomicrons and VLDL to their remnant form, triglyceride, soluble apoproteins (A and C), and phospholipids are rapidly transferred to the HDL fractions.

In man, 90 per-

cent of labeled apo A peptides from chylomicrons and VLDL are found
localized in HDL one hour after intravenous injection (309).

The action

of lipoprotein lipase on VLDL and chylomicrons has been documented.
The shrinkage of the lipid core probably causes a redundance of the
polar surface constituents.

The increase in lateral pressure on the

surface causes the monolayer to fold into bilayers that protrude from
the cell surface.

Some of the bilayers may be dissolved as discoidal

micelles in association with the detergent A or C apoproteins present
on the VLDL surface.

Since there are not enough A or C apoproteins to
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convert all the bilayers to discs, most of the fragments probably
leave the surface as larger sheets that can seal into phospholipid
vesicles (310).

Subsequently, these vesicles are converted into

spherical HDL by their interaction with circulating HDL and LCAT.
Apo AI, released from the HDL pool, leads to the formation of soluble phospholipid apoprotein complexes (311).

During the trans-

formation of precursor particles into HDL, a large influx of cholesterol occurs.

The driving force for this influx is the relative de-

ficiency of cholesterol in the VLDL derived precursor of HDL which
results in a concentration gradient for the movement of cholesterol
into HDL.
Plasma HDL half-life
5.8 days (312-313).

valu~s

are reported to range from 3.3 to

HDL catabolism is enhanced in nephrotic patients

and in hypertriglyceridemic subjects, especially on high carbohydrate
diets (312-314).

Studies in animals indicate that the liver and

kidney lysosomes play an important role in HDL catabolism (315-316).
More recent research is consistent with the concept that extrahepatic
tissues may play a predominant role in HDL catabolism.

Normal human

fibroblasts have been shown to take up, internalize, and degrade HDL
in vitro (317).

Another possible mechanism for HDL catabolism was sug-

gested by Tall and Small (310).

Since apo AI is loosely integrated

into the HDL molecule, plasma HDL acts as a pool of AI for VLDL and
chylomicron formation.

As a consequence of HDL losing some of this apo

AI emulsifier, the spherical HDL particle becomes thermodynamically unstable and can fuse with another lipoprotein.

Since remnants are avidly

taken up by the liver, their fusion with unstable HDL could provide
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another route for HDL catabolism to the liver.

H. Role in Clinical Disorders
Increased plasma lipoprotein concentrations may be seen as either
a primary manifestation associated with a genetic defect or a secondary
hyperlipoproteinemia due to a primary disease state.
The classification of the hyperlipoproteinemias proposed by
Fredrickson and Lees (318) in 1964 is based on plasma concentrations
of the various lipoprotein types (Table 2).

In patients suspected of

having hyperlipoproteinemia, analysis of fasting triglycerides or
cholesterol usually gives a reasonable estimate of their lipoprotein
phenotype.

Type I is a

primar~

hyperchylomicronemia; this is followed

by Type V, which is mixed familial lipoproteinemia with elevated VLDL
and chylomicrons.

Types IIA and IIB usually show a predominant eleva-

tion in LDL with Type IIB indicating an increase in VLDL as well.

Type

III or broad beta disease dysbetalipoproteinemia is characterized by
VLDL and LDL lipoproteins which electrophoretically comigrate.

Finally,

Type IV hyperprebetalipoproteinemia is characterized by an elevation of
the VLDL lipoprotein.
Abetalipoproteinemia is an uncommon disease in which levels of apo
Bare either reduced or non-existent (319-320).

The patients appear

normal at birth, but at some time in infancy develop foul-smelling
diarrhea due to malabsorption of fat.

The defect involves a critical

factor in the synthesis or secretion of the lipoproteins that contain
apo B.

Thus, undetectable levels of chylomicrons, LDL, and VLDL are

usually observed in this disease.

Table, S,
Chylomicron&
Type I

Disorders of Lipoprotein tletabolism Characterized by Elevations in Lipoprotein Classes

Chylomicron&
Type V

+

VLDL

VLDL
Type IV

VLDL + LDL
Type lib

LDL
Type IIa

ApoE2 homozygosity

Familial hypercholesterolemia
( LDL receptor
abnormalities)

Familial hypercholesterolemia
(LDL receptor
abnormalities)

ApoE deficiency,.

LCAT deficiency

Betas itoaterolemia

ApoE1
phenotype

Familial combined hyperlipi4emia

Familial combined hyperlipidemia

VLDL
Type Ill

IIDL

Increased Levels
Lipoprotein
lipase
deficiency

Faailial
hypertriglyceridemia
(severe)

Familial
hypertriglyceridemia

ApoC-II
deficiency
Familial combined hyperlipidemia

Familial combined hyperlipidemia '

llyperalpha1 ipoproteinem ia

I

ApoE4 variant
combined ApoC-II
and i.'ipoprotein
Lipase Deficiency

Hepatic lipase
deficiency

llypcrapobctalipoproteinem ia

Table 2: Description of Fredrickson's Classifications of Hyperlipemia.

The disease stages

17'

~

and primary cause of the elevat~d plasma lipid are represented.
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Familial dysbetalipoproteinemia or broad beta disease is
characterized by the accumulation, in the density range of VLDL and
LDL, of an unusual class of lipoproteins with reduced electrophoretic
mobility relative to normal lipoprotein groups.

Chemical studies show

that this B-VLDL differs from normal VLDL in having more cholesterol
esters and fewer triglycerides in their core (219-223}.

Studies have

shown that the particles have a disproportionate amount of apo E with a
missing or altered apo EIII (223, 227-228}.

Schneider et al. {321}

demonstrated that apo E isolated from the plasma of these patients is
markedly defective in binding to LDL receptors.
It is believed the VLDL from dysbetalipoproteinemic individuals
is normally metabolized in the ;periphery by extrahepatic lipoprotein
lipase.

The lipoproteins lose triglyceride and apo C with remnant-like

particles remaining, containing more apo E and apo B, that are not
cleared by the liver because of the mutant apo EIII.

Thus an elevated

concentration of VLDL is present in the plasma pool of these patients.
Familial hypercholesterolemia is one of the best defined clinical
disorders of lipoprotein metabolism.

The disorder is characterized by

elevated concentrations of LDL-cholesterol and deposition of cholesterol
in specific sites to form subcutaneous lipid deposits called xanthomas
(322}.

The disease is inherited as an autosomal dominant and is ex-

pressed phenotypically as a deficiency in the LDL receptor that regulates the uptake and degradation of LDL (323).

The mean total choles-

terol in these affected individuals is twice normal.

Although the con-

centration of LDL is increased in the plasma of patients with familial
hypercholesterolemia, the lipoprotein is of essentially normal campo-
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sition and structure (324).
The primary hypertriglyceridemias are manifested in two forms,
familial endogenous hypertriglyceridemia and familial multiple lipoprotein-type hyperlipidemia.

Familial endogenous hypertriglyceridemia

is a disorder inherited as an autosomal dominant in which heterzygotes
manifest an isolated elevation in plasma VLDL (325-326).

In addition

to hypertriglyceridemia, the affected individuals have one or more of
the following metabolic disturbances:

adult obesity, insulin resis-

tance coupled with fasting hyperinsulinemia, glucose intolerance and
hypertension (326).

Most patients demonstrate an elevated VLDL con-

centration in excess of 1000 mg/dl with larger particles of chylomicron-like characteristics

obs~rved.

These patients are carbohydrate

sensitive and will develop fasting chylomicronemia by increasing carbohydrate intake (327).
Familial multiple lipoprotein-type hyperlipidemia (familial combined hyperlipidemia) has been recently studied.

In affected indivi-

duals, elevations in VLDL, LDL or both, could occur, making diagnosis
of the disease difficult.

Patients with familial multiple lipoprotein-

type hyperlipemia exhibit elevated LDL, but this disorder is genetically
distinct from endogenous familial hypercholesterolemia and hypertriglyceridemia.

First, the plasma lipid level, while significantly in-

creased, tends to be lower than in other disorders (326, 328).
the pattern of lipid abnormalities is unique.

Second,

About one-third of the

affected relatives have isolated hypercholesterolemia, about one-third
have hypertriglyceridemia and one-third have both.

Third, in contrast

to the findings of familial hypercholesterolemia, plasma cholesterol
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concentrations in children with the combined disease are normal (326).
In patients with primary endogenous hypertriglyceridemia, VLDL are
larger, contain more core triglycerides and cholesteryl esters and
fewer surface components.

Particles of comparable size from multiple

lipoprotein type hypertriglyceridemic individuals usually contain
more cholesterol esters and fewer triglycerides in the lipoprotein
core (331).

VLDL size is a combined function of synthetic, secretory

and catabolic rates (330).

The differences in VLDL between the two

groups may reflect a longer plasma half-life of these lipoproteins
and a greater transfer of cholesteryl ester to VLDL from HDL in the
patients with mixed hyperlipoproteinemia.
also tend to have more apo CI

t~an

VLDL from these patients

apo CII protein (155).

There are numerous secondary disorders of lipid transport, but
the major category in which some of the selected patients for this
dissertation study can be grouped, is diabetic hyperlipemia associated
with insulin resistance.

As the key anabolic hormone, insulin has a

major role in the transport and utilization of fatty acids and glucose.
All states of insulin deficiency and/or resistance are accompanied by
hyperlipemia, mainly involving triglyceride-rich lipoproteins.

Insulin

deficiency is commonly seen in type I (insulin dependent) diabetes,
whereas insulin resistance is normally found in type II (non-insulin
dependent) diabetes.

The pathogenesis of these forms of diabetes are

characterized by a deficiency in the action of insulin in peripheral
tissues causing a mobilization of fat from adipose tissue.

Although

much of the fat is utilized by the liver for energy, an appreciable
fraction is esterified to form triglycerides (332).

Initially, the
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increased production of triglyceride is accompanied by augmented VLDL
excretion.

After a few days however, a reduction of hepatic VLDL

secretion is observed along with a reduction in lipoprotein lipase
activity (333-334).

Fatty acids not taken up in the periphery are re-

cycled back to the liver, leading to a futile cycle in which the liver
eventually becomes engorged with fat.

Reports on VLDL transport in

poorly controlled diabetics suggest that FFA and VLDL secretions are
often increased along with ineffective VLDL catabolic mechanisms (335).
The abnormalities of lipid transport in obesity and diabetes may combine
to increase hepatic secretions of VLDL, reduce removal, or both.

Many

questions still remain unanswered regarding the effect of diet and carbohydrate intake on

triglycerid~

concentrations.

Low fat diets, which

are inherently high in carbohydrate, have been used effectively in the
management of diabetes.

However, these diets still remain to be evalu-

ated for their effects on diabetic hypertriglyceridemia.

I. INSULIN & GLUCAGON:

ROLE IN HYPERTRIGLYCERIDEMIA

a. Introduction
Mammals have developed elaborate homeostatic requisites in the
regulation of energy supply and consumption.

They must maintain blood

glucose levels within a very narrow range and have an optimal storage
level of glycogen for emergency fuel needs with the capability to convert any excess carbohydrate calories into fat.

Mammals also must main-

tain an optimal supply of protein for both enzyme production and structural development.

They must also have the ability to preferentially

use fat for energy during times of caloric need.

All of these meta-
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bolic guidelines are accomplished by the dynamic equilibrium of two
well-studied hormones, insulin and glucagon.
Insulin, with a molecular weight of 5734 daltons is manufactured
in the

cells of the islets of Langerhans in the pancreas.

Circulat-

ing insulin serves to coordinate fuel storage and fuel mobilization
· into and out of various depots according to the needs of the organism.
High insulin levels reflect a non-fasting state.

Insulin's main effects

occur in peripheral tissue where it exerts many metabolic effects on responsive cells, altering membrane characteristics such as glucose permeability, amino acid transport and potassium flux.

Insulin modulates

RNA, protein, and fat synthesis intracellularly and lowers cyclic AMP
levels in target tissues.

Insulin also inhibits lipolysis in adipose

tissue and probably proteolysis in muscle.

Its versatility is undoubt-

edly due to the initiation of second messengers, which in turn alter
enzymes involved in the aforementioned mechanisms.
Glucagon is an antagonist to insulin.

It is synthesized in the

alpha cells in the islets of the Langerhans of the pancreas and has a
molecular weight of 3485 daltons.

Constant availability of glucose for

the brain and other organs depends on glucagon mediated maintenance of
hepatic production of glucose at whatever rate is required to prevent
hypoglycemia.

In periods of starvation, glucagon stimulates the pro-

duction of ketones which substitute for glucose as cerebral fuel.
Such glucagon mediated catabolism (the production of fuels from the
macromolecules, glycogen, protein and fat) is modulated by the anticatabolic effect of insulin.

Both the rate and direction (anabolic vs.

catabolic) of fuel fluxes are therefore governed by the relative con-
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centrations of these two antagonistic hormones.

b. Role in Diabetic Hypertriglyceridemia
Since insulin plays a critical role in both the production of
triglyceride rich lipoproteins and their removal from plasma, it is
not surprising that alterations in insulin secretion can lead to hypertriglyceridemia.

At one extreme, severe insulin deficiency associated

with untreated symptomatic Type I insulin dependent diabetes mellitus,
leads to impairment of tissue lipoprotein lipase (LPL) activity and
consequently impaired clearing of circulating triglycerides (443).

The

insulin deficient state is also associated with accelerated mobilization of free fatty acids (FFA) from adipose tissue which adds to the
hyperlipemic condition (444}.
Endogenous hypertriglyceridemia can also occur when Type II noninsulin dependent diabetic patients ingest high carbohydrate diets.
This hypertriglyceridemia is proportional to the postprandial hyperinsulinemia produced by the diet {445}.

The underlying abnormality in

most Type II diabetic patients with endogenous hypertriglyceridemia is
resistance to insulin mediated glucose uptake {446).

In an effort to

maintain glucose homeostasis these insulin resistant patients secrete
increased amounts of insulin.

The compensatory hyperinsulinemia in

turn acts upon the liver to accelerate hepatic triglyceride synthesis
and secretion resulting in elevated plasma triglyceride levels.

Thus,

the central role in the control of triglyceride metabolism may be insulin concentration.

Evidence that insulin can directly promote

hepatic VLDL-TG production was observed by Salans et al. {447) who
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demonstrated in liver slices that insulin increases incorporation of
14
carbon atoms from C-glucose into hepatic total lipid and trigly~
ceride.

Using perfused liver slices, Letarte and Fraser (448) showed
insulin promotes the incorporation of 14 C-glucose into fatty acid

moieties of hepatic lipid and increases their subsequent release into
the media.

Other in vitro studies show considerable evidence that

hyperinsulinemia in the diabetic could influence VLDL-TG levels by
promoting hepatic TG synthesis and secretion (449-450).
Glucagon is closely linked with insulin secretion, not only because of its antagonistic properties, but because the alpha cell
belongs to a family of sensitive cells in which insulin is necessary for
permitting glucose entry into
glucagon release.

t~e

cell resulting in inhibition of

The hypersuppressibility of plasma glucagon after

oral glucose, reported by Hatfield (451) in hyperinsulinemic patients,
contrasted against the lack of suppressibility of the lean insulin deficient diabetic subject supports the concept that insulin, when
present, may permit glucose to inhibit glucagon secretion.

In type II

diabetics with hypertriglyceridemia, abnormalities in glucagon secretion exist despite the persistence of insulin.

In these patients, a

hyper-response to arginine or protein infusion accompanied by decreased suppressibility by glucose are two of the major malfunctions
(452).

A possible reduction in the sensitivity of

could be possible.

cells to insulin

Glucagon dysfunction is most probably linked ex-

clusively to the hyperinsulinemia caused by insulin resistance in
these patients which seems to be the leading causative factors in
hypertriglyceridemia.
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J. THE PLATELET
a.-..I!.!.nt: :r. .:o. .:d.: . uc.: . t.: . i;. .:o_n
Platelets are approximately two

~m

in diameter and normally

number 200,000 to 400,000 per cubic millimeter of human blood.

They

are produced in the megakaryocytes of bone marrow by the coalescence
of cytoplasmic membranes formed by invaginations of the megakaryocyte surface (339).

Under normal circumstances, platelets circulate

in the blood for ten days as smooth, disc-shaped cells that are nonadherent to each other and to vascular endothelium.

When the endo-

thelium is ruptured, platelets can adhere to a variety of substances
such as collagen, basement membranes and microfibrils associated with
elastin.

Adhesion initiates a process during which substances found

in platelet secretory granules such as adenosine diphosphate are extruded (340-342).

The term primary or first phase aggregation refers

to the direct aggregation of platelets by exogenous ADP and other substances such as epinephrine, serotonin, thrombin and ristocetin.
Aggregation mediated through the release of endogenous ADP from platelets is sometimes referred to as second phase aggregation.

b. Structural Properties
The platelet is found to have a trilaminar plasma membrane
similar to that of other cells covered with an amorphous coat 100o

200A thick (339).

Many of the plasma proteins that are absorbed to

the platelet surface (for example, fibrinogen and IgM) are probably
located within this amorphous coat.

Platelet specific proteins appear

to be arranged asymmetrically within the membrane with only a few of
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the membrane glycoproteins exposed extracellularly (343).

The plate-

let surface contains adenyl cyclase and various glycosyl transferases
which may influence adhesion and aggregation (344,345).

Another dis-

tinguishing feature of the platelet membrane is its invagination at
many points to form a network of channels that burrow through the
platelet cytoplasm.

This system enlarges the surface area of the

platelets, serves in the uptake of plasma-borne substances and allows
for the extrusion of granule-bound secretory products during the release reaction.
Two types of granules have been identified in platelets.

The

major form is the alpha granule which is of moderate electron density
and contains enzymes such as aci9 hydrolases and cathepsins characteristically associated with liposomes (346).

The second type of granule

is found to contain calcium, serotonin, ATP and ADP complexed in high
molecular weight aggregates (347, 348).
Platelets also contain a circumferential band of hollow, cylindrical structures similar in appearance to microtubules observed in
many other cells (349).

The walls of these microtubules contain protoo

filaments approximately 35A in diameter and are composed of tubulin
(350, 352).

White (351) has suggested the theory that microtubules

provide a cytoskeleton which orients contractile activity in the
platelet.

c. Role in Coagulation
Platelets can adhere to a variety of substances present in the
vessel wall and in the perivascular tissue (354).

Injury to the endo-
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thelial cells causes the exposure of subendothelial tissues such as
collagen and basement membrane to platelets.

Platelets adhere to

collagen, become degranulated, and recruit other platelets to form a
superimposed platelet thrombus.

Basement membrane and non-collagenous

substances appear to be much less effective than collagen in inducing
platelet release reactions or platelet aggregation (355).

These obser-

vations suggest that collagen is the most platelet-reactive material
present in the vessel wall and that the adhesion of platelets to
collagen may be a critically important step to arrest bleeding (356).
Once adhesion has occurred, release of ADP and thromboxane triggers the formation of platelet aggregates.

The release reaction is the

secretory process whereby substances are packaged and extruded from the
cell.

Studies by Nachman and Ferris (360) suggest that ADP may bind a

specific receptor on the platelet membrane.

Present evidence suggests

that the binding protein may be related to actomyosin and the surface
actomyosin may mediate ADP-induced aggregation.

In addition to ADP,

substances released from platelets include serotonin, a product that can
neutralize heparin, acid hydrolases, and other factors that modify vascular permeability (349, 362).
When platelets are stimulated by release inducers, arachidonic
acid, probably made available by hydrolysis of membrane phospholipids,
is converted by cycle-oxygenase to a labile cyclic endoperoxide that
is a precursor of prostaglandin E2 and F a (364). The endoper2
oxide can directly induce the release reaction resulting in second
Phase aggregation (365).
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d. The Platelet and Diabetes
Many reports have emphasized the abnormalities in platelet adhesion and aggregation that occur in patients with diabetes mellitus
(88-91, 374, 375, 380).

An increased tendency for thrombosis and a

higher incidence of occlusive vascular disease in patients with diabetes mellitus is generally recognized.

Abnormal factors in diabetic

plasma could alter the platelet response and cause hyperaggregation
(Figure 2).

Kwaan et al. (376) discovered that normal platelet-rich

plasma, mixed with small amounts of diabetic platelet poor plasma, resulted in normal platelets aggregating as if they were from diabetic
subjects.

Colwell (93) postulated that von Willebrand's factor may be

the cause of the increased

aggr~gation.

He also found increased levels

of cyclo-oxygenase which converts arachidonic acid to prostaglandin E2
and suggested the increased activity of the enzyme plus excess arachidonic acid could cause platelet hypersensitivity.

Halushka (374) found

that prostaglandin endoperoxidases and one of their byproducts, thromboxane A2 could be responsible for initiating the platelet release reaction as well as aggregation. He observed that platelets obtained
from diabetic subjects synthesized much greater amounts of PGE-like
material than those of control subjects when (luM) ADP was given
~·

~

Increased PGE synthesis seen in diabetic platelet-rich plasma

may reflect increased activity of the prostaglandin synthetase system.
It has been demonstrated that impaired glucose or insulin metabolism could lead to an increased activity of the prostaglandin synthetase system.

Tannebaum (378) demonstrated that increased glucose
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concentrations and blood osmolality can increase malondialdehyde formation, a product related to the thromboxane pathway.

Recently,

Halushka (379) found that platelets from diabetic subjects synthesize
much greater amounts of thromboxane A2 and that malondialdehyde was
formed in equimolar quantities with thromboxane A2. He also found
that hyperglycemia may be associated with enhanced platelet aggregation and thromboxane A2 synthesis.
e. Hyperlipemia and the Platelet
The effect of long chain saturated fatty acids on platelet aggregation was studied by Haslam in 1964 (381).

He found that palmitate,

stearate, arachidate, beherate,. and ligrocerate at a concentration of
0.1mM caused rapid platelet aggregation in the presence of 1.1mM calcium
chloride.

Haslam believed that fatty acids functioned by releasing ADP

through direct damage to the plasma membrane or by activation of an absorbed protease (381).

Previous investigations had shown that injec-

tion of unbound long chain fatty acids in dogs was followed by generalized thrombosis and death (382, 383).

Since most fatty acids travel

in the plasma either bound to lipoproteins or to albumins, Hack et al.
(384) evaluated the effect of albumin-bound fatty acids on thrombus
formation and found the platelet aggregation and thrombus was increased,
but the hypercoagulability was not as great as with unbound fatty acid
injection.

In a later paper, the same group went one step further and

stated that thrombus does not result from the effect of bound fatty
acids until the concentration is such that the two tight binding sites
on albumin are no longer available (385).

If fatty acid levels climb
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Figure 2: Graphical representation of platelet aggregation response to
different aggregating agents.
patients are represented.

Both normal and diabetic

These curves were generated from a

chronolog platelet aggregometer, Model #330.

Note the second

phase response of the diabetic platelet is more exaggerated
than the normal platelet response.
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above a threshold value of 1150 to 1200 u Eq/liter, as can be found in
certain disease states, than the unbound fatty acids could cause thrombogenic complications.

Renaud et al. (386) studied the effects of

different types of fat on platelet aggregation.

Butter and stearic acid

are highly thrombogenic, but corn oil and linoleic acid appear to inhibit the potentially thrombogenic effect of cholesterol and butter.
Oleic acid, despite its effect on inducing hypercholesterolemia, did
not induce hypercoaguability or increased susceptibility of platelets
to aggregation.
Dietary manipulations and their effects on platelet aggregation
have been investigated {387).
was much greater in

Thrombin-induced platelet aggregation

platelet-ri~h

plasma (PRP) prepared from blood

taken from rats fed stearic acid than the (PRP) from rats fed oleic
acid.

This study was the first to clearly demonstrate alterations in

platelet function related to dietary fat.

Evidence that dietary sat-

urated fat produces changes in platelet function suggests alterations
of the fatty acids in platelet membranes may be involved.

Similar

studies were conducted in humans with comparable results indicating decreased aggregatability of platelets in subjects receiving diets low in
saturated fat as compared to those who consumed diets high in such fat
levels (94).
Shattil and Cooper (388) studied platelet membrane microviscosity with the fluorescent probe, 1, 6 diphenyl, 1, 3, 5-hexatriene
(DPH) under conditions where the platelet membrane had larger amounts
of cholesterol and fat (in patients with type IIB hyperlipidemia).
Platelets with high membrane cholesterol showed increased microvis-
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cosity over platelets that had low membrane cholesterol.

Cholesterol

decreases molecular motion of the hydrocarbon chains within the hydrophobic core of the lipid bilayer and increases the degree of order in
the platelet membranes leading to increased membrane viscosity.

Thus,

changes in membrane viscosity could be assumed to cause increased
platelet aggregation.
Since platelets acquire cholesterol by an exchange or fusion
fashion, the lipoproteins that carry fat and cholesterol are thought
to be important in membrane changes observed in the platelet.
Farbiszewski et al. (389) investigated the effect of alpha, beta and
chylomicron lipoproteins on platelet aggregation, finding that LDL had
a distinct effect on platelet aphesiveness.

Chylomicrons also affect

platelet aggregation, but only at elevated levels.

It seems the

lipoprotein interacts with certain receptor sites on the platelet surface.

This was demonstrated in experiments in which lipoproteins

altered platelet electrophoretic mobility (98).

Platelets may incor-

porate total low density lipoproteins or components into their membranes altering surface characteristics when they circulate for long
periods of time in hypercholesterolemic plasma.

Shattil (390) demon-

strated this exact phenomenon in platelets from type IIA individuals,
in which he found an increase in the C/PL ratio caused by cholesterol
enrichment of the membrane.

A good correlation was found to exist

between the magnitude of free cholesterol in the platelet membrane
and the amount of LDL in the plasma.

Receptors for LDL were isolated

from platelets quite recently by Aviram (391).

The LDL interaction

with platelets is similar to the LDL interaction with fibroblasts.
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Using chemical modification, Aviram et al. (392) concluded that
arginine and lysine, but not tyrosine and histidine, are

importan~

amino acids for the binding of LDL to platelets.
An interesting observation on the effect of increased cholesterol and lipid incorporation into the membrane of platelets was reported by Sinha and Shattil (398).

They investigated the membrane

enzyme adenyl cyclase and the production of CAMP in normal platelets
and those of hypercholesterolemic individuals.

Since CAMP is a potent

inhibitor of platelet aggregation, a decrease in CAMP concentration
would cause increased platelet aggregation.

These studies demonstrated

that increased membrane cholesterol in platelets is associated with decreased stimulation of adenyl c,yclase and decreased amounts of CAMP.
These investigators concluded that phospholipids were found to be involved in adenyl cyclase activity and therefore cholesterol might inhibit the phospholipid-adenyl cyclase interaction by competing directly with the enzyme.

Alternatively, cholesterol could restrict phospho-

lipid mobility and impair transmembrane events necessary for stimulation of the enzyme (398).

Finally, Zahavi et al. (99) demonstrated en-

hanced in vivo platelet release reactions and MDA formation in patients
with hyperlipemia.

The mechanism of the enhanced release reaction and

MDA formation could be related to the elevated serum lipids observed.

3.

PROPOSED INVESTIGATION AND SPECIFIC OBJECTIVES

The relevance of diet in the production of metabolic disease
states such as hyperlipemia and atherosclerosis is of prime importance
in the diabetic population.

Knowledge of the specific effects of the

disaccharide sucrose on lipid production is contradictory, if not absent
in many respects.

Therefore, investigations must be undertaken to

determine the effects of sucrose on lipid production in diabetic
patients prone to hypertriglyceridemia.

Since many studies used normals

or hyperlipemic individuals who were obese, the patient population must
be well defined as diabetic with specific attention given to the
metabolic state of the individual upon entry into the study.

In

addition, most reports dealing with the effects of sucrose on a given
population used artificial diets, either composed of liquid nutrients
or extremely high in carbohydrate proportion.

In this study, the diets

are composed of natural nutrients which more closely mimic the intake
pattern observed in these diabetic individuals.
The experimental work will involve the characterization of the
specific effects of sucrose on blood lipid concentrations over an extended period of time.

This will include individual measurements of

these lipids, along with the hormones insulin and glucagon, which are
important in lipid production and catabolism.

Specific correlations

will be made as to the concentrations of both hormone and lipid as they
relate to each other during ingestion of the study diets.

To ascertain

the metabolic effect of high sucrose, high carbohydrate diets on diabetic homeostasis, blood glucose and urinary glucose output will also
be monitored during the entire study.
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In an effort to determine if dietary manipulation results in
hyperlipemia, due to increased lipid synthesis, a part of the study
will attempt to characterize the triglyceride production and removal
rates of these individuals.

The most commonly used technique, trigly-

ceride turnover, labels the endogenous pool of triglyceride with radio. active precursor (either labeled glycerol or free fatty acids).

Assum-

ing that at equilibrium, synthesis equals removal, the rate of loss of
the label from the pool is used to calculate the synthetic rate of triglyceride.
Another line of approach will involve the assumption that high
sucrose, high carbohydrate diets could alter apoprotein composition of
VLDL in sensitive individuals
protein from the plasma pool.

a~d

thus affect the removal of the lipo-

Using SDS-polyacrylamide gel electro-

phoresis and isoelectric focusing, I hope to separate the different
apoproteins that comprise the VLDL and determine if changes occur in
these proteins when different diets are administered.

Total lipo-

protein electrophoresis will also be done in an attempt to monitor all
lipoprotein fractions and determine their changes in relation to VLDL.
It appears likely that hyperlipemia could be caused by a combination
of events in which increased synthesis could be coupled with decreased
peripheral removal.

The studies with apoproteins of VLDL will provide

the opportunity to compare their concentrations in relation to triglyceride levels over a long term ingestion of a study diet.

It is hoped

that some correlation will be found between individual apoproteins and
triglyceride concentrations.
In a parallel study, the relationship of sucrose ingestion to
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hyperlipemia will involve study of the effects of this diet on platelet aggregation.

Since sucrose may cause hyperlipemia, and consider-

ing it has been demonstrated that hyperlipemia causes increased platelet aggregation, a natural link is developed between sucrose consumption and platelet aggregation.

I hope to demonstrate changes in

· platelet aggregation during sucrose ingestion by using sensitivity
studies of platelets to different concentrations of aggregating agents.
The turbidometric method of platelet aggregation will be used to
measure platelet sensitivity.

The percent of primary and secondary

aggregation will be compared from control to study diets to determine
the change in platelet response to different amounts of sucrose consumption.
Finally, since three dietary levels of sucrose will be given to
the patients, I hope to ascertain the amount of dietary sucrose needed
to elicit these metabolic changes.

It could be possible that a critical

level of sucrose may have to be reached in order to metabolically alter
an individual's metabolism toward hyperlipemia.

Perhaps, low levels of

sucrose may be well tolerated by the patient population in question.
From these different studies, it is hoped that the objectives of
this work will gain some insight into the physiological complications
involved in the hyperlipemic response when different levels of sucrose
are ingested in these sensitive patients.

4. MATERIALS AND METHODS

A. Description of Patients Used in this Study
Patients for this study were recruited from in-patient subacute
and chronic care facilities, as well as outpatient clinics at Hines V.A.
Hospital, Hines, Illinois.

All observations and studies were done on

hospitalized patients in the Special Diagnostic and Therapeutic Unit
(SDTU) at Hines.

Informed consent was obtained from these patients

prior to their entry into the study.

Participation was strictly volun-

tary and patients were informed that they could withdraw from the study
at any time.

Subjects for this study were overt adult onset male dia-

betics, 30 to 70 years old, who did not require insulin or oral hypoglycemic agents and had fasting; hypertriglyceridemia (exceeding 1.5 g/L
or higher).

Patients with type V hyperlipemia of the Fredrickson•s

classification were excluded as well as those whose weight exceeded 20
percent of ideal body weight.

I. Patient Type
a. Description of Procedure to Evaluate Patients
Patients were incorporated into the study only if the previous
criteria were satisfied.

The patients were judged as diabetic by the

NIH criteria for the classification of diabetes, frankly overt hyperglycemia (394).

The patients selected for the study had to have per-

sistent fasting blood sugars of at least 140 mg/dl a minimum of 3 times
prior to admission.

These diabetics has to be insulin independent, not

ill and non-ketotic (type II diabetics).
84

The study patients had to be
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within 20 percent of normal body weight as classified by the method
developed by Abraira et al. (395). Ideal Body Weight (IBW) was determined by the following:

height (without shoes) 5 ft.

for each additional inch of height.
issued hospital clothing.

= 105

+ 5 lbs.

All patients were weighed in

Patients with complicating diagnoses that

could independently affect weight or diet (such as congestive heart
failure, cirrhosis of the liver, or renal insufficiency) were not admitted into the study. Finally, patients who were receiving any drugs
known to affect blood lipid levels (such as clofibrate, cholestyramine,
nicotinic acid, or glucose sulfonylureas) were not allowed in the study.
Before patients entered the study, blood samples were drawn for
triglycerides, blood glucose,

~lectrolytes,

zymes and total protein analysis.

BUN, creatinine, liver en-

Any patient with triglyceride levels

of less than 150 mg/dl at the initiation of the study was released. ·
Also, patients who had abnormal SMA-12 values, (excluding glucose) before the study began were dropped from the study if the values did not
return to normal after hospitalization.
Finally, a lipoprotein electrophoresis was done to determine the
patient•s hyperlipemic classification.

Fredrickson•s guidelines were

used indicating all of the patients to be type IV hyperlipemic individuals.

Type I and V individuals were dropped from the study because the

interest in this study was limited to VLDL 1 s and endogenously derived
tri glycerides.

b. Informed Consent
Written informed consent was obtained from patients prior to study
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initiation.

All procedures and protocols were explained to patients

before admission and patient compliance was monitored by the SDTU
technician and dietitian.

The study was sanctioned by the Research

committee at Hines V.A. Hospital.

Human studies approval at Hines and

IRB board approval at Foster G. McGaw Hospital have been obtained for
the project (along with the written consent).

The project has also

received approval by the Department of Nuclear Medicine at Hines, with
all Food and Drug Administration guidelines followed from the U.S.
Department of Health, Education and Welfare's report on 11 Clinical Testing for Safe and Effective Drugs 11 (296-297).

Participation was on a

voluntary basis with certain procedures exempted upon patients request.

c. Care of Patients
Subjects were followed under the usual inpatient clinical care
scheme and seen by medical residents spending a 3 month rotation on the
ward.

Each patient was seen by a clinical dietitian twice weekly and

instructed on compliance procedures for the study.

The residents re-

ported directly to Dr. M. Emanuele who was one of the physicians responsible for and in charge of patient care.

Any manipulations or drug

therapy prescribed for the patients were first assessed to determine
any potential effect on the planned experiments.
the study, all diabetic medication was halted.

When patients entered
The only medications

allowed were Tylenol or sleeping pills (Dalmane R.).

Though ambulatory,

the patients were restricted to the SDTU and only allowed occasional
off-ward activities.

Direct supervision of all patients and clinical

responsibility was assumed by Dr. C. Abraira.

Once patients were in-
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corporated into the study, they were hospitalized a minimum of six
weeks to a maximum of eight weeks.

During this time, they were UDder

strict supervision by the SDTU technician and the author so that no
breach in protocol occurred.

Any meals which were not eaten or other

changes in study protocol were noted and results from that day•s testing were discarded for that patient.

d. Dietary Description and Study Protocol
One week prior to entry into the hospital all patients were given
dietary instructions for an individual weight maintenance diet similar
to the regular diet at Hines V.A. Hospital consisting of 50% carbohydrate, 35% fat and 15%

protein.~

One hundred and fifty grams of carbo-

hydrate must be sucrose or other definable disaccharides.

Once the

patients enter the hospital, they are given a diet designated as the
control diet (intermediate sucrose content) which is isocaloric with
the outpatient diet except the sucrose intake is recalculated to be 120g
per day.

The 120g approximation is based on the average intake of suc-

rose in the American population (11).

After two weeks consumption of

the control diet, the patients are randomized to a high sucrose diet
(HSD) approximately 225g or low sucrose diet (LSD), approximately 3g
daily.

All of the nutrients were composed of natural food stuffs and

were made from normal trays given to the rest of the patient population
to approximate a mixed American diet.

Dietary intake was divided into

three meals per day, with 20% of the calories consumed during breakfast,
40% during lunch and 40% during dinner.

No bedtime snack was given.

Fiber was kept constant at 20g per day along with sodium at 150 mmol
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(approximately 4g per day) (461). Each diet was individualized according to the size and weight of the patient.

There were approximate)y 30

different nutrients which could be consumed, several of which were
singled out to be kept as constant as possible (10% variation).
Calories, protein, fat, carbohydrate, sodium, fiber and sucrose content
remained constant in the individual diets.

The dietary pattern from one

diet to another remained the same, with each patient receiving vegetables, meat, potatoes, and salads for lunch and dinner, with eggs and
high fiber cereals consumed at the breakfast meal.

Sucrose content was

altered by adding or subtracting sweet jellies, different juices and
different types of sucrose containing soft drinks.
specifically monitored, were

as~umed

Vitamins, though not

to be constant because of the repe-

tition of the diet and substitution of similar foods with varying sucrose content during the study (137).

Patients were ambulatory, but were

confined to the metabolic unit during the six-week period.

Study com-

pliance was excellent with the dietary trays prepared and checked in the
metabolic kitchens of Dr. H. Spencer.

Intake was monitored by the meta-

bolic dietitian who checked the trays to ensure complete nutrient consumption.
The study was six weeks in duration, the first two weeks comprising the control period, with the subsequent four weeks comprising the
study diet period.

The study is novel, in that each patient acts as

his own control, with most experimental results compared against those
previously determined while the patient was consuming the control diet.
Since we were interested in the mechanism by which sucrose induced
hyperlipemia occurs, we wanted to study these patients before dietary
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adaptation to sucrose content began.

A four-week study period was

chosen because the effect of sucrose had been observed to maximize and
remain relatively constant after this time (453).

A total of 30 pat-

ients were studied, 17 consuming the high sucrose diet with 13 consuming diets low in sucrose.

B. Description of Methodology for Basic Clinical Tests
The different procedures used to ascertain the blood levels of
glucose, triglyceride, cholesterol and HDL-cholesterol were basic
techniques routinely used in hospitals.

Routine quality control pro-

cedures were performed with these assays since some of the values were
also used in patient

monitoring~

during the study.

Blood and urine

glucose values were measured in the Special Diagnostic and Therapeutic
Laboratory by myself and the technician in charge.

All other blood

chemistries were done in the diabetes research laboratories using
manual methods.

I. Serum Glucose
a. Specimen Collection
Samples were drawn for serum glucose three times weekly, both
fasting and three hours postprandially.

A small amount of whole blood

was placed in a 500 ul microfuge tube and allowed to clot.

It was spun

at high speed for three minutes on the Beckman Microfuge, Model #152
(Beckman Instruments, Palo Alto, California).

The serum was collected

using a Pasteur pipette and immediately assayed for glucose.
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b. Procedure for Glucose Determination
The Y.S.I (Yellow Springs Instrument) glucose analyzer,

Mod~l

23A

(Yellow Springs Instrument, Yellow Springs, Ohio) uses an oxidase enzyme hydrogen peroxide sensor.

This technique allows direct readout of

glucose concentrations and no sample modifications are required.
Twenty-five (25) microliters of serum is needed per sample (all samples
were run in duplicate).

The principle involves the conversion of glu-

cose and oxygen to gluconic acid and hydrogen peroxide.
The H2o2 , generated in proportion to glucose concentration is
oxidized at the platinum anode. The subsequent oxidation at the anode
and reduction at the silver electrode creates a current that is proportional to the amount of H2o2 wh)ch diffused in. This is directly
calculated as a glucose reading on the instrument utilizing an analog/
digital converter (414).

c. Calculation of Results
Precision of the assay was determined using Monitrol I and
Monitrol II Standards (Dade Scientific Co., Miami, Florida).

Percent

coefficients of variation were calculated as mean divided by standard
deviation times 100.

Interassay variation of glucose measured at con-

centration level of 104 mg/dl and 230 mg/dl were 0.96% and 1.3% respectively.

II. Urine Glucose Measurement
a. Specimen Collection for 24-hour Urine
Patients were instructed to collect 24-hour urines in receptacles
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provided by the SDTU.

At the beginning of the collection period

(usually when the patient awakens) the bladder was emptied, the specimen discarded, and the time noted.

All urine specimens passed there-

after were collected for a 24-hour period with the bladder being emptied
at the same time the following day and this urine specimen being added
to the collection.

To prevent loss of glucose via bacterial glycolysis,

the jugs contained 5 ml of glacial acetic acid.

All urine collection

bottles were refrigerated during collection.

b. Procedure for Determination
The urine samples were collected from the refrigerators every
morning and the volumes were measured and recorded.

An aliquot was sent

to the clinical labs at Hines for creatinine measurement.

Another ali-

quot was used to determine the urinary glucose concentration with the
sample procedure and analyzer utilized for serum glucose assays.

c. Calculation of Results
Glucose concentrations outside the instrumental range of linearity
were appropriately diluted with total 24-hour glucose excretion in the
urine calculated by multiplying the urinary concentration of glucose by
the total volume of the daily urinary output.

Coefficient of variation

(CV) determinations for the assay were similar to those determined for
the serum controls.

Fisher Urichem Level I with a spiked glucose at

100 mg/dl was used for control purposes.

cv•s for the urine were com-

parible with plasma having a value of 1.7%.
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111. Triglyceride Determination

a. Specimen Collection
Patients were instructed to fast for 12 hours before blood was
drawn for fasting triglyceride levels.
or take prescribed medications.

They were allowed to drink water

The patients sat quietly for 10 minutes

before blood was collected (generally obtained from the antecubital or
another convenient arm vein).

A tourniquet was used, but released be-

fore drawing samples because an artifactual increase in plasma lipid
concentration can occur with prolonged interruption of venous blood flow
(398, 399).

The blood was allowed to stand at room temperature for 30

minutes, a time in which the blood should completely clot.
was centrifuged at 2000 RPM for 15 minutes at 5°C.

The sample

The serum was im-

mediately transferred to an ice bath and kept at 2-4°C for subsequent
analyses.

Duplicate samples were drawn, and if gross hemolysis did

occur, the sample was discarded.

b. Specimen Storage
Samples for triglyceride measurement were immediately transferred
to a clear 12 X 75 mm Falcon polystyrene tube and capped.

The sample

could be stored at 4°C for a few days or for longer periods at -20°C.
Samples were removed from the freezer and allowed to thaw at room
temperature prior to analysis.

Since certain serum components tend to

concentrate at the bottom of the storage vial when the sample is frozen
and water from the plasma may condense on the inner walls and cap of the
vial during storage, the vial was mixed by gentle inversion before unsealing until a homogenous sample was observed.
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c. Assay Protocol
Triglycerides were assayed in the laboratory by the manual method
of Biggs et al. (400).

In this extraction technique, serum is mixed

with water, sulfuric acid, isopropanol and heptane.
occurred was negated by this extraction procedure.

Any hemolysis that
The resulting two-

layer system is allowed to separate with triglycerides entering the
heptane phase once the sulfuric acid loosens the lipid-lipoprotein
bonds.

Saponification of an aliquot of the heptane (upper) layer with

a solution of sodium methoxide converts triglycerides to glycerol and
free fatty acids.

On addition of sodium periodate solution contain-

ing acetic acid and ammonium acetate, glycerol is converted to formaldehyde and formic acid (the

Mal~prade

Reaction).

On treatment of the

formaldehyde with acetylacetone, a yellow cyclic 3, 5-diacetyl-1, 4dihydrotutidine compound is formed (the Hantzach Reaction) which can be
read at 410 nm on a Gilford spectrophotometer, Model #240 (Gilford
Instruments, Oberlin, Ohio).

c. Calculation of Results
A calibration curve is prepared to check the linearity of the
instrument and is performed every 6 months.
a range of 0-500 mg/dl.

The assay is linear over

Patient samples higher than these values must

be diluted with saline, reassayed and final results multiplied by the
appropriate dilution factor.

Triglyceride concentrations may be deter-

mined by comparing the absorbance of the unknown with that of the
standard.
3.9%.

Interassay variation at a triglyceride level of 508 mg/dl

=
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IV. HDL-Cholesterol Determination
a. Specimen Collection
Blood was drawn from the antecubital vein and serum specimens were
assayed both fasting and postprandially for HDL-cholesterol.

b. Specimen Storage
The serum can be stored at room temperature up to three days or at
2-8°C up to six days.

Refrigerated or frozen specimens which have com-

pletely thawed require a 24-30 hour period to fully resolubilize the
lipoproteins at room temperature.

Specimen results determined before

the required equilibration period may be artificially low.

c. Assay Protocol
Many different methods have been used to analyze cholesterol and
HDL-cholesterol {402-402).

The kit used for cholesterol determinations

is the Pierce Rapid Stat Kit (product #44100, 44102, Pierce Chemical
Division, Lancer Chemical, Rockford, Illinois) which utilizes cholesterol oxidase and esterase with a peroxidase/phenol/4-aminoantipyrine
system.

The method involves selective precipitation of LDL and VLDL by

a magnesium/phosphotungstate precipitant reagent (403).

The HDL-

cholesterol fraction present in the supernatant is then analyzed with
the enzymatic cholesterol reagent.

The enzymatic reagent breaks all

cholesterol ester bonds via cholesterol esterase and the total free
cholesterol is oxidized in the presence of 02 by cholesterol oxidase
to give cholest-4-ene-3-one and H2o2 • The peroxide and phenol react
with 4-aminoantipyrine via peroxidase enzyme to give a quinoneimine dye,
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which is colored pink and read at 510 nm on a spectrophotometer.

d. Calculation of Results
The procedure for HDL-cholesterol is linear over a concentration
range of 0-150 mg/dl.

HDL-cholesterol concentration is calculated by

comparing the absorbance of the unknown to that of the standard and
multiplying by the known concentration of the standard.

Since the

original sample was diluted with the precipitant reagent, a factor of
2 is needed to correct for the dilution.
Lipemic specimens on occasion may give a supernatant that is turbid after addition of precipitating reagent and centrifugation.

If an

additional centrifugation at 12,000 X g (5000 RPM) does not clear the
supernatant, the specimen is diluted 1:1 with saline and the precipitation step is repeated.

The final result is multiplied by 2 to obtain

total serum HDL cholesterol.
cholesterol level of 30 mg/dl.

Interassay variability was 6.3% at an HDLCalibration curves for HDL-cholesterol

were performed every six months to check spectrophotometer response and
calibration.

V. Cholesterol (total) Determination
a. Specimen Collection
Collection procedures for total cholesterol were exactly the same
as those for HDL-cholesterol.

Serum collected from patients was used

for the determination of total cholesterol.
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b. Specimen Storage
Specimens for cholesterol determinations were stable up to six
days at 2-8°C or 2 days at 20-25°C.
require freezing at -5°C.

Storage for longer periods of time

Samples to be assayed should be thawed at

room temperature and serum mixed by inversion until homogenous.

A re-

solubilizing period for total cholesterol is not needed and samples
may be assayed after complete thawing and mixing.

c. Assay Protocol
The identical chemical procedure for HDL-cholesterol determinations were also used for total cholesterol measurements.
were changed, however, and no

~recipitation

Sample volumes

step was performed.

d. Calculation of Results
The range of linearity for this assay was from 0-500 mg/dl.
Again, the absorbance of the standard was compared to that of the unknown patient sample.

A ratio was obtained, the value of which was

multiplied by the known value of the standard.

Since no dilutions were

made except in cases where total cholesterol was greater than 500 mg/dl,
a dilution factor was not used.

A standard curve was again determined

for this assay to measure the linearity at differing cholesterol concentrations.

Interassay variation at a level of 200 mg/dl cholesterol

=

5.9%.

C. The Development and Use of the Radioimmunoassay for Insulin and
Glucagon
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I. Introduction
Radioimmunoassay, introduced by Yalow and Berson for the measurement of insulin concentrations (404), is based on competition for an
antibody between a known amount of radioactively labeled antigen and
its unlabeled counterpart in the unknown.

The amount of bound radio-

active antigen is inversely proportional to the concentration of this
same antigen in the patient•s sample.

Different methods have been used

to separate the bound insulin from the unbound moiety (405-406).

The

two antibody system described by Morgan et al. (407) was used because
of its greater sensitivity and specificity.
reaction is as follows:
specific antibody usually

In summary, the two step

1) insulin forms a soluble complex with its
raise~

in guinea pigs (Ains-GP);

2) this

soluble complex is precipitated by an antibody to guinea pig serum
which is obtained from a goat.

The percent of radioactivity in

the precipitate is inversely proportional to the concentration of unlabeled insulin in the reaction mixture.

Temperature ranges between

O-l0°C caused relatively little change in antibody-antigen binding.

At

37°C however, the binding of the complex is much less (407).
In order to determine the amount of unknown in the sample, the
amount of competitive inhibition observed in the unknown is compared to
that obtained in separate solutions in which known amounts of purified
antigen are added.

A standard curve plotting the known concentrations

of antigen against the ratio of bound to unbound antigen can thus be
obtained (Figure 3).

This curve is used to ascertain the level of un-

known antigen in the sample by comparing its ratio of bound to unbound
With that of the standard curve.
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Ratio 8/Bo
Radioactive C*

0.25
0o~--~------~IO~----~IO_O_____
IO~OO

Concentration of Unlabeled
Purified C )Ju/ml

Figure 3:

Standard calibration curve for radioimmunoassay.

8/Bo

represents the ratio of bound to unbound antigen present.
C* represents cold unlabeled antigen.
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In the double antibody system, the first antibody which is
directed against the antigen to be measured is added at a level that
enhances competition between labeled and unlabeled antigens for binding sites.

The second antibody (anti-antibody) is added in excess to

ensure complete immunoprecipitation of the first antibody antigen complex.

II. Insulin RIA
a. Preparation of Insulin Standards
Stock purified insulin was obtained from Eli Lilly and Company
(Indianapolis, IN) at a concentration of 21.7
priate dilutions of the stock

i~sulin

~/mg

protein/ml.

Appro-

must be made to obtain concen-

tration ranges which would be normally found in patients.

A 1:1000

dilution of stock insulin was first made (stable for 10 days at 2-8°C).
50 ul of this solution was diluted to 2 cc with V/A buffer (final
concentration of standard was 542

~U/mg/ml).

Serial dilutions were

done to this standard with gelatin buffer 0.1%.

Once standard dilutions

were prepared they were pipetted into the assay tubes in triplicate,
with one set of NSB tubes per standard curve.

b. Assay Protocol
The performance of this specific assay was dependent on antibody
concentration, amount of labeled antigen added and incubation times
which all influence the specificity and reactivity of the assay.

Bind-

ing studies were done with varying concentrations of insulin antibody to
obtain the correct antibody dilution to perform the assay.

A 1:16,000

100
dilution of first antibody was found to produce the greatest reactivity.

A subsequent study was performed to ascertain the amount of

antibody that could be added to obtain the greatest reactivity between
insulin and insulin antibody (Figure 4).

Insulin excess will use all

antibody added and give the most accurate binding results.

A volume

of 100 ul of the 1:16,000 dilution of first antibody was determined to
be the best.

The second antibody is a goat-antiguinea pig antibody

(Pel-Freeze, Rogers, Arkansas) specific for the
guinea pig first antibody.

a

globulins of the

A 1:12 dilution of this second antibody

was found to give the optimum degree of precipitation of insulin.

c. Data Reduction-Insulin Radioimmunoassay
All radioactivity was counted on a Micromedic System 2/200 gamma
counter (Micromedic Systems, Philadelphia, PA).

Assay data reduction

was performed using a Hewlett-Packard Clinical Laboratory Radioassay
Computer {programmed by cassette tape) (Hewlett Packard, Loveland, CO).
This program evaluates the standard curves by weighted and unweighted
least square regressions using the log dose vs. % bound, logit of %
bound and probit of% bound (Figure 5).

These data reduction transfor-

mations are automatically analyzed for best fit and the curve plus all
pertinent data are printed via automatic printout.

All samples were

done in triplicate with each sample having an (NSB) tube run.
Spiked insulin buffer samples {100

~U/ml

as internal controls on 20 insulin assay runs.
deemed acceptable.

and 50

were used

CV% of 10% or less was

At levels of 103 uU/ml and 49

variation were 9.7% and 10.2%, respectively.

~U/ml)

~U/ml,

coefficients of

101

--

"0
Q)

700

0

Antibody Excess

Antigen Excess

c.

·u
~

600

a..

>.

::-

.::: E
t5a.
ou

.Q"0
0

0::

c
Q)

400

-

.en

c
<I

0

0.2

0.4

(ml) Antibody Solution
Increasing Antibody

Figure 4: Precipitin curve for monospecific system, one antigen and
corresponding antibody.

This binding study was performed to

ascertain the amount of insulin antibody that should be added to obtain the greatest reactivity between insulin and
antibody.
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III. Glucagon (RIA)
a. Preparation of Glucagon Standard Curves
Stock purified glucagon was obtained from Lilly and Company
(Indianapolis, IN) at a standard concentration of 1 mg/ml.

Appro-

priate dilutions of stock glucagon must be made in order to obtain
physiological concentration ranges approximating patient•s samples.
40 of stock solution was diluted to 4 cc (1:100 dilution) to obtain
10,000 pg/ml concentration.
Once standards were prepared (0-10,000 pg/ml), they were
immediately used for assay.

Standards were pipetted in triplicate with

one set of NSB tubes.

b. Assay Protocol
For the glucagon assay, binding studies similar to the insulin
assay were performed with different antibody dilutions.

Anti-glucagon

guinea pig antibody, lot number (OJA-G2) obtained from Dr. A. Lawrence•s
lab was used for the study.

Final dilutions of first antibody which

gave best binding results were 1:17,500.
10 ul (OJA-G2) was diluted to 17.5 ml with glucagon buffer.
ul/cc of normal guinea pig sera (NGPS) was added as a carrier.

5

All

assays were incubated at 4°C with assay tests run in 12 X 75 culture
tubes.

c. Data Reduction-Glucagon Radioimmunoassay
Radioimmunoassay data were treated similarly for the glucagon
assays as for insulin determinations.

Weighted regression and best
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fit analysis for the standard curves were performed (Figure 7).

All

unknown samples were determined by comparison to the standard curve.
Normal ranges for human serum glucagon are 0-300 pg/ml.
control was monitored by spiked glucagon buffer.

Internal

At levels 1011 and

495 pg/ml, coefficients of variation were 13.4% and 11.3% respectively.

IV. Specimen Collection Procedures
Fasting (14 hour fast) and postprandial, insulin (3 hours)
samples and fasting glucagon samples were collected.
asked to sit quietly for 10 minutes.

Patients were

Blood was then drawn from the

antecubital vein and placed directly into tubes containing 0.3 ml of
the aprotinin trasylol which inh,ibits protease breakdown of insulin
and glucagon (Mobay Chemical Corp. FBA Pharmaceuticals, New York, NY).
These samples were immediately placed in ice baths and after 45 minutes
the blood was spun in a refrigerated centrifuge at 3000 RPM.

In the

rare instances when gross sample hemolysis occurred, the sample was discarded.

After centrifugation, the serum was aspirated with Pasteur

pipettes and placed in 12 X 75 em polystyrene tubes with snap caps and
frozen at -20°C.

Frozen samples were thawed at room temperature and in-

verted several times to provide a homogenous sample for assay.

D. Triglyceride Turnover Methodology
I. Introduction
The use of 3H-glycerol in the labeling and measurement of triglyceride transport in the plasma pool is well-documented (53-59, 408411).

The method first developed by Farquhar (412) was used to directly
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assess the input and removal rates of human plasma triglycerides.
Using glycerol tritiated on carbon number two instead of a fatty

~cid

carbon is preferable since glycerol recycling by the body is minimal.
The procedure is based on the principle that plasma concentrations of
any solute will change as a function of its removal from or release
into the plasma.

After radioactive glycerol is injected into the

patient, the appearance and disappearance of radioactivity from the
plasma pool is monitored from the monoexponential portion of the curve.
A K value or decay constant is then calculated.

Biphasic decay curves

have been observed suggesting either two triglyceride pools, one rapidly
removed from the plasma and one removed slowly possibly due to recycling, or one single pool in

whi~h

stepwise removal of triglyceride is

slowed as the case in remnant VLDL formation (413).

II. Preparation of Labeled Glycerol for Injection
a. Purification and Dilution of Label
23H glycerol in ethanol, 1 mCi/ml, was obtained from Amershame
Searle (Arlington Heights, IL).

The stock solution was diluted with

saline to an approximate concentration of 10 uCi/ml.

This working

solution was lyophylized to dryness to remove radioactive water and then
resolubilized with saline.

No loss in radioactivity was observed.

All glassware and instruments were autoclaved for 15 minutes at
120°C and a sterile hood was used to prepare the radioactive label for
injection.

Pharmacological purity was insured by pouring the samples

through a Nalgene membrane filter with a 22 urn pore size.

Once the

sample was filter sterilized it was poured into autoclaved pharmaceu-
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tical serum vials and capped.

An aliquot of this solution was given

to the Chief Research Microbiologist for culturing of bacterial

g~owth.

No evidence of bacterial growth after seven days culturing was considered proof of sample sterility.

Standard procedures for radioactive

handling and spillage were utilized.

For added safety, sterilized

samples for injection were refiltered upon injection by the use of a
Swinex syringe filter (Millipore Corp., Bedford, Mass.).

b. Calculation of Total Body Dosage by Tritium Injection
Approximately 50 uCi per patient of 23H-glycerol was injected
for each turnover procedure.

FDA policy stipulates that calculated

radiation absorbed dosages be

e~timated

obtained.

and total body dose estimates be

Amershame Searle Data indicates the maximum body burden for

tritium ( 3H) to be 1 mCi per dose with an effective biological half
life of 12 days.

Safe dosages for any drug according to FDA rulings

have to be less than 3 RADS. Maximum penetratable range for tritium in
tissue is 6 X 10- 3mm. Dosage rate was calculated from the MIRD index

'

for dosimetry (MIRD pamphlet #1 and #10) (396-397).

III. Specimen Collection Procedures
a. Injection of Label
A 20 gauge polyethylene catheter was inserted into the patient•s
left antecubital vein with extension tubing leading into a 3 way flow
stopcock.

A slow intravenous saline drip was initiated and blood flow

from the stopcock was checked.

In the right antecubital vein, a butter-
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fly catheter was implanted momentarily and the radioactive bolus was
injected.
fasted.

During the interim course of the study the patient was
Water was taken ad libitum and a small evening meal (broth and

dietetic lemonade) was consumed.

The total turnover procedure is 24

hours in duration with the catheter in place for eight hours.

Patients

were continually monitored throughout the period with P.M. blood
collections obtained by the medical staff.
I

b. Specimen Collection and Processing
During the 24 hour period, specimens were drawn from patients
using both the indwelling catheter and venupuncture methods.
collected during the first
catheter and stopcock.

eigh~

Specimens

hours were drawn by the indwelling

After this time, the I.V. system was removed

and the remaining samples were collected by venupuncture.

Seventeen

samples (12 ml each) were drawn from the patients at different times
during the twenty-four hour period.
The blood was allowed to clot at room temperature (approximately
45 minutes) and then centrifuged at 1000 X g/15 min (2000 RPM) to
separate red cells from serum.
servative and stored at 4°C.

The serum was collected without a preAt the end of the procedure, all samples

were frozen in polystyrene vials at -28°C.

Two turnovers were performed

on each patient during the study, one at the end of the control diet and
one after two weeks on the study diet.

IV. Assay Protocol
a. Isolation and Purification of Radioactive Triglyceride Sample
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A chloroform-methanol extraction procedure was used in the separation
and purification of lipids.

The non-polar triglyceride was solubil-

ized in chloroform and the polar lipids which were solubilized in the
methanol layer were discarded.

Once the lipids were isolated and

washed, they were concentrated and resolubilized in a fluor scintillant
used for counting.

P.C.S. {phase combining system), (Amershame Searle,

Arlington Heights, IL), the scintillation fluor used, is a complete
xylene surfactant which contains all ingredients necessary for counting
organic and inorganic samples.

The P.C.S. fluor and samples were poured

into Kima glass scintillation vials.
to dark adapt.

The vials were cooled and allowed

They were then counted along with a blank and tritium

standard for 20 minutes on a Packard Tricarb liquid scintillation
counter, Model 3390 (Packard Instruments, Downers Grove, IL), with an
appropriate external standard to correct for quenching.

b. Scintillation Counting Procedures
The external standard method for quench correction employs Compton
electrons derived from the interaction of
glass vial and the scintillation solution.

y

-rays with the counting
Different color intensity

blanks were run with the external standard in place for a period of
time.

The changes in counts from the non-colored blank as compared to

the different intensity colored blanks were used to determine the counting efficiency of the colored samples.

VI. Calculation of Results
a. Fractional Turnover Rate
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Quench corrected counts were obtained from all patient samples.
Radioactive time curves were plotted on semilogarithmic scale paper
with plasma activity plotted against time.

A Hewlett Packard Model

7830A computer was used to obtain the slope and intercept from linear
regression analysis of the monoexponential portion of the decay curve.
The line was extrapolated back to zero and total injected dose of tritiated glycerol was determined.

Ascertaining the time when half the

total number of counts has disappeared (T 1/2) allowed calculation of
k by the following equation:

K=

0.693
T 1/2

where 0.693

=

1n 2

b. Total Turnover Calculations
The fractional turnover rate (k) of the total plasma triglycerides was used to calculate the turnover rate (V) which equals the removal rate as mg/kg/hr and was calculated from the following formula:

V = k (h~) X S{mg/dl) X 0.45 (~)X b {57)
s

= the triglyceride concentration in mg/dl

0.45

=

indicates a mean plasma volume of 0.45 expressed as
deciliters/kg

b

= a body weight correction factor. Since plasma volume is
less in excess adipose tissue, all turnovers must be weight
corrected.

= 4500100+ +a cx c 45
a = plasma volume/kg adipose
b
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c

=

excess of relative body weight (RBW)

(RBW %-100)

c. Kinetic Determinations and Statistical Calculations
Enzyme kinetic data was calculated by plotting triglyceride concentration/turnover ( [S]

/V) versus triglyceride concentration ([S]).

This is comparable to a linear regression analysis performed on turnover plots after control diets and study diets were consumed.

In this

type of plot the point at which the lines intercept the X-axis gives
the value for Km with Vmax estimated as 1/slope.
The relationship between radioglyceride determined triglyceride
turnover and triglyceride concentration was determined by plotting one
against the other.

The lines of best fit were determined by linear re-

gression analysis.

Again control values were compared to study diet

values (high and low sucrose diets).
Correlation coefficients were calculated to determine if any relationship exists between fractional turnover and plasma TG levels after
the control diet and after two weeks on the study diet.

E. Total Lipoprotein Electrophoresis
I. Introduction
The principles of lipoprotein electrophoresis are based upon the
fact that a charged particle placed in an electric field will migrate
toward one of the electric poles of the field (419).

After electro-

phoresis, proteins are visualized by specific chemical detection.

Pro-

tein levels can be interpreted qualitatively (by visual inspection) or
quantitatively (subjected to densitometric scanning).
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11. Specimen Collection and Storage

Blood samples were drawn for lipoprotein electrophoresis by techniques similar to those for triglyceride and cholesterol measurement.
Lipoproteins are unstable and easily disturbed by sheering forces or
hemolysis.

Therefore, samples for lipoprotein analysis should be

collected in EDTA tubes with enough anticoagulant to produce a final
concentration of 1-1.5 mg/ml (the EDTA also protects against lipoprotein oxidation).

The collection tubes were filled to capacity (6 ml)

and immediately immersed in an ice bath.

The specimen was next placed

in a refrigerated centrifuge and spun at 1500 x g (3000 RPM).

The

plasma was transferred to a clean storage vial using a Pasteur pipette.
Lipoproteins will not tolerate freezing or long term storage in solution without undergoing changes that are reflected in alterations in
their ultracentrifugal and electrophoretic characteristics (415-417).
Lipoprotein concentrations are therefore most accurately measured in
fresh samples as soon as possible.

If samples were stored for longer

periods of time (7 days), the plasma fraction was kept in the dark at
4°C.

III. Agarose Gel Method
a. Importance in Lipoprotein Measurement
The agarose gel system was used to detect lipoproteins by means of
charge and size separation.

A sample densitometric scan of a few of the

basic lipoprotein types representing patients from our study is seen
(Figure 9}.
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Figure 9: Graphical representation of lipoprotein patterns obtained in
normal, type IV and type III hyperlipemic individuals.

In

type III individuals, the pre-s band is again elevated, and
migrates similarly to the
broad

s band observed.
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b. Assay Protocol
The agarose gel electrophoresis system used was the Beckman
Microzone system (419).

In this system, electrophoresis must be per-

formed after rehydration of the gel.

Excessive equilibration (longer

than 45 minutes) was avoided since this may result in high current
levels and joule heat which distorts the appearance of the patterns.

c. Staining Procedure
After fixing and drying the gel, it was stained with Sudan Black
B in a flat tray of appropriate size for 5-10 minutes.

If overstaining

of the gel occurred it was destained by placing it in the gel/fixative
solution until the background

co~oration

disappeared (usually 10-20

minutes).

d. Densitometric Scanning and Data Interpretation
All gels were scanned with a Gelman Computing Densitometer, Model
#ACD 18 (Gelman Instruments, Ann Arbor, Michigan).

All gels were

scanned at a wavelength of 500 nm and the area under each peak integrated to determine the percent of total lipoprotein present.

Data Interpretation
Densitometric scans were compared to the standard electrophoretic
patterns of the Fredrickson classification of hyperlipoproteinemia and
patients were classified accordingly.

Normal values for percentages of

the different lipoprotein fractions have been established and these were
used in objective classifications (420).
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F. VLDL Apoprotein Analysis by SDS-polyacrylamide Gel Electrophoresis and Isoelectric Focusing
I. Introduction
The reliability and resolution capabilities of SDS (sodium dodecyl
sulfate) polyacrylamide gel electrophoresis and isoelectric focusing
have made these techniques invaluable in lipoprotein determinations
(421).

The measurement of apoprotein species from different lipo-

proteins, by these high resolution techniques, have enabled quantitation
of individual apoprotein subunits (63, 64, 66-72, 422-426).

These gel

systems were used to isolate individual apoproteins in sufficient
quantity and purity.

II. Sample Collection and Storage
Sample collection procedures were identical to those for triglyceride and lipoprotein determinations except that blood was placed in
tubes containing sodium citrate.

These samples were placed in an ice

bath for 10 minutes and plasma was separated in a refrigerated centrifuge at 1000 x g/15 min (2000 RPM).

The plasma was removed carefully

with Pasteur pipettes and placed in polystyrene storage vials.

One

mg/ml of EDTA was added to prevent oxidative breakdown of some of the
protein constituents.

Samples were refrigerated at 4°C and analyzed

within one week of collection.

III. Isolation of VLDL Apoprotein
a. Ultracentrifugation of Total Plasma for VLDL
The method of Havel et al. (431), based on flotation ultracentri-
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fugation, was used to provide VLDL lipoprotein for quantitative analysis of apoprotein subfractions.

Density adjustments were made with

solutions containing NaC1 and KBr up to a density of 1.006 (gm/ml).
The plasma mixture was gently poured into 5/8 x 3 polyallomer
ultracentrifugation tubes (total volume 13 ml) which were filled to
capacity, sealed with flat gasket caps and placed in a Ti-50 fixed angle
rotor.

Samples were centrifuged at 105,000 x g (40,000 RPM) for 20-22

hours at 10-15°C in a Beckman Spinco Ultracentrifuge, Model #L2-65B
(Beckman Instruments, Palo Alto, CA) (Figure 10).
Following the centrifugation, lipoproteins of less than the solvent density of 1.006 were concentrated at the top in a layer approximately 1/2 inch thick.

Beneath" this layer, occupying 1/2 of the length

of the tube, a clear zone was observed.

Concentrated at the bottom,

the remaining serum was stratified below the clear zone.

The lipid

layer at the top and approximately 2/3 of the clear zone were carefully
collected by aspiration with a Pasteur pipette.

The collected fraction

was then purified and delipidated.

IV. Purification Procedure
a. Dialysis and Delipidation of VLDL
Separated VLDL lipoproteins were placed in cellulose dialysis
membrane tubing 1-1/8 mm inflated diameter.

The sample solutions were

dialyzed against a bath containing 0.05 M tris buffer, 0.05% EDTA, and
4.0 M NaC1, pH 8.6 for 48 hours at 4°C.
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PLASMA LIPOPROTEINS
VLDL

CHYLOMICRONS

Oo~
1--------apo-B

0

HDL

0

1.006

0.95

Density, g/ml:
Major Apeprotein:

0

LDL

1.063

--------1

1.21
apo·A·I

TRIGLYCERIDE

Figure 10: Schematic representation of plasma lipoproteins separated by
size and lipid composition.

The largest lipoproteins are the

least dense and contain the most triglyceride.

The smallest

lipoproteins are the most dense and contain the largest
amount of lipid as cholesterol.

Apo B is found in all lipo-

protein classes with the exception of HDL.
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The dialyzed VLDL solution was then poured into a serum bottle
and quick frozen in an acetone dry ice bath.

Samples were then freeze

dried on a Virtis lyophilizer for approximately eight hours.

The

freeze dried samples were removed and immediately delipidated with 10
mls of chloroform: methanol (2/1, V/V).

Lipid-free protein was washed

twice with 10 ml volumes of chloroform/methanol and placed in 15 ml
conical glass tubes and centrifuged at 1000 x g for 10 minutes (2000
RPM) at 5°C.

Protein samples (pelleted after centrifugation) were

dried under a stream of nitrogen for three hours.

b. Solubilization Procedure for Isolated Apoprotein
Delipidated apoprotein

wa~

solubilized in a series of steps that

involve reduction with mercaptoethanol and dialysis against dithiothreitol.

For 24 hours at room temperature, the apoprotein pellet was

suspended in 1.0 ml of a solution consisting of 2.5% sodium dodecyl
sulfate, 1.0% Na 2co 3 and 10% B-mercaptoethanol, pH 8.5. After this
time, partial solubilization of protein occurred. The protein suspension was gently poured from the conical tubes into 1-1/8 mm dialysis
tubing where it was dialyzed for 48 hours at room temperature against
200 ml of 0.1% SDS, 1.6 M urea, 0.05% dithiothreitol and 0.01 M trisHC1, pH 8.6.

Solubilized protein was removed from the dialysis bath

and poured into 12 X 75 mm glass culture tubes.

One gram of sucrose

was added to each tube and the sucrose was allowed to dissolve in the
apoprotein solution to increase the density.

c. Protein Analysis of Sample
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To determine the protein concentration of the solution, a Lowry
protein assay modified to assay SDS solubilized proteins was performed (432).

High backgrounds developed upon addition of folin-phenol

reagent during color development and it was determined that the interference was due to residual mercaptoethanol which was not dialyzed out
of solution.

A method was employed which is considerably less suscept-

ible to interference.
Bradford et al. (433).

This is the dye binding technique developed by
In this assay, the absorbance of an acidic

solution of Coomasie Brilliant Blue G250 (BioRad Laboratories, Richmond,
CA) shifts from 465 nm to 595 nm when binding of the dye by protein
occurs.

Thus Coomasie Dye can be used for quantitative protein deter-

minations by measurement of optical absorbance at 595 nm.
An aliquot of mercaptoethanol buffer, dialyzed with the patient•s
samples was used as a reagent blank with bovine serum albumin, treated
similarly to the patient•s samples used as a standard.

The protein-

dye mixtures were incubated for 60 minutes at room temperature.

Absor-

bance at 595 nm was quantitated on a Gilford Spectrophotometer, Model
#240 (Gilford Instruments, Oberlin, Ohio).

d. Calculation of Protein Concentrations
All spectrophotometric measurements were done with the absorbance
of the instrument set to zero with the reagent blank.

The concentration

of the unknown was determined by comparison of the absorbance of the unknown with a known standard or read against a standard curve (Figure
11).
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Standard Curve Protein Assay

1.0

0.8

~

0.6
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0

0

0.4
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Bovine albumin (Protein Standard)
mg/dl

Figure 11: Standard curve determined from the dye binding technique of
Bradford et al. (433).

This method is used to determine the

amount of unknown VLDL lipoprotein collected by ultracentrifugation of human plasma samples.
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v.

SDS - Polyacrylamide Gel Electrophoresis
a. Explanation and Brief Summary of the Principles
The methodology for disc electrophoresis and its application to

human serum proteins was introduced by Davis et al. (434).

Shapiro,

et al. (435) reported that the separation of proteins by polyacrylamide
electrophoresis in the presence of the anionic detergent sodium dodecyl
sulfate is dependent on the molecular weights of their polypeptide
chains.

Since the dodecyl sulfate ions negate any charge related migra-

tion, the proteins separate strictly on the basis of their diameters and
thus, their molecular weight.

Thus, with this system, the pore size is

tailored to the dimension of the molecule to be separated by varying
polyacrylamide gel

concentratio~

(437).

b. Protocol
Preparation for Electrophoresis
The electrophoretic unit used was a Canalco Model #12, (Canalco
Instruments, Rockville, Maryland) electrophoresis cell, designed for
disc gel separations.

Both stacking and separating gels were used in

the determination of VLDL apoproteins.

The separating gel was a 10%

SDS gel and the stacking gel was 2.5%.

The dense sucrose-protein sample

was added to the top of the gel with a Hamilton syringe.

The addition

occurs in the cold room at 5°C with the gel tubes in the electrophoretic
cell.

The protein solutions were layered on the gel through the upper

tank buffer (approximately 150 ug of protein per gel).

122
~lution

Used to Prepare Gels were Modified from Existing Procedures

Separating Gel
10% gel pH 8.6

Solution A
0.12 M tris-HC1 buffer, pH 8.6
0.23% V/V TMED (N,N,N 1 ,N 1-tetramethylethylene diamine)
0.02 M sodium dodecyl sulfate solubilized with 8 M Urea

Solution B
40% W/V acrylamide
1.1% N, N 1 -methylenebisac~ylamide solubilized and diluted to
100 ml with 8 M Urea

Solution C
0.01 M (NH 4 ) 2 s2o8 (ammonium persulfate) in 8 M Urea
Gel solutions were mixed in the following ratio:
4 ml (A) + 8 ml (B) + 4 ml (8M Urea) + 16 ml (C)

Stacking Gel Solutions
2.5% gel pH 6.6

Solution D
0.7 MTris-HC1 buffer pH 6.6 - 6.8
1N HC1
TMED
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8 M Urea

Solution E
5% W/V acrylamide solution
2.5% NN methylene bisacrylamide
8 M Urea

Solution F
1 X 10- 4 M riboflavin
8 M Urea

Solution G
40% sucrose in 8 M Urea

The solutions for the stacking gel were mixed in the following
proportions:
1 ml (D) = 2 ml (E) + 1 ml (F) + 4 ml (G)

Photoflo 600 Solution
0.17% V/V Photoflo 600 (Eastman Kodak Co., Rochester, N.Y.)

Upper Tray Cathode Buffer pH 9.0
0.04 M Tris
0.05 M glycine

1N HC1
8 M Urea
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Lower Tray Anode Buffer pH 8.1
0.12 MTris

IN HCl

Bromphenol Tracking Dye
10 mg dissolved in 1000 ml H20
Electrophoresis
Samples were electrophoresed for 8 hours at approximately 3mA per
tube at 5°C.

1.5 hours after the marker dye migrates off the gel, the

flow of current was halted and gel tubes were removed from the cell.
Since the apoproteins migrate mu.ch slower than the tracking dye, the 1.5
additional hours were found to be the time of maximum migration of the
apoproteins.

The gels were recovered for protein staining by placing

them in an ice bath.

After five minutes, they were removed and gently

rimmed free from the gel tube with a stream of water.

c. Staining Procedures
The recovered gels were placed in 12 X 75 mm tubes and were
stained with a solution of 1% Amidoschwarz lOB in 7.5% acetic acid for
16 hours at room temperature.

Gels were removed from the stain and ex-

cess dye was removed by repeated washings of 7.5% acetic acid (48 hours
is the usual destaining time).

The gels were scanned densitometrically

and peak integration was used to obtain a quantitative measurement of
the constituent apoproteins.
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VI. Isoelectric Focusing
a. Explanation and Brief Summary of Principle
The technique of isoelectric focusing has been applied to the
analysis of many proteins, including human apolipoproteins (423, 426).
Proteins of similar molecular weight but different charge will also
separate in this system enabling the identification of isoprotein
species.

b. Assay Protocol
The protein preparations were electrophoresed in the electrophoretic apparatus as described IV, b, 1.

However, the system was

equipped with a larger lower taDk to accommodate gels which were polymerized in tubes 12 em long with an J.D. of 5 mm, 7.5% polyacrylamide
gels, with added ampholytes, were poured into the tubes to a depth of
approximately 11 em.

Gel Solutions
Acrylamide Solution
37.5% acrylamide solution
0.8% NN 1 methylenebisacrylamide

Ampholine carrier ampholytes were obtained from commercial preparations by LKB Instruments, Inc., (Rockville, MD).

The ampholyte

solution consists of different aliphatic polyamino-polycarboxylic acids.
The pH range chosen for this assay was pH 4-6.
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Ammonium Persulfate Solution
1.07% ammonium persulfate

Upper and lower chamber buffers are prepared as follows:
Upper Chamber (cathode buffer) pH 13
0.02 M NaOH
Distilled H20
Lower Chamber Buffer (anode buffer) pH 1
0.01 M phosphoric acid
Distilled H20
The cell unit containing the gels was placed in a cold room at
5°C and the gels were prefocused at 1mA/tube for 30 minutes to establish
the pH gradient.

Electrophoresis was terminated and protein samples

were directly applied to the buffer gel interface with a Hamilton or
tuberculin syringe (400 ug of protein in 500-700 ul volume).

c. Electrophoresis
Proteins were electrophoresed at 400 volts until the current
stabilizes at around 1-1.2 rnA for 12 gels (12-15 hours).

One gel in

each run was used as a blank for pH gradient determinations.

Gels were

removed after electrophoresis by rimming the tube with water.

The gels

containing the separated protein were fixed and stained, as described
previously.
ments.

The blank gel was sliced with a razor blade into 5 mm seg-

These segments were transferred to small test tubes, 1 ml of
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deionized water was added, the tubes were capped and stored at 4°C.
subsequently, the pH of the 1 ml solution was measured at room temperature with a Model 26 Radiometer pH meter (Radiometer, Copenhagen,
NV, Denmark).

d. Staining Procedure
A method developed by Malik and Berrie (438) utilizes Coomassie
Brilliant Blue, but eliminates the need for fixing, deampholyting and
destaining.

This method avoids intense background staining and has

resolution capacities comparable to other procedures using Amidoschwarz
and Coomasie Brilliant Blue.
placed directly in the stain

After focusing, the gels were removed and
fi~ative

(1% stain solution).

Protein

bands appear within 15 minutes and intensify with longer staining
periods (overstaining has not been encountered with treatment times as
long as 48 hours).

Gels were typically stained for 12 hours and were

transferred to distilled H20 (a suitable storage media). A short
immersion in 0.2% H2so 4 will decolorize unwanted background, if desired, but prolonged exposure to H2so4 will eventually remove all
stain.
Stained and fixed gels were photographed and then placed in
scanning tubes.

The Gelman densitometer used previously to scan and

integrate the protein peaks of the SDS polyacrylamide gels was also
used to determine the protein content of the isoelectrically focused
gels.

All apoproteins were identified by their isoelectric point which

was compared with tables of known standard apoproteins (Table 3).
tein peaks were expressed as percent of total apoprotein present.

Pro-
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Multiple samples were collected for apoprotein determination
during the control and study diet periods.

Therefore, any

change~

in-

duced by the diet would conceivably be detected since each patient can
serve as his own control.

Changes in apoprotein composition determined

from the values obtained while consuming an isocaloric control diet
could thus easily be identified.

G. Platelet Aggregation Analysis
Platelet aggregation is a term used to denote the adherence of
one platelet to another.

A variety of agents to which platelets may be

exposed in vitro cause them to change shape, aggregate and release the
constituents of their storage granules.

Some of these constituents are

collagen, thrombin, ADP, epinephrine, serotonin and vasopressin.

a. Sample Collection and Preparation for Platelet Aggregation
By sterile venupuncture of the antecubital vein, 9 ml of whole
blood was drawn into a vacutainer containing 1 ml of 3.8% sodium
citrate.

The blood was drawn after an overnight fast with the patient

seated and rested 15 minutes before drawing.

The blood was collected

in 17 X 100 mm polypropylene tubes and spun and assayed within two
hours.
The blood was centrifuged at room temperature at 150 X g/15
minutes (800 RPM).

The upper plasma layer was syphoned off (approxi-

mately 2 ml) and transferred to polypropylene tubes with plastic transfer pipettes.

This was designated platelet-rich plasma (PRP).

The re-

maining plasma was centrifuged at 2000 X g/15 minutes (2100 RPM).

The
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TABLE 3

TABLE

Classification of apolipoproteins of HI)L and VlDL

laoelccaic
Daignation

>6.00

U!l

ProteiD
Designation"

C-1

Estinwcd
Mol. WL

7,000

Sephadc:s;·

Fraction

HS-3
(VS-3)

5.75
5.65
5.55

A-I

27,000

·~I

ARP
and

55,000

A-IV.

46,000

HS.I

A·II
C-11
C-111..0
C-111-1?
C-111-2?

8,000
8,000
10,000

HS-3

HS-2

5.46~

5.41
5.!9
5.56
5.51
4.85
4.74
4.67
4.61
4.57
4.50
4.45

e-m..:s

HS-1
(VS-2)

HS-3
(VS-3)

11,000

C-111-4?

Isoelectric points of all apolipoproteins found in HDL and
VLDL lipoproteins.

Apo B is considered insoluble because

of its large size and is not represented.

ARP is synonymous

with apoprotein E, the arginine rich protein.
from reference 430.

Data represented
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remaining plasma was pipetted off the red cells and this is designated
platelet poor plasma (PPP).

These two plasma preparations were used in

the platelet aggregation assay.

b. Description of Aggregometer
The platelet aggregometer measures changes in light transmission
scattering through platelet-rich plasma that is maintained at 37°C and
constantly stirred at 1000 RPM (440-442).

The instrument used was a

Chrono-log Aggregometer, Model #330 with a Linear Instrument Chart
Recorder #702.

(Chrono-log Corp., Havertown, PA).

The instrument

operates on the principle that platelets in a stirred solution will
adhere to one another and fall 9ut of solution when an aggregant is
added.

The platelet-rich plasma situated in a small cuvette is slight-

ly turbid due to the presence of platelets in suspension.

When aggre-

gating agents were added, the turbidity decreases because of the clumping action of the platelets.

When a light beam is passed through the

cuvette containing platelet-rich plasma, the amount of light transmitted
will increase as turbidity decreases.

This quantity was recorded on a

linear strip chart recorder and the resultant curve was a record of the
rate and amount of platelet aggregation.

c. Assay Procedure
Platelet solutions were counted and (PRP) concentrations were adjusted by dilution with (PPP).

2.5 ml of the working (PRP) was made

with a final concentration of platelets set at 200,000
platelets/ml.

±

20,000

For each separate patient, a platelet poor blank was made
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by taking 0.45 ml of (PPP) and adding 0.05 ml of saline to it.

This

blank was used to adjust the baseline of the instrument to zero.
Triplicate tubes of patient platelet-rich plasma (PRP) were made with
0.45 ml of the working solution.

The cuvettes were allowed to warm

up to temperature (37°C) and then 0.05 ml of aggregating agent was added (adrenaline chloride, final concentration of epinephrine-hydrochloride in saline was 0.1 mg/ml, Parke-Davis, Grand Rapids, MI).

d. Sensitivity Studies
Platelet sensitivity to the aggregating agent was monitored when
serially diluted epinephrine mixtures were added to the (PRP). The
concentration of aggregating mixture at which both first and principally
second phase aggregation was lost is considered to be the threshold
level of epinephrine needed to elicit an aggregation.
used range from a concentration of 50

~m

to 0.1

~m.

The solutions
None of the

patients from the study demonstrated an aggregation response with concentrations of less than 0.1 uM.
The maximum change of OD = ODf- ODi.

ODf was measured at

the maximum point of aggregation and ODi was measured at the initial
point, before the aggregant was added.

The values were expressed as

percent aggregation using the (PRP) working solution as 0% and the (PPP)
as 100%.

Aggregation curves obtained were compared between the control

and study diet periods.

The changes in aggregation response or sensi-

tivity of the platelets from control diets were recorded.
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H. Statistical Analysis of Data
Except in experiments where statistical evaluations of data are
listed, results were analyzed by the paired or nonpaired two tailed
t test.

In essence t is the ratio of the difference between two means

to the standard deviation of the difference.

Since there is no justi-

fiable basis for selection of pairs of subjects which can be expected
to behave or respond more nearly alike than any other two, the unpaired
t test for significance treats the individuals from each sucrose group
as independent samples from a common population.

The t value is based

on the number of degrees of freedom (the number of samples or subjects
involved minus two).

Since the unpaired tallows each series to be

summed independently to obtain

~wo

sample means, 2 restrictions to the

number of degrees of freedom are usually imposed.

The t value is used

to find the significance level or probability level that the two sets
of data are the same.

In this study, a 5% significance level (p<.05) or

below is considered significant.

Thus, if t were found to have a P

value of < .01 this would indicate that the two sets of data have a less
than 1% chance of being the same.

Paired t analysis was used to compare

values from the same patient when consuming the control diet or study
diet.

5.

RESULTS

A. Description of Patient Population at Time of Entry Into Study
All patients matriculated into the Sucrose Study were adult onset diabetics who were hypertriglyceridemic and non-insulin dependent.
Pertinent patient information is given in Table 4, including age and
weights, along with fasting serum glucose, triglyceride, HDL-cholesterol and cholesterol ranges and means.

TC/HDL-C, a ratio used in

assessing susceptibility to atherosclerosis and coronary heart disease,
was also determined indicating the majority of patients to be in a
range consistent with their age group.
hyperlipemic individuals.

All patients were type IV

Fasting serum chemistries for all test sub-

jects were indicative of hyperlipemic adult onset diabetes.

Fasting

mean values observed were a serum glucose level of 198 mg/dl, a serum
triglyceride level of 300 mg/dl and a serum cholesterol level of 207
mg/dl.

A total of thirty patients participated in the study for a six

week time period.

B. Results of Chemical Determinations During Study Diet Period
Serum glucose levels were obtained fasting and postprandially
along with a 24 hour urine glucose determination.

Daily weights were

also obtained from the patient population during the study.

The re-

sults are depicted in Figures 12-15.

a. Fasting and Postprandial Serum Glucose
Fasting and postprandial serum glucose levels were monitored on
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TABLE 4
DESCRIPTION OF PATIENT POOL USED FOR SUCROSE STUDY

.Number

Subject

Subject

Fasting

Fasting

Fasting

Fasting

of

Age

Weight

Serum

Serum

Serum

Serum

Subjects
Range

30

39-74

Range

Lipoprotein
TC /HDL-C Pattern

Glucose

Trigs

HDL-C

Cholesterol

Range

Range

Range

Range

Range

14-46

142-310

3.9-12.5

144-282 96-308

150-752

Type

pre 8
Mean

Mean

Mean

Mean

Mean

Mean

Mean

60

202

198

300

35

207

6.4

nr

elevated
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all patients during the control and study diet periods.

The data in

Figure 12 demonstrates that fasting blood sugars in both study groups
fell from control values when patients consumed either the high or the
low sucrose diets.

However, a more significant decrease {p < 0.02) in

serum glucose was observed in patients consuming high sucrose diets.
The mean control values for this group were approximately 195 mg/dl
with study diet mean fasting glucoses as low as 160 mg/dl.

Decreases

of this magnitude were not observed in the low sucrose study group.
The mean postprandial serum glucose levels showed no significant
changes from the control values.

Again, a slight decrease in mean

postprandial serum glucose was observed in the high sucrose study individuals.

An interesting observation is noted concerning the patients

consuming the low sucrose diet.

Their mean serum postprandial glucose

showed a small increase from the control values until the fourth week,
at which time glucose levels were comparable to those observed during
the control diet period.
The data in Figure 13 demonstrates the direct relationship between fasting and postprandial serum glucose levels while consuming
the different study diets.

No significant differences were observed

between fasting and postprandial mean serum glucose levels at any time
point for either diet.

b. 24 Hour Urine Glucose Measurements
24 hour urine glucose measurements were obtained on all patients
during the study and Figure 14 summarizes the pertinent data.

Since

many of the patients had markedly different levels of glucose excretion
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Fasting and Post Prandial Serum Glucose
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Figure 12: Fasting and postprandial serum glucose levels averaged from
17 patients consuming high sucrose diets and 13 patients consuming low sucrose diets. C represents a control period in
which patients consumed an intermediate diet consisting of
120 g of sucrose per day for. 2 weeks. The value represents
the last 2 measurements from this period. The Wl-w 4
values represent the weekly periods of high and Tow sucrose
dietary consumption after the control period. All weekly
values are compared to the control period values for that
particular group. Three values obtained per week with the
mean and S.E.M. of all patients per group per week are
represented by each point.
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Figure 13: Direct relationship between fasting and postprandial serum
glucose is demonstrated. Control period fasting (F) and
postprandial (PP) values along with W and W of the
study diet periods are represented. ~ach po1nt is the
mean and S.E.M. of weekly glucose values obtained per
group. The difference between fasting and postprandial
serum glucose is measured for significance.
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into the urine, the average of the results from each group did not reflect the changes that occurred.

In order to obtain the best represen-

tation of the spread in urine glucose excretion, the patient population
was divided into two groups, those excreting in excess of 15 g of glucose daily (>15g) and those excreting less than 15 g of glucose daily
{<15g).

Results were expressed as the change from the mean urinary

glucose excretion during the last 5 days of the control diet to the
particular week of the study.

Urine glucose excretion showed little

change from control values regardless of the study diet in individuals
who excreted low amounts of glucose in their urine, in contrast to the
substantial changes observed in those who excreted high amounts of glucose in their urine.

When

pati~nts

began consumption of the low sucrose

diet an immediate drop in urine glucose from the control values was observed.

Patients consuming the high sucrose diet showed little change

from control values during the first two weeks on the study diet.

Both

groups, however, showed significant decreases in 24 hour urine glucose
output after 4 weeks.

By this time, high sucrose study patients de-

creased their urinary glucose output an average of 10 grams/day
{p< 0.01) and low sucrose study patients lowered their urinary glucose
output by approximately 25 grams/day {p = 0.05).

c. Average Weekly Weights
An important aspect for this study was the assurance that the different diets administered were kept relatively isocaloric and the
patients metabolically stable.

Large decreases or increases in weight

can not be tolerated because of the metabolic consequences of weight
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Figure 14: 24 hour urine glucose levels obtained for both high and low
sucrose diet study groups.

Two subgroups consist of those

excreting more than or less than 15 grams of glucose per 24
hours.

All values are expressed as changes from the control

period values which are averaged for the last 5 days before
the study diet is initiated.

All figures represent means

and S.E.M. for all patients sampled per group per week.
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changes on hormonal levels and fatty acid metabolism.

Figure 15 is a

graphical representation of patient weight change from the control
period during the administration of the two study diets.
change of ±5% was considered tolerable for the study.

A weight

As observed,

the mean weight change from control values was insignificant for both
study groups.

C. Lipid Levels During High and Low Sucrose Diets Compared Against
Control Diet (120 gm Sucrose Level).
Fasting and non-fasting lipid levels were obtained on all of the
patients studied.

Triglycerides, HDL-cholesterol and serum cholesterol

were measured three times weekly in all test subjects.

Results were

averaged and in all cases were depicted as alterations from the concentration obtained during the control period.

These results are sum-

marized in Figures 16-21.

a. Serum Fasting and Non-Fasting Triglyceride Levels
Blood for fasting serum triglycerides was usually drawn following
a 12 hour fasting period.

The results are shown in Figure 16.

Patients

switched to a high sucrose diet showed a large and rapid increase in
their fasting triglyceride concentration from control diet levels.
Within the first two weeks of consuming the high sucrose diet, triglyceride concentration in these patients averaged 65 mg/dl higher than
their control period values (p <0.01).

This increase reached approxi-

mately 70 gm/dl by the third week (p <0.01}.

However, patients on the

low sucrose diet demonstrated minor fluctuations in triglyceride
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Figure 15: Patient weights were taken daily, averaged weekly per patient
and combined by study group.

Each point represents the mean

and S.E.M. for all patients per group per time sequence in
diet.
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Figure 16: Fasting serum triglycerides measured from both patient populations. All values are compared to the control period
value which was designated as the average of the last 3
measurements during the control (intermediate) diet. Each
point represents the mean and S.E.M. for all patients per
group measured during that time sequence. Significance is
calculated as the difference from the values obtained during the control period. Each patient value per week is an
average of 3 values obtained during that time period of the
study.
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concentration.

The displacement from control diet triglyceride

values was neither large nor sustained in this group.
The results delineated in Figure 17 represent the change in nonfasting triglycerides

fro~

control period levels.

Both groups of study

patients increased their non-fasting triglyceride concentrations by the
fourth week.

However, the patient group consuming the low sucrose diet

showed the largest jump in triglyceride concentration with an average
increase of 75 mg/dl over control values by the fourth week {p< 0.01).
This can be compared to a 20 mg/dl increase over control values in
patients consuming high sucrose diets.

The rise in postprandial tri-

glyceride concentration during low sucrose consumption is almost instantaneous with diet change
tered.

and~may

reflect the type of diet adminis-

This diet contained higher (10%) proportions of fat compared

with the control diet.

b. Serum Fasting and Non-Fasting HDL-Cholesterol Levels
Figures 18 and 19 represent HDL-cholesterol levels during both
fasting and non-fasting periods respectively.

It can be observed in

Figure 18 that the mean increase in HDL-cholesterol levels is 5 mg/dl
over control diet values with consumption of low sucrose diets {p
0.05).

=

High sucrose diet group patients showed a slight decrease in

HDL-cholesterol levels during the first two weeks which was not significant (p

=

0.198).

Figure 19 illustrates HDL-cholesterol levels obtained during nonfasting periods.

These values were relatively unchanged from control

values when either study diet was consumed.

Non-fasting HDL-cholesterol
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Figure 17: Non-fasting serum triglycerides measured from both patient
populations.

The description of the graph and the relative

relationships are the same as described in Figure 17.
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Figure 18: Fasting serum HDL-cholesterol changes from the control period values are observed for both groups of patients studied.
The points represent the mean and S.E.M. values for all
patients per group measured during each particular time
sequence.

All values are expressed as mean change from the

control period point which is the mean of the last 3 days
averaged during the control period.

Significance is ex-

pressed as the difference from the control point.
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Figure 19: Non-fasting serum HDL-cholesterol changes from the control
period values are observed for both groups of patients
studied (high and low sucrose).

The description of the

graphical relationships is identical to and found in
Figure 19.
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levels were found to average 5 mg/dl lower than the fasting values
observed.

c. Serum Fasting and Non-Fasting Cholesterol Values
The data presented in Figure 20 shows the effect of diet on fasting serum cholesterol levels.

A mean decrease of 17 mg/dl in choles-

terol concentration is observed during the second week of the study
period with consumption of high sucrose diets (p

= 0.05). Patients who

were given the low sucrose diet after the control diet showed no significant changes in fasting cholesterol concentrations, although a
slight increase in serum cholesterol concentrations from the control
period can be observed during

w~eks

2 and 3.

Figure 21 illustrates the changes in non-fasting serum cholesterol
levels from control values.

Again, patients consuming high sucrose

diets showed a significant decrease of approximately 10-15 mg/dl in
serum cholesterol concentrations (p = 0.05) relative to serum values
when consuming the intermediate control diet.

Patients consuming the

low sucrose diet after the control diet showed no significant change
during the first two weeks of study diet consumption.

However, during

weeks 3 and 4 a slight decrease in non-fasting cholesterol was observed
from control values.

D. Effect of (120 gm) Intermediate (control) Diet on Patient
Population Subgroups
Administration of 120 grams of sucrose per day to patients prone
to hyperlipemia could cause their lipids to increase.

The 120 g/day
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Figure 20: Fasting serum cholesterol changes from the control period
values are observed for both groups of patients studied.
Each point represents the mean and S.E.M. for all patients
per group measured during each time sequence.

Significance

is expressed in the difference from the control period
value.
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Figure 21: Non-fasting serum cholesterol levels expressed as changes
from the control value are observed for both groups of
patients.

The description of the graphical relationships

and points is identical to Figure 21.
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value is representative of the average daily sucrose consumption in
the American diet (11).

In order to determine the effects of the con-

trol or intermediate diet on the patient population, two studies were
done.

All patients who were incorporated into the study were monitor-

ed during the control period.

Fasting and postprandial blood sugars

and triglyceride levels were used as measures of the dietary effect of
120 gm of sucrose on all patients.

Patient values were monitored at

day 0 (entrance into the study) and at day 10 of the control diet.
Also, six additional patients who were incorporated into the study
were kept on the control diet for two weeks and then maintained for an
additional 4 weeks on the same intermediate or control diet as before.
The results of these two studie$ are presented in Table 5 and Figure 22.

a. Blood Glucose and Triglyceride Values Compared During the
Control Period
Table 5 shows the changes that occur in triglyceride and blood
sugar levels in fasting and postprandial specimens from day 0 and day
10 of the control period.

Fasting glucose decreased from admission

values by an average of 18 mg/dl while postprandial serum glucose decreased by an average of 10 mg/dl.

Fasting triglycerides remained

fairly constant with a mean decrease of only 20 mg/dl from the admisston values in all patients studied.

Postprandial triglycerides

showed a similar mean drop of 30 mg/dl from admission values.
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TABLE 5

EFFECTS OF CONTROL DIET (120GM SUCROSE)
ON PLASMA GLUCOSE AND TRIGLYCERIDE LEVELS
<ALL SUBJECTS)
DAY 0 (ADMISSION)

DAYlO

FBS
4PM BS

211 ± 16
218 ± 19

193 i 14
208 ± 19

FASTING TG 290 + 31
4PM TG
378 ± 53

270 + 21
358 ± 26

The effects of the control diet given to all subjects before they were
randomly assigned to the study diets.

All values are expressed as mean

and S.E.M. for all patients (36) studied.

Day 0 represents their fast-

. ing admission blood values and day 10 represents that number of days
consuming the control diet.
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b. Fasting Blood Glucose, Weights, Triglyceride, Cholesterol,
HDL-Cholesterol and Urine Glucose Results Monitored in
Control Subgroup
Results of basic chemistries obtained from a subgroup of patients
on the control diet for four weeks are illustrated in Figure 22.

All

routines and protocols were identical to the study diets except no
dietary changes were incurred after the two week control interval.
Average weekly weights for this subgroup showed relatively little change
from the control period weights.

This demonstrates that weight loss

and gain is not a contributing factor for the changes observed while
consuming the control sucrose diet.
Fasting serum

triglycerid~s

for the control subgroup decreased

when patients were administered the 120 gm sucrose diet for an additional 4 weeks after the initial 2 weeks.

These results parallel those

of the low sucrose subgroup which showed no change or a decrease in
triglyceride values compared to control period values.

Although a de-

crease was noted in the triglyceride concentration from the control
during the four additional weeks on the intermediate diet it was not
significant (p> 0.05).
Mean cholesterol values showed no significant change from those
of the initial two week control period when patients were given the
intermediate diet for four extra weeks.

In contrast, HDL-cholesterol

rose significantly (p< 0.05) with continuation of the control or intermediate diet.

A mean rise of 5 mg/dl was observed at week four of the

study portion of the diet following a steady rise from week 1.

Again,

these changes are comparable to those observed in patients who were

:;;

153

Fasting Blood Glueose

~0

0

.s
-e

~

c

<l

en

(!)

LL
2~0

Weights
-;;

~

...

200

~

0

~
1~0

100

c

w.

W2

Triglycerides

~
0

.§

2

i:
0

Control

c.J
<l
(!)

....
-~

le

50

Cholesterol

c
8

<l

e~

Control

W•

J!0
6

~-

..5"'
2

.

-~o

HDL- cholesterol

~

.!!
0

Control

~

u

5

w.

W2

w.

w.

:I:

<l

....

~

-I 0

~

Urine Glucose

N

.....0

...
."'
0

u

Control

.2

.s;

:=>
c.J
<l

-sol
Time

Figure 22: The effects of a prolonged intermediate (120g) sucrose control diet on a patient population subgroup. The composite
graph represents some of the blood chemistry changes observed in 6 patients who continued the control diet after the
initial 2 week period. All values, with the exception of
urine glucose, were determined from fating samples and were
expressed as changes from the control period. Each point
represents the mean and S.E.M. of all patients in this subgroup.
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consuming the low sucrose diet during the study period.
As demonstrated in Figure 22, urine glucose decreased slightly.
The decrease was non-significant when compared to control period
values (p<0.2), but does reflect the general trend observed when the
other two study diets were consumed.

Fasting blood glucose in these

control patients showed a drop after week two of the control period
similar to high and low sucrose study groups.

A mean drop of 15 mg/dl

was observed during weeks 3 and 4 which was not significant (p> 0.1).
Other values of interest were the insulin and glucagon values
(data not shown) which did not change appreciably during the 4 weeks
after the control period.
mediate sucrose consumption

These observations suggest that interseems~

to have little effect on lipid

values in non-insulin dependent diabetic hypertriglyceridemic patients.
Results with this group seem to reflect similar trends observed in
individuals consuming sucrose restricted diets.

E. Serum Glucoregulatory Hormone Levels
The effect of high and low sucrose consumption on the glucoregulatory hormones is expressed in Figures 23-26 and Table 6.

Insulin re-

sults are expressed as a weekly mean of all patients in each group during the control and study diet periods.

Glucagon values and insulin/

glucagon ratios were determined per group from one dietary period to
another.

a. Fasting Serum and Postprandial Insulin Levels
Figure 23 illustrates the effect of sucrose consumption on serum
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Figure 23: Fasting insulin concentrations observed during high and low
sucrose consumption.

Each point represents the mean and

S.E.M. for all patients per group per time sequence studied.
Significance is measured in difference from the control period value.

Each patient's weekly sample is the average of

3 samplings throughout the week.
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insulin following a twelve hour fast.

The control values indicate

that many non-insulin dependent hyperlipemic diabetics are also hyperinsulinemic (445).

This patient population had a mean fasting insulin

concentration of 23-25 uU/ml, higher than mean normal fasting insulin
levels of 10-15 uU/ml.

Patients consuming the low sucrose diet demon-

strated a consistent decrease in I.R.I. (immunoreactive insulin) levels
of 5 uU/ml below the control value of 23 uU/ml by the third week of the
study.

However, these values were insignificant compared to the effects

of high sucrose consumption on fasting serum insulin.

Patients on high

sucrose diets after the control period showed increases in fasting serum
insulin as high as 11 uU/ml over control levels by the third week of the
study (p <0.05).
The effects of sucrose consumption on postprandial insulin levels
are illustrated in Figure 24.

Only weeks 2 and 4 of the study diet are

illustrated along with the control period.

Control period values in

both groups were similar with mean insulin levels of approximately 50
uU/ml.

A large highly significant increase was observed after two weeks

of high sucrose consumption with mean values of 75 uU/ml after 2 weeks
and 80 uU/ml after 4 weeks (P< 0.05).

Patients ingesting the low suc-

rose diet showed little change from control period insulin values with
slight decreases of approximately 5 uU/ml observed during weeks 2 and 4
of the study diet period.
Figure 25 combines the results of both fasting and postprandial
insulin values from the control period with those from weeks 2 and 4
of the study diets to demonstrate the concept of insulin increments.
Increments in insulin concentration demonstrate the effect of diet on

157
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Figure 24: Postprandial serum insulin during the control period and 2
and 4 weeks of the study period.

H represents the high

sucrose diet, L represents the low sucrose diet.

Signifi-

cance is expressed as differences from the baseline on
control period.

All figures represent means and S.E.M. for

all the patients measured per group.
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Fasting and Post Prandial Serum lnsulins
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Figure 25: Fasting and postprandial serum insulin relationships during
control period and week 2 and week 4 of the study diet
period.

F represents fasting and PP represents postprandial.

Significance in this figure is determined by the difference
between the fasting and postprandial insulins within each
group.

Points are determined by mean and S:E.M. of all

patients per group per time period measured.

All patients

values are expressed as the mean of 3 values taken during
the week of measurement.
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insulin release.

The significance obtained is the difference be-

tween fasting and postprandial levels of insulin in each group of
patients during each study period measured.

During the control per-

iod, both high and low sucrose study diet groups showed approximately
a 24 uU/ml increase in insulin levels after a meal.

During week 2 of

the study diet, the patients consuming high sucrose showed a significant postprandial increase of almost 50 uU/ml (p< 0.01) as compared
to approximately 15 uU/ml
(p< 0.05).

for patients consuming low sucrose diets

This difference in incremental insulin response between

high sucrose and low sucrose consumption was maintained through the
fourth week of the study diets ( p

= 0.05).

b. Fasting Glucagon Levels
Serum glucagon levels are shown in Figure 26.

The results are

expressed in mean concentration changes from control period values.
The third week data is not included in this set because several of the
third week samples were accidentally thawed and an incomplete number
of results could only be obtained for the high sucrose group.

This

figure shows that fasting glucagon levels fluctuated from control values
while consuming the low sucrose diets.

But at 4 weeks, glucagon values

were similar to control period levels.

No substantial pattern of de-

crease or increase could be ascertained.

Serum glucagon values from

individuals on the high sucrose diet showed a significant decrease from
control levels.
(p <0.05).

Values dropped by 40 pg/ml during the first two weeks

These depressed levels were maintained with 4 week values

approximately 25 pg/ml less than control diet values.
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c. Insulin/Glucagon Ratio, High and Low Sucrose Diets
Insulin and glucagon ratios were calculated for all patients.
during the control and fourth week of the study diet periods.

The

two study groups were then compared to their control diet values with
the data summarized in Table 6.
I/G ratios increased by 30.2% from control values when patients
consumed a diet rich in sucrose.

This increase reflects the large

rise in fasting insulin concentration and drop in glucagon concentration observed in this group.
the low sucrose diet group.

A decrease in I/G ratio was observed with
This result reflects the smaller decrease

in insulin concentration and little change in glucagon concentration
observed in patients on

sucrose~restricted

diets.

F. Lipoprotein Levels During Study Diets
Blood was drawn twice weekly for lipoprotein electrophoresis during the control and study diet periods.

Each group of patient results

were averaged with mean values per week of study represented in Figure
27.

All results were compared to control values and significance was

determined as changes from control levels.

a. Effect of High and Low Sucrose Dietary Consumption on
Lipoprotein Levels
Figure 27 shows circulating lipoprotein changes from control
values while consuming sucrose enriched or sucrose depleted diets.

All

lipoprotein concentrations were expressed as percentage of total lipoprotein present.

Patients who consumed low sucrose diets demonstrated
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Figure 26: Fasting serum glucagon values expressed as changes from control period value.

Each point represents the mean and S.E.M.

of all patients per group per time period studied.

Signifi-

cance is expressed as the difference from the control period
value for each group.

The control period value is the

average of the last 3 measurements during that period before
patients were switched to a high or low sucrose diet.
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TABLE 6
TABLE OF THE RATIO OF INSULIN OVER GLUCAGON

Change in 1/G ratio
Experimental Situation

due to diet
From

Control Period to
High Sucrose Diet Period
r------------------Control Period to
Low Sucrose Diet Period

0

/o Change
in 1/G

To

7.1 ±1.0

5.1 ± 1.2

f 39.2 °/o

------------------ -------6.4 ±1.3

5.5±0.4

J. 14.1 °/o

Insulin to glucagon ratios were calculated from control diet period and
week 4 of the study diet period values.
is that from the control value.

The percent change expressed

The values are the means and S.E.M. of

all patients from each group for the time period designated.
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Figure 27: The percent of total lipoprotein present is expressed forS,
pre s and s 1i poprotei n species. Each point represents the
mean and S.E.M. of all patients per group per time period
measured. All values are compared to the control period
values (C) for each group. Significance is measured for each
point with non-significant changes designated by (ns).
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nonsignificant changes in 8, pre 8 or
control levels.

a

lipoprotein percentages from

The only lipoprotein fractions showing any change

were pre 8 lipoproteins which dropped slightly, possibly reflecting
the decreased fasting triglyceride concentration observed in low sucrose study group patients (Figure 17).
also noted for

a

An insignificant increase was

lipoprotein which probably reflects the increase in

HDL-cholesterol observed with consumption of low sucrose diets (Figure
19).
High sucrose study group patients showed highly significant
changes from control values in all three lipoprotein fractions.

The

8 lipoprotein fraction showed a significant decrease of approximately
10% from control values (p <0.01).

This percentage was maintained

from the second week of the study diet to the end.

This drop in fast-

ing 8 lipoprotein levels most probably represents the decrease in fasting cholesterol observed while consuming high sucrose diets (Figure 21).
Pre

s lipoprotein

levels increased significantly, 10% over control

levels while consuming high sucrose diets (p< 0.01).

This increase

is probably due to the fasting triglyceride increase observed in high
sucrose patients (Figure 17).

Finally, a decrease in

centage was observed after the first week (p

a

lipoprotein per-

= 0.05) on high sucrose

diets with a rise back to control values by week three.

This slight

decrease could be a reflection of the decrease in HDL-cholesterol observed with increased sucrose consumption (Figure 19).

Not surpris-

ingly, when diets with different sucrose content are consumed lipoprotein pattern changes seem to reflect, in general, blood lipid alterations.
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G. Triglyceride Turnover
A commonly used method to estimate triglyceride production is
based on the two assumptions that the decline in radioactivity of
plasma VLDL triglycerides after pulse injection of a precursor into
this pool is essentially monoexponential and the calculated rate constant obtained provides a valid measurement of the turnover rate of
plasma triglycerides (419).

Radioactive labeling of the triglyceride

precursor glycerol is generally preferred to free fatty acid labeling
because less recycling of glycerol occurs after pulse injection and
a greater monoexponentiality in the decay curve is attained.

This

period is presumed to reflect less glycerol returning to the liver
from hepatic triglyceride catabqlism (recycling).

Figures 28 and 29

represent single patient decay curves where linear regression analysis
was used to derive patient•s turnover results.

Figures 30 and 31 are

graphs depicting the fractional turnover rates (K values) of the patient
population plotted against triglyceride concentration.

Table 7 demon-

strates changes in total turnover rate relative to the respective study
diet.

Figures 32 and 33 illustrate total turnover rates plotted against

triglyceride concentration.

a. Typical Patient Curve
Figure 28 illustrates the plasma radioactivity plotted semilogarithmically against time for one study patient.

Two turnovers were

performed, the first at the end of the control diet period and the
second after two weeks on either the high or low sucrose study diet.
A decay curve of the methanol fraction containing polar constituents is
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Figure 28: Triglyceride radioactivity curves after intravenous injection of tritiated glycerol in one of the patients who participated in triglyceride turnover studies.

The open squares

represent the turnover data collected immediately after the
control diet period was completed.

The closed circles re-

present the curve generated after two weeks on the study
diet. The open triangles represent the counts found in the
polar methanol wash after Folsch extraction procedures for
nonpolar lipids were performed from the sample taken during
the second turnover procedure.

This fraction represents free

glycerol, labeled free fatty acids and all other labeled
material other than nonpolar lipid.
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shown, representing free glycerol and glycerol that has been used to
manufacture free fatty acids.

Removal of the labeled

triglycerid~

from

this patient•s plasma pool was monoexponential for approximately 17
hours.

Figure 28 was not uniformly indicative of all the patients

studied.

In some instances, the monoexponential component only occurred

between 1-12 hours.

With these patients, a slower decay with a de-

creased slope was found to occur 12 hours after the test was initiated.
This slow decay section of the curve could occur from recycling of the
glycerol, from the plasma compartment, into new triglyceride or it could
represent another slow synthetic triglyceride pool.

In these cases, the

portion of the curve with the greatest slope was used to calculate fractional turnover rates.

A linear regression analysis was performed on

this section of the curve and this line was extrapolated back to zero
since this Y intercept value is considered the maximum radioactive
incorporation of label into the plasma triglyceride pool.

The patient

represented in Figure 29 is given two pulse injections of glycerol, one
at the end of the control diet and one two weeks after the initiation of
the study diet.

The Y intercept of 12, 115 disintegration in 20 minutes

is obtained after the first pulse injection and the intercept at 95%
disintegrations in 20 minutes is obtained after the second injection two
weeks later.

b. Calculation of K Value Turnover
K values for this patient were determined by estimating the decay
half life (T 1/2) from the most linear part of the decay curve.

This

patient had T 1/2 values of 8.5 hours and 7 hours for the first turnover
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Figure 29: Representative plots of first and second turnover determinations in a patient demonstrating a biphasic decay.

The slow

decay component was dropped from the curve and linear regression analysis was performed on the rapid decay portion.
The best fit lines are extrapolated back to the Y intercept,
the value considered to be the maximum incorporation of
labeled glycerol into the plasma triglyceride pool.

T l/2

values are calculated directly from these figures by observing the time in which half of the total counts are lost.
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and second turnover procedure respectively.

The K values are calculated

from the relationship

K = 0.693
T 1/2
and for this particular patient were 0.081 hr - 1 and 0.099 hr - 1 for
the first and second turnover procedures respectively.

c. Fractional Turnovers as Plotted Against Triglyceride
Concentration
The fractional turnover rates (K value) obtained after consumption
of the control diet from all patients studied were plotted against serum
triglyceride values obtained during this same time period (Figure 30).
A significant relationship betwe,en fractional turnover and triglyceride
concentration was found with a coefficient of correlation of 0.812 and
a significance of {p <0.001).

It should be emphasized that as fraction-

al turnover rate (K) decreases, triglyceride concentration increases.
This inverse relationship was seen in all patients studied.

d. Plasma Total Turnover for Triglyceride Removal
Total plasma VLDL triglyceride turnover rates were calculated
from the fractional turnover rate and the plasma VLDL triglyceride
concentration using the following equation:
triglyceride turnover= plasma triglycerides {mg/dl) X
plasma volume (dl/kg) X
_
fractional turnover rate (hr 1)
The relative plasma volume for this population was considered to
be 0.45 dl/kg {57).

This assumption has been validated by Adams and
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FRACTIONAL TURNOVER vs. TRIGLYCERIDE CONCENTRATION
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Figure 30: Fractional turnover rates, obtained from decay curves generated after the control diet period was completed, were
plotted against triglyceride values in 19 patients.

These

control fractional turnovers were used to construct a line
which was considered to be representative of the patient
population studied.

This control line was used to assess

changes in the relationship between fractional turnover
and triglyceride concentration due to diet.
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Kissebah (59).

Changes in total triglyceride turnover when patients are

switched from the control diet to the study diet (high and low sucrose)
are illustrated in Table 7.

The values listed in the

11

from 11 column are

control diet total turnovers calculated from the patients who were
randomized to either high or low sucrose diets.

The 8.0 mg/kg/hr repre-

sents the mean of the control total turnover values from 10 patients
before they were switched to a high sucrose diet.

The total turnover

value of 9.8 mg/kg/hr represents the mean value of total triglyceride
turnover before nine other patients were switched from the control diet
to the low sucrose study diet.
diets after control diets, their

When patients consumed high sucrose
~ean

total turnover values in-

creased significantly from a mean value of 8.0 mg/kg/hr to 10.8
mg/kg/hr (P< 0.01).

Low sucrose study patients showed the opposite

effect with a decrease in total turnover values from 9.8 mg/kg/hr to
9.2 mg/kg/hr (not significant p=0.2).

e. Plasma Total Turnover Rates Versus Triglyceride Concentration
Figure 31 and Figure 32 demonstrate the relationship between
total triglyceride turnover, which represents total body pool triglyceride turnover and triglyceride concentration.

It has been suggest-

ed that the hyperbolic curve relating triglyceride concentration to
triglyceride turnover is analogous to the relationship between substrate concentration and reaction velocity described by the Michaelis
Menton equation (418).

Figure 31 illustrates the patients who were
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TABLE 7

TURNOVER RATES FROM
CONTROL PERIOD TO STUDY PERIOD

TOTAL TURNOVER
GROUP

VALUES
mg/kg-hr
From
To

l

High Sucrose Diet

S.Q + O.SjiO.S+I.O

SIGNIFICANCE

p <0.01

i

I

Low Sucrose Diet

9.8 ±1.2 19.2-1-0.9
j

NS

Changes in total turnover values from control dietary period
to study diet.

The significance was determined by paired t

analysis which compared control values with study diet turnover values for each individual patient.
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studied while consuming the control diet.

Their control total turn-

over values were plotted against their triglyceride concentration
during the same period.

The results indicate that higher plasma tri-

glyceride concentrations are generally associated with increases in
triglyceride turnover (r

= 0.851, P< 0.001). It can also be seen that

triglyceride concentration and turnover rates are not linearly related
throughout the entire range of triglyceride concentration.

As total

turnover rates exceed 12 mg/kg/hr the triglyceride concentrations increase much more rapidly.
The shape of the curve suggests that the removal rate for plasma
triglycerides follow the kinetics of a saturable enzyme system.

The

Vmax calculated from this curve is approximately 12.5 mg/kg/hr for this
patient population.

In normal adult populations the Vmax for the

enzyme system was found to be 30 mg/kg/hr (402).

Therefore, this

patient population demonstrates depressed total turnover rates relative to normal population studies.

The comparison of data from HSD

and LSD to the normal line represents the metabolic changes in the
triglyceride removal system that occur when patients are switched
from the control diet to either study diet.

The patients who consumed

the high sucrose diet demonstrated no change or a slight increase from
control values.

Patients consuming the low sucrose diet showed little

change from control values when their points where plotted against the
line generated during the control diet (Figure 32).
Finally, Figures 33 and 34 demonstrate the change from control
values that occur in total turnovers when the study diets were consumed.

These results were obtained after body weight correction fac-
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Figure 31: The relationship between plasma triglyceride total turnover
and plasma triglyceride concentration in 19 patients after
the two week control dietary period was completed.

The

line generated represents this patient population consuming a diet of average sucrose content.

Vmax was determined

by the point at which the system demonstrated zero order
kinetics and was found to be 12.5 mg/kg/hr.
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tors were determined.

Total turnover rates (TO) are increased when

body weight factors are included.

One observation predominates,

patients who consumed the high sucrose diet demonstrated a slight increase in turnover rate with large TG increases (Figure 33).
small

The

TO/ TG ratio may suggest a removal defect predominates in the

grossly lipemic individual (TG >200).

The low sucrose study group

predominantly showed the opposite effect whenever the changes in turnover rate exceeded 3 mg/kg/hr possibly suggesting synthesis stimulates
remova 1 (Figure 34).

H. Triglyceride Turnover Kinetic Evaluation of System
a. Linear Transform of Michaelis Menton System
Even though an approximation of Vmax is obtained by plotting
total turnover versus triglyceride concentration (Figure 31).

Vmax

and Km values can be calculated more accurately from a linear transformation of the Michaelis-Menton equation.

By this process a plot of

[S /V] versus [S] is produced (Figure 35).

Data reduction in the for-

mat of triglyceride concentration/turnover ( S/V) versus triglyceride
concentration ([S]) was performed separately for patients consuming
high sucrose, low sucrose, and control diets.

The control group data

is generated from all patients who consumed the control diet (n=19)
before being switched to either the high sucrose (n=10) or the low sucrose diet (n=9).

The three lines generated intercept theY axis at

approximately the same point.

The X intercept of the line generated

from patients consuming the control diet was found not to be statistically different from the X intercept of the lines obtained after con-
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PLASMA TRIGLYCERIDE TURNOVER vs. TRIGLYCERIDE
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Figure 32: The relationship between plasma triglyceride total turnover
and plasma triglyceride concentration in 10 patients consuming high sucrose diets (black circles) and 9 patients
consuming low sucrose diets (open circles).
Vmax shown are from Figure 31.

The line and

The points demonstrate the

changes that occurred in this relationship due to dietary
manipulation.
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Figure 33: Plot of total turnover vs. triglyceride concentration in
patients who consumed the high sucrose diet.

Each line

represents one patient whose control and study diet values
are compared.

Most lipemic patients demonstrated large in-

creases in triglyceride concentration with small increases
in total turnover with the exception of one patient who
demonstrated the opposite relationship in this overall
effect (*).
feet.

These results suggest a possible removal de-

The area designated by the box represents the normal

patient response area (54).
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Figure 34: Plot of total turnover vs. triglyceride concentration in
selected patients who consumed the low sucrose diet.
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line represents one patient whose control and study diet
values are compared.

Note the opposite trend in results

as compared to Figure 33.
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sumption of the study diets (high and low sucrose).

Since the X inter-

cept represents the triglyceride concentration at 1/2 Vmax (Km), this
suggests the Km for the patients consuming high or low sucrose diets
remained unchanged from control Km values.

Linear regression analysis

for all groups demonstrated a highly significant correlation of r=0.745,
p<O.OOl for the control group, r=0.890, p<0.001 for the high sucrose
group and r=O. 929 with a p < 0. 001 for the 1ow sucrose study group.
Figures 36 and 37 represent the results obtained from each group
after consumption of the control diet compared with the results of the
same study group after consumption of the study diet (high or low
sucrose).

In these plots, Vmax equals 1/slope and Km equals the X

intercept or the product of the vertical y intercept and Vmax. The
slope of the control line in Figure 36 is 0.052 ± 1.5x10- 2 . Therefore, the Vmax for the high sucrose group consuming the control diet
is 19.3

±

5.76 mg/kg/hr.

Though this Vmax value is higher than con-

trol group Vmax from Figure 31 it still reflects a lower than normal
Vmax for the enzyme system.

The higher Vmax calculated above re-

flects a more accurate measurement of Vmax done by this linear method
of analysis.

The Km obtained for the HSD obtained group consuming the

control diet is approximately 260.7

±

101.3 mg which is the product of

the vertical intercept of the line (13.48 ± 3.36) times the Vmax (19.3
±

5.76 mg/kg/hr).
Consumption of a sucrose enriched diet after the control diet

altered [S] and S/V values so that linear regression analysis produced
a new line with a slope of 0.039
cept of 13.17

±

2.13.

±

. 1 y inter6.5 x 10 - 3 an d a vert1ca

The Vmax calculated for the triglyceride trans-
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Figure 35: The relationship between [S] and S/V, where [S] is the serum
triglyceride concentration (mg/dl) and Vis the triglyceride
turnover rate in mg/kg/hr, produces a linear transform of
the turnover system. The solid line with open circles represents all 19 patients whose turnovers were performed
immediately after the control dietary period had ended. The
line with the open triangles and line dot configuration was
generated from the 10 patients who consumed high sucrose and
the open square dashed line represents the 9 patients who
consumed the low sucrose diet. Both high and low sucrose
diet turnover studies were performed after a two week interval in which individuals consumed the appropriate study diet.
The control turnovers were done in the same patients after a
two week interval while patients consumed the control diet of
120 gms of sucrose per day.
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port system was determined to be 25.6
(calculated as above) was 337.6

±

±

4.3 mg/kg/hr and the Km

78.4 mg.

Though slightly higher than

control values these differences were found to be not statistically
significant using two tailed t analysis.
Figure 37 shows the comparison of the triglyceride transport data
obtained from the low sucrose study group after control and sucrose restricted diets were consumed.

The line generated from the turnover data
after consumption of the control diet had a slope of 5.5 x 10- 2 ± 1.54
x 10- 2 with a y intercept of 9.36 ± 4.16. The Vmax obtained from the
reciprocal of the slope was found to be 18.2
group was determined to be 170.2
Consumption of the

±

±

5.1 and the Km for this

89 mg.

depleted diet after the control diet
produced a new line with a slope of 0.041 ± 7.3 x 10- 3 and a y intercept of 13.71

±

1.8.

sucros~

The Vmax was 24.3

group was determined to be 332.8

±

73.4.

±

4.3 and the Km of this
Again no significant dif-

ference in Km and Vmax values could be obtained when the kinetic
values from the control and low sucrose period were compared.
The results above indicate that the Vmax for both study groups
remained relatively unchanged from the Vmax obtained during the control
period.

Both groups demonstrated no change in Km values from the con-

trol group when two tailed t analysis was used.

The lack of change in

Km values when the high sucrose diet was consumed demonstrates an unresponsiveness of the removal system to increased triglyceride which is
released into the plasma pool after synthesis in the liver.
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I. Polyacrylamide Gel Electrophoresis and Isoelectric Focusing of
VLDL Apoproteins
a. Pattern of apo VLDL on SDS Polyacrylamide Gels
Polyacrylamide gel electrophoresis in sodium dodecyl sulfate was
performed on samples which were obtained from each patient during both
control and study diet periods.

These assays were performed to assess

the changes in apoprotein composition which occurred from dietary
changes during the study.

A typical pattern from several of the

patients samples is shown in Figure 38.

These patients have a large

CIII 1 band which is always prevalent in hyperlipemic individuals.

The

CII band is observed as a thin, sharp band which migrates to a position
above the CIII 1 band. The E banQ is seen as a large diffuse band
which migrates a short distance into the gel. The B apoprotein, because of its large size and molecular weight, does not penetrate into
the gel ·but remains as a large band between the interface of the
stacking gel and separating gel.

The CIII 2 band migrates furthest
and is observed as a band occupying a position slightly below the
large CIII 1 band. A typical densitometric pattern usually observed
from these VLDL samples is diagrammed in Figure 39. Reading this
pattern from left to right corresponds to the bottom and the top of
the gel respectively.

Again the typical apoprotein pattern of a

hyperlipemic individual is observed.

All apoprotein fractions from

the VLDL sample are expressed as the percent of total soluble apeprotein present.
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Figure 36: Plot of triglyceride concentration/turnover ([S]/V) versus
triglyceride concentration ([S]) done separately for the
group of patients who were randomized to high sucrose diets
after control sucrose diets were consumed. Ten patients were
studied in this group.
with a p< 0.01.

r value for control equals 0.685

The r value for the line generated after

high sucrose consumption equals 0.890 with a p < 0.001.
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Control vs. LSD
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Figure 37: Plot of triglyceride concentration/turnover ([S]/V} versus
triglyceride concentration ([S]} done separately for the
group of patients who were randomized to low sucrose diets
after control sucrose diets were consumed.
were studied in the group.

Nine patients

The r value for the control

equals 0.651 with a p <0.01 and the r value for the line
generated after the low sucrose diet was consumed equals
0.929 with a p < 0.001.
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Figure 38: SDS polyacrylamide gel electrophoresis of VLDL apoprotein
derived from ten of the patients who participated in the
study.

Ten percent polyacrylamide separating gel with 2.5 %

stacking gels were used.

Two hundred ug of protein was

added to each gel and electrophoresed for approximately 8
hours at 2.5 rnA per tube.
tion containing

1~

Gels were stained with a solu-

Amido Schwarz in acetic acid.

186

b. Soluble Apoprotein Percentages Observed in This Patient
Population
Data from 20 study patients listing the composition of the apeprotein fractions present at the time of entry into the study is seen
in Table 8.

The mean values of these fractions can be compared with a

table of apoprotein fractions from normal individuals in Table 9.

It

should be observed that the greatest differences between the two groups
of patients is that hyperlipemic individuals demonstrate a large increase in the apo CIII 1 fraction and a noticeable decrease in the apo
E component relative to the normal patient population.
c. Isoelectric Focusing Patterns Observed for Apo VLDL
Isoelectric focusing in 7.5% polyacrylamide gels through a pH
gradient of 4-8 was performed on all samples obtained for VLDL apeprotein determination.

The major advantage of isoelectric focusing

on apoprotein samples is the separation of isoprotein subunits of the
apo E fractions.

Figure 40 is a print of isoelectric patterns from

several of the patients who were incorporated into the study.

The apo

E fraction can be divided into 3 isoprotein subunits.

The E1 isoprotein band migrates roughly to the midpoint of the gel and has an isoelectric point of approximately 5.31.

The band is diffuse and is com-

posed of several minor subfractions.

Apo EII migrates to approximately

the same position in the gel, but is found slightly above apo E1. Its
isoelectric pH is 5.39. Apo EIII, the heaviest staining band, migrates
the shortest distance into the gel with an isoelectric point of 5.44.
The densitometric pattern of one of these gels is shown in Figure 41.
Apo C proteins are the most acidic and migrate to an isoelectric point
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Figure 39: Typical densitometric scan of SDS polyacrylamide gel electrophoresis of VLDL apoprotein derived from hypertriglyceridemic
patient. A Gelman, Model #ACD-18 was used to produce the scan
represented.
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TABLE 8

SOLUBLE APOPROTEINS AS PERCENT OF
TOTAL SOLUBLE APOPROTEIN
APO

PATIENT

E

APO

CII

APO

CIII

APO

CII 12

21.5
19.4
29.8
10.1
13.6
25.7
22.2
30.7
20.3
23.3
25.3
20.9
24.4
22.6
23.0
36.3
23.4
16.8
28.6
37.8

16.3
20.6
20.7
13.4
27.7
18.2
28.1
22.0
12.0
17.3
14:4
15.8
21.4
27.3
18.8
19.8
8.5
8.7
15.3
17.9

51.0
37.2
31.9
55.3
27.6
44.7
25.3
29.4
41.6
37.5
47.5
45.0
23.3
21.6
32.7
31.3
45.3
48.2
25.9
18.5

11.3
22.4
17.5
21.2
28.2
11.4
20.3
17.9
26.0
22.0
12.8
17.9
28.9
28.5
25.4
12.6
9.5
26.3
30.2
25.5

X

23.8

18.2

36.0

20.8

SEM

f,5

1.2

2.4

1.5

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

18
19
20

Table of soluble apoproteins represented as percent of total
soluble apoprotein present in 20 of the patients who participated in the study.

Values were obtained at time of patient

incorporation into the study.
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TABLE 9

Table 2. Distribution of Cholesterol in Lipoproteins
No.
In
group

Group

Control
Diabetic
Normolipidemic
f VLDL
t LDL

17
25
15

6C
7C

R.. auve distribution,

A.baofute distribution, •
mg/L serum (and SEM)
LDL
IDL

% of total (and SEM)
U9

VLDL

IDL

LDL

HDL

VLDL

12/5
10/15
7/8
2/4
2/5

6 (1)
10(3)
7 (1)
16 (4)"
13 (3)

1 (0.3)
4(1)
4(7)
4(1)
3 (1)

65 (2)
64 (2)
63 (2)
60 (3)
71 (4)"

27 (2)
22 (2)"
26 (1)
20 (8)
13 (2) 0

130(20)
250 (120)
140 (20)
480 (120)"
410 (100)

30 (10)
90 (30)
80 (10)
110 (40) 0
100 (20)"

HDL

1350 (90)
1550 (100)
1310 (70)
1760 (260)
2210 (110)d

570 (50)
530 (50)
580 (40)
590 (200)
400 (60)•

• Recovery of cholesterol in the ultracentrifugal fractions was 78-91% of the serum value; the absolute distribution as based on the relative distribution 1n the
ultracentritugal tractions, corrected to 100% recovery (disregarding chylormcrons).
tt Differs from control value, p <0.02.
c See Table 1.
dQiffers from control value, p <0.001.

Table 3. Apoprotein Composition of Soluble VLDL Protein, in Percent (±SEM)
Group (no.)

(1)•

Cl

E

en

Clll1

em•

Control (12)
Diabetic (27)
Normolipidemic
(14)
f VLDL (6)d
f LDL (7) 1

5.2 (0.8)
3.7 (0.7)
3.8 (0.9)

10.6 (1.7)
11.0 (1.4)
13.1 (1.8)

32.4 (3.1)
28.1 (2.1)
28.6 (2.9)

11.4 ( 1.1)
14.3 (0.8)c
13.4 (1.1)

18.2 (1.9)
24.4 (1.9)C
21.9 (5.8)

15.8 (1.5)
17.9.(0.9\
17.5 (1.5)

3.6 (1)
3.6 (0.7)

8.7 (2.2)
6.5 (1.2)

24.7 (3.8)
31.5 (3.8)

15.2 (1.9)
16.5 (1.2) 8

29.2 (4.5)•
23.4(2.1)

18.6 (0.9)
18.4 (1.2)

Minor components 111

6.1 (1.8)

<JC

CII/CIII,

0.65 (0.04)
0.66 (0.2)
0.68 (0.06)
0.56 (0.06\ 8
0.71 (0.04)

• Band 1 on the electrophOretic qel. near the ongin; ldentity not determined.
0 Includes AI, All, and one Wlidentified band mov•ng between All and CU.
c Analysis of variance: difference between diabetics and controls significant at p <0.025.
Includes ttvee subrects with 1ncrease 10 VLOL (phenotype IV) and three subjects with increase in both VLOL and LOL (phenotype 118). Thera was no difference

d

observed between these two subgroups.
• Within analySIS of variance. differs from control with p <O.OS.
1 Phenotype IIA.

Distribution of cholesterol in lipoproteins and apoprotein composition in percent of soluble VLDL protein in percent from a
normal control, diabetic, and normolipemic population as reported
from reference #63.

The apoprotein percent composition from these

three groups should be used for comparison with the VLDL apoprotein
composition of the hyperlipemic patients participating in the suerose study.
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The most basic protein observed is apo c1 which
has an isoelectric point between pH 6.0 and 6.5. The isoelectric

of approximately 4.3.

gradient which was generated during each electrophoresis is seen in
Figure 41.

The pH range was between 3.5 and 8.0.

d. Changes Observed in Apo VLDL as a Result of Different Sucrose
Diets
The composition of apoprotein subunits in VLDL lipoproteins were
compared between control diet and study diet periods in all patients who
participated in the study.

Samples were obtained three times weekly

during both the control and study diet periods.
apoprotein concentrations found

i~

The different VLDL

patients consuming the high or low

sucrose diets as compared to the control diet are illustrated in Figure
42.

All apoprotein concentrations are represented as the percent (%)

of total peptide present.

This includes total apo E and all apo C pro-

teins, but the apo B protein, because of its size, does not penetrate
the gel and is considered an insoluble apoprotein.

Total apo E does

not change significantly in these hyperlipemic patients from the control dietary period to either the high or low sucrose dietary period
(Figure 42).

Apo CII also remained stable throughout the study with

no significant changes observed between control and study diet periods.
Significant changes were observed in the apo CIII 1 and apo
CIII 2 protein fractions of the VLDL lipoprotein during the study. The
apo CIII 1 fraction increased significantly in patients consuming the
high sucrose diet, from a control value of 34% to almost 47% of total
soluble peptide present.

This increase was statistically significant
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Fiaure 40: Isoelectrically focused gels of VLDL apoproteins derived from
9 of the patients who participated in the study.

7.5 % poly-

acrylamide separating gels were used and samples were
electrophoresed and stained as described in Materials and
~1 ethods.
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Figure 41: Typical densitometric scan of an isoelectrically focused gel
containing apo VLDL derived from a hypertriglyceridemic
patient.

Gelman Model #ACD-18 was used for scanning and peak

integration of samples.
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(p<0.05 using paired t analysis).

The apo CIII 1 fraction decreased
from the control period values in patients consuming the low sucrose
diets.

However, this decrease was not significant.

In general, the

apo CIII 2 fraction changed in an opposite fashion relative to changes
observed for the apo CIII 1 fraction with consumption of both study
Specifically, the apo CIII 2 fraction decreased slightly from
the control diet concentrations with consumption of the high sucrose

diets.

diet (nonsignificant, p <0.02).

However, apo CIII 2 fraction increased
significantly when patients consumed the low sucrose diet, from a con-

trol value of approximately 20% of the total apoprotein to a study diet
value of 28% of total apoprotein {p=0.05).
In summary, nonsignificant

~hanges

were observed in total apo E

and apo CII concentrations from control values when patients consumed
either high or low sucrose diets.

Apo CIII 1 and CIII 2 showed the
most significant changes observed. Apo CIII 1 increased significantly
from control values when patients consumed a diet rich in sucrose.

In

contrast, apo CIII 2 increased significantly from control values when
low sucrose diets were consumed.
Data generated from the isoelectric focusing measurements indicated relevant changes that occurred in the concentration of the apo E
isoprotein subfractions with consumption of different sucrose study
diets.

Figure 43 graphically demonstrates changes in these subfractions

-from control diet values when diets rich in sucrose or low in sucrose
were consumed.

Minor changes from control values were realized in apo

El and apo E2 isoprotein concentrations when either high sucrose or
low sucrose diets were consumed (nonsignificant p > 0.30). The apo EIII
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DISTRIBUTION OF APOPROTEIN
IN VLDL

C 0 N T R 0 L vs. STUD Y D I E T

% PEPTIDE

* Significant
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p:! 0.05
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Figure 42: Effect of different sucrose content diets on apoprotein composition of VLDL.
low sucrose n

Group II high sucrose n

=

17.

Group III

= 13. Group I control n = 30. Results

represent soluble peptide in the apoprotein as percent of
total soluble peptide present.

Values represent mean

S.E.M. of all patients per group.

±
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isoprotein subspecies showed a significant increase from control values
when patients consumed high sucrose diets (p <0.05).

Patients consuming

sucrose restricted diets had relatively unaltered apo EIII levels from
control period values.

e. Correlations Between Apoprotein Subfractions and Triglyceride
Concentrations
The importance of alterations in apoprotein content of the VLDL is
demonstrated in Figures 44 through 48.

These illustrate the relation-

ship between apoprotein content and triglyceride concentration observed
in study patients.

All of the correlation studies performed were done

during the last week of the study diet for both high and low sucrose
groups.

Figure 44 illustrates the relationship between the percen-

tage of apo CIII 1 observed and the triglyceride concentration
measured in all patients consuming high sucrose diets. The correlation was significant (r=0.723 and P< 0.001).

Figure 45 also demon-

strates this same relationship in all patients who consumed low sucrose
diets.

The correlation was again highly significant (r=0.823,

p< 0.001).

From Figures 44 and 45, it is observed that as apo CIII 1
protein percentages increased, triglyceride concentration also increased.

Patients who had apo CIII 1 concentration composing 50% or
more of their soluble apoproteins present had triglyceride concentrations sometimes as high as 400 to 600 mg/dl.

Thus, in these patients,

apo CIII

levels correlate directly to triglyceride concentration.
1
The relationship between apo CII/CIII 1 ratios and triglyceride

concentration is illustrated in Figures 46 and 47.

In both groups of
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Effect of Sucrose Diets on Apo E Jsoprote1n
Distribution in VLDL Lipoprotein
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Figure 43: Changes in each apo E isoprotein subunit as a result of
dietary manipulation.

Values from all patients in a parti-

cular study group while consuming the control diet are compared to values from these same patients while consuming
either high or low sucrose content diets.

C represents the

control diet and S represents the period of either high or
low sucrose intake.
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patients the ratio of apo CII/CIII 1 had an effect on triglyceride concentrations. As the apo CII/CIII 1 ratio increased, triglyceride co~
centrations decreased.

A significant correlation was observed in apo

CII/CIII 1 ratios and triglyceride concentrations in patients who consumed high sucrose diets (r=0.682, a p< 0.001).

Patients who consumed

the sucrose restricted diet also demonstrated a strongly significant
correlation between apo CII/CIII 1 ratios and triglyceride concentrations (r=-0.871 and a p<0.001).
Finally, the relationship between apo CIII 2/CIII 1 and triglyceride concentration in the high sucrose patient population is observed
in Figure 48.
lationship.

The low sucrose population demonstrated a similar reIt should be observe,d that the negative correlation be-

tween apo CIII 2/CIII 1 and triglyceride concentrations was significant (r = -0.60 and a p = 0.05). When triglyceride concentrations
were elevated apo CIII 2/CIII 1 ratios were depressed. Patients with
apo CIII 2/CIII ratios of 0.25 or less had triglyceride concentra1
tions of 350 mg/dl or more. Similarly, those patients with ratios
of 1.25 or greater had triglyceride concentration of 150 mg/dl or
less.
In summary, the above results show that apoprotein concentrations, especially apo CII, CIII 1 and CIII 2 had significant effects
on triglyceride levels in this population of patients . As apo CIII 1
increased, triglyceride concentration also increased. Apo CII/CIII 1
ratios and triglyceride concentrations were inversely related. With
more apo CII present relative to apo CIII 1 , lower plasma triglyceride
concentrations were observed in the study group. In addition, a similar
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COMPARISON OF apo CII!j WITH TRIGLYCERIDE CONCENTRATION HSD
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Figure 44: The effect of apo CIII 1 in VLDL on plasma triglyceride concentration in 17 patients on the high sucrose diet. A significant positive correlation was found (r=0.723, p<0.001).
These values were generated from patients during the final
week of the high sucrose diet.
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Figure 45: The effect of apo CIII 1 in VLDL on plasma triglyceride concentration in 13 patients on the low sucrose diet. A significant positive correlation is observed (r=0.823,
p < 0.001). These values are taken from patients in the final
week of the study after being randomized to the low sucrose
diet.
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relationship was observed between apo CIII 2/CIII 1 ratios and triglyceride concentrations in this patient population. With more apo C~II 2
present relative to apo CIII 1 , triglyceride concentrations found in
individual patients were decreased.

J. Abnormal VLDL Found in Several Patients Participating in the
Sucrose Study
a. Observations of VLDL Lipoprotein Electrophoresis
A particularly interesting observation was found in 4 patients
who consumed sucrose enriched diets.

While the lipoprotein electro-

phoresis measurements were done during both control and study diet
periods, it was noticed that

thes~

patients demonstrated a variable

hyperlipemic electrophoretic pattern.

This pattern could be classi-

fied as type IV while they were consuming the control diet, but
changed to a type III hyperlipemic pattern when they consumed the
high content sucrose diets.

A sequential electrophoretic pattern from

one of these patients is illustrated in Figure 49.

The relatively

large pre Sband associated with type IV hyperlipemic individuals
gradually disappears during the study diet and is incorporated into
the S band.

This pattern is characteristic of an individual with type

III hyperlipemia having the broad

band pattern.

b. Isoelectric Focusing on Abnormal VLDL Lipoproteins
Since the possibility existed that these patients could have a
VLDL different in composition from the rest of the high sucrose patient
population, their apoprotein electrophoresis results were compared to
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Figure 46: The apo CII/CIII 1 ratio and its effect on plasma triglyceride concentration in 17 patients who consumed high suerose diets.

A significant negative correlation was ob-

tained (r= -0.6817, P<0.001).

These values were obtained

after patients had consumed the high sucrose study diet
for a 4 week period.
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CORRELATION OF apo CIT/ CliG vs. TRIGLYCERIDE CONCENTRATION
400

0

300

=

CORR.COEFF.=-0.871

"0

......

p<O.OOI

c>

5

200
0

(.?

1-

0

0

100

0.25

0.50

0.75
apo

1.00

1.25

1.50

crucm1

Figure 47: The apo CII/CIII 1 ratio and its effect on plasma triglyceride concentration in 13 patients who consumed the low
sucrose diet.

A significant negative correlation was

obtained (r= -0.871 and a p <0.001).

These values were

obtained after patients had consumed the low sucrose
study diet for a period of 4 weeks.
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Figure 48: The apo CIII 2/CIII 1 ratio and its effect on plasma triglyceride concentration in patients who consumed the high
sucrose diet.

..

A significant negative correlation was ob-

tained (r= -0.600 with a p = 0.05).

These values were

obtained after patients had consumed the high sucrose
study diet for a period of 4 weeks.
used to obtain the results shown.

Eleven patients were
Similar results were

obtained from patients who consumed the low sucrose study
diet for the 4 week period.
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that from the remaining high sucrose patient population.

No appreci-

able differences could be found in the SDS PAGE patterns from the
designated abnormal VLDL subgroup and the rest of the patient population.

Comparison of the patterns obtained from isoelectric focusing

procedures on abnormal VLDL and the VLDL from other patients consuming high sucrose diets illustrated an interesting difference.

A

typical isoelectrically focused gel containing the VLDL from a hyperlipemic individual consuming the high sucrose diet is shown in Figure
50.

Particular attention must be paid to the apo E isoprotein pattern

of this patient.

The typical apo E pattern with the most acidic apo

E1 being a diffuse band, and two thick apo Ell and apo EIII bands is
observed. Figure 50 also repres~nts the isoelectrically focused VLDL
from the 4 patients in question.

Again observe the apo E isoprotein

pattern.

The diffuse apo E1 band is present and the apo Ell band is
directly above. However, no apo EIII band can be observed in these
patients.

Several repeat electrophoreses were performed on these

patients with the same apo E isoprotein pattern observed.

It is

possible that the loss of this particular apo E isoprotein band could
be responsible for the differing pattern observed in these 4 patients
during lipoprotein electrophoresis.

K. The Effect of Variable Sucrose Content Diets on Platelet
Aggregation
a. Effects of Sucrose Content on Total Platelet Aggregation
The possibility that variable sucrose content diets could also
affect platelet aggregation was studied in all the patients who parti-
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High Sucrose Diet

Control Period ----+Study Diet Period

Fiaure 49: Typical lipoprotein electrophoretic pattern obtained from
VLDL abnormal individual during the control and study diet
period.

Observe how the pre- B band seems to migrate a1ong

with the B band after high sucrose dietary consumption.
This pattern was found in 4 individuals who consumed the
high sucrose diet.

,
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cipated in the project.

Platelet aggregation measurements were done

once a week during both control and study diet periods.

The aggrega-

tions done during the control period were compared to those done during either high or low sucrose consumption.

In this way, changes in

platelet aggregation due specifically to diet could be ascertained.
Figure 51 shows the effect of high sucrose dietary consumption on
platelet aggregation.

Data from 4 representative patients from the

high sucrose study group are shown.

All results are represented as

percent light transmittance through the mixing cuvette, where more light
is transmitted when more platelets have aggregated.

In all patients

consuming the high sucrose diet illustrated in Figure 51, an increase
in aggregation occurred over

th~

control aggregation values.

In some

cases the increase was as high as 55 units on the percent transmission
scale.

In other cases, the increase observed was slight, consisting

of only 10% units.

However, in all cases, an increase in platelet

aggregation was realized.

Figure 52 illustrates the effect of low

sucrose diets on platelet aggregation using data from 3 representative
patients.

All the patients shown in Figure 52 demonstrated a slight

decrease in aggregation while consuming the low sucrose study diet as
compared to the control diet.

However, relatively little change from

control diet values was observed in many of the patients who consumed
the low sucrose diet and these patterns far outnumbered patient data
demonstrating a slight decrease.
The overall effect of sucrose content in diets on platelet aggregation is shown in Figure 53.

The figure represents measurements done

on 30 patients, 17 consuming high sucrose diets and 13 consuming low
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N

Fi gure 50: Isoelectrically focused samples of VLDL from patients who
consumed the high sucrose diet and demonstrated a shift in
their lipoprotein pattern from type IV to type III.

This

VLDL designated VLDL abnormal (VLDL abn) was found in only
4 of the patients studied.

Observe the apo E isoprotein

pattern as compared to the normal.
in the VLDL of these 4 patients.

No apo EIII band exists
These samples were ob-

tained at the end of the high sucrose dietary period.
preparation and focusing procedure done as described in
Materials and Methods.

Gel
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Fig ure 51: Platelet aggregation curves from 4 patients who consumed the
high sucrose diet after consumption of the control diet.
Each patient is designated by number.

The dark line repre-

sents that patient•s total aggregation at the end of the
control period.

The light line represents that patient•s

aggregation at the end of the high sucrose study diet.
Aggregation results are represented as % light transmitted through the measuring cuvette.
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sucrose diets.

Each group is an average of the platelet aggregations

obtained while consuming the study diet as compared to that groups•
average aggregation while consuming the control diet.

A slight, but

insignificant decrease in total aggregation was observed from control
aggregation values in the patient group consuming the low sucrose diet.
However, in patients consuming the high sucrose diet, a significant increase in average aggregation was observed over the control platelet
aggregations.

The patients who consumed high sucrose diets had mean

control aggregation values of approximately 50% which increased to 65%
light transmitted after high sucrose consumption.

This 15% increase

in light transmission was significant (p <0.05).

b. Platelet Sensitivity Studies
Platelet sensitivity studies were also done in both study groups
by varying the concentration of the aggregating agent, epinephrine.
Seven patients from each group had 30 cc of blood drawn.

Appropriate

plasma dilutions with platelet rich and platelet poor plasma were made
to obtain enough samples to perform 20 aggregations per study.

The

platelet sensitivity assays were performed during both control and
study diet periods.

Each patient's platelet sensitivity results during

the study diet were compared to the results obtained when the same
patient consumed the control diet.

The concentration of aggregating

agent at which the second phase platelet response disappeared was considered to be the lowest concentration of aggregating agents at which
the platelets could adequately respond.

21 0

Low Sucrose

Time in Minutes
Fi gu re 52: Platelet aggregation curves from 3 patients who consumed low
sucrose diets after consumption of the control diet.
patient is designated by number.

Each

The dark line represents

that patient 1 S total aggregation at the end of the control
period.

The light line represents that patient 1 s aggrega-

tion at the end of the sucrose dietary period.

Aggregation

is measured in % light transmittance through the measuring
cuvette.
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AGGREGATION OF PLATELETS DURING
DIFFERENT DIETARY SUCROSE CONSUMPTION
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Figure 53: The effects of dietary sucrose on platelet aggregation in 30
patients: 17 consuming high sucrose and 13 consuming low
sucrose diets.

Each group consuming either study diet is

compared with itself after consumption of the control sucrose
diet.

C represents the mean SEM aggregations of all patients

from the study group after consumption of the control diet.
HSD and LSD represent the mean SEM aggregations after consumption of the high and low sucrose diet respectively.
Significance (*) is at the p< 0.05 level.
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The platelets of patients consuming the low sucrose diet showed
little change in sensitivity when compared to the control diet values.
However, the patients who were placed in the high sucrose regimen after
the control period demonstrated an increased sensitivity to the aggregating agent as compared to the control diet.

Table 9 illustrates the

effect of sucrose enriched diets on platelet sensitivity.

Platelets of

all patients consuming sucrose-enriched diets were more sensitive to the
aggregating agent.

In some cases, concentrations of epinephrine as low

as 0.25 and 0.1 uM elicited the second phase response.

The concentra-

tion of aggregating agent that elicits the second phase response in a
normal population is between 2.5 and 5 uM.
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TABLE 10

PlATELET SENSITIVITY WITH VARYING CoNCENTRATICl'lS OF EPINEPHRINE
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Platelet sensitivity in 7 patients who consumed the high sucrose
study diet after consumption of the control sucrose diet.

C

represents the sensitivity results at the end of the control
diet period.

S represents the sensitivity results at the end of

the study diet period.

Results are expressed as the % light

transmittance through the cuvette after 5 minutes of incubation
with aggregating agent.

The effect of the aggregating agent is

considered non-significant (NS) if no second phase response is
initiated after addition of aggregating agent.

6. DISCUSSION AND SIGNIFICANCE

This study sought to ascertain the metabolic consequences of high
carbohydrate diets in diabetics with hypertriglyceridemia.

This was

initially prompted by the observations of Anderson et al. (10) as to
the effect of carbohydrate restriction and high carbohydrate diets in
men with chemical diabetes.

The clinical relevance of this question

was underscored in 1979 when the American Diabetes Association (ADA)
released its new dietary guidelines for diabetics.

The ADA recommended

allowances for carbohydrate intake be increased to 50 or 60% of the
total calories consumed in contrast to 40% as recommended only a few
years earlier (6}.

Reduction of dietary fat was the main objective of

these proposed changes since excess fat was presumed to be the pathogenic factor in accelerated arteriosclerosis observed in diabetics.
In a recent editorial, Reaven states that 11 although it is commonly considered to be a temporary phenomenon, the transient nature of
carbohydrate induced increases in triglyceride levels is not supported
by a great deal of experimental data 11 (102).

Reaven succinctly re-

viewed the incidence of favorable and unfavorable effects of high carbohydrate diets and concluded that most of the reported studies dealt
with normal well controlled diabetics and treated type I or type II
diabetics on high fiber diets (102).

He felt the need of a study with

"diets .•• similar in all but proportion of carbohydrate and consisting of food stuffs that patients will be able to tolerate chronically".

He particularly expressed concern for the effect of high carbo-

hydrate diets on hypertriglyceridemic, non-insulin dependent diabetics.
The need to know the advantages, if any, of a truly sucrose
214

215
restricted diet in the treatment of the 85% of diabetics having type
II (non-insulin dependent) diabetes, a form of the disease in

whic~

a

third of the patient population is hypertriglyceridemic, is of great
importance.

It is also important to ascertain critical levels of

dietary sucrose at which glycemic control and triglyceride metabolism
may become altered in these patients.
Our experimental protocol specifically focused on sucrose ingestion in the above group.

Sucrose is the least studied component

in diabetes, yet is the largest chemically homogenous component in the
regular diet (11).

Sucrose intake amounts to 40 to 60% of dietary

carbohydrate in the non-diabetic population of industrialized countries
(11).

Since a great proportion ;Of processed foods have variable but

large proportions of added sucrose not reported or quantitated (137),
the increased consumption of processed carbohydrate containing foodstuffs by the diabetic population predisposes these patients to increased sucrose ingestion.
As discussed in the literature review, most reports dealing with
the effects of sucrose on a given population used artificial diets,
either composed of liquid nutrients or extremely high in carbohydrate
proportion.

Albrink and Newman (38) found that high and low fiber

diets also affected insulin and glucose responses to a meal rich in
carbohydrate.

In this study, the diets were composed of natural

nutrients which closely mimic the intake pattern and fiber content of
a normal outpatient diet.
Initial experiments were concerned with the specific effects of
sucrose enriched or sucrose restricted diets on relevant blood chemistry
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parameters of the diabetic patient.

The effects of different sucrose

content diets on levels of serum glucose, urinary glucose,

trigly~

ceride, cholesterol, HDL-cholesterol, and patterns of lipoprotein
electrophoresis are summarized in Table 11.

Specific effects of

dietary sucrose content are represented since each patient's results,
while consuming either low or high sucrose diets, are compared to the
results obtained when the same patient ingested the control sucrose
diet.

Basically (and intentionally), sucrose content is the only para-

meter of the diet that changes significantly.
Surprisingly, alteration of dietary sucrose levels had essentially no effect on serum or urine glucose levels (Figures 13 and 15).
These results are in contrast to the findings of Reiser (40), Cohen
(26), and Akgun (31) who state that increased sucrose ingestion causes
a rise in blood serum glucose levels in normals and diabetics.

Reiser

(40) found that high sucrose diets caused an increase in mean glucose
levels compared to low sucrose intake in non-diabetic subjects.

Cohen

(26) administered high and low sucrose diets with subsequent testing of
glucose tolerance.

He found impaired glucose tolerance after high

sucrose consumption and suggested that because sucrose consisted of one
half glucose, its ability to stimulate insulin release was also halved.
Akgun (31) also found plasma glucose levels were lower when sorbitol or
fructose was ingested, but when sucrose content in the diet was increased, plasma glucose levels rose.

He could not find any link be-

tween plasma glucose levels and insulin response.
The results of the other studies discussed above are questionable, since in many cases other dietary factors which could effect
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TABLE 11

HIGH SUCROSE DIET

LOW SUCROSE DIET

P~1

+ p <0. 001
+ NS

HDL-Cho1esterol

AM
PM

-No

Cho 1estero 1

AM
PM

- p=0.05

Serum G1 ucose

AM
PM

-

AM

:Triglyceride

-

NS
Change

+ p ~ 0. 005

p=O.OS

No Change
- NS

a Lipo
a Lipo
. Pre a 1i po

No Change

p ( 0. 02
NS

p c::O.Ol
No Change
Low Spiller High Spiller

Urine
Glucose

No Change
+ p ( 0. 001

- NS
- NS
No Change
-p=O.OS
Low Spiller High Spiller

-

NS
- p <0. 01
+ p ( 0. 01

+ NS

No Change
- NS

Summary of the effects of different sucrose diets on blood and
urine chemistries in the patient population, (+) designates an
increase in values, (-) designates a decrease.
significant change observed.
by p value.

NS signifies no

Significant changes demonstrated

AM values signify the fasting state, PM values

represent the postprandial state.
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plasma glucose concentrations were ignored.

The studies of both Akgun

(31) and Reiser (40) utilized sucrose diets which were artificial
not consistent with normal dietary intake patterns.

~nd

In both studies,

sucrose solutions were given and no dietary fiber content considerations were made.

Dietary fiber has been clearly documented as having

favorable effects on postprandial glucose concentrations in normal and
non-insulin dependent diabetic subjects (460, 461).

When sugar and

pectin were incorporated into a large breakfast, postprandial glucose
levels were significantly reduced as compared to the same individual
eating fiber free meals containing similar nutrients.

When patients

with mild diabetes were given a water soluble fiber along with an
oral glucose tolerance test

solu~ion,

postprandial glucose concentra-

tions were significantly lower compared to similar test solutions
without fiber.

Other investigators (15) have confirmed the short

term beneficial effects of fiber supplements on glucose and meal
tolerance tests.

Others have demonstrated long term improvement in

glucose tolerance or metabolism with fiber supplemented diets (462,
463).

The extent to which plant fiber induces carbohydrate malab-

sorption has not been quantitated.

The total absorption of simple

sugars ingested with soluble fibers does not appear to be diminished,
but the hydrolysis and absorption of complex carbohydrates may be decreased.

With high fiber diets, fasting and average blood glucose con-

centrations were significantly lower and urine glucose excretion was
also significantly impaired (464).

Glucose metabolism was also im-

proved with the high fiber diet, despite lower endogenous insulin concentrations.

When patients were subsequently placed on a low fiber
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diet, the improvement observed with the high fiber diet was reversed
and average glucose concentration was similar to values observed on
the initial low fiber diet.
Plant fibers influence glucose metabolism and insulin requirements by altering intestinal absorption of carbohydrate and by indirectly affecting hormone secretion probably by influencing insulin
sensitivity and glucose metabolism in various tissues (464).

The

effect of plant fiber on the rate of carbohydrate absorption has been
examined in greater extent than other possible mechanisms that would
affect glucose metabolism.

However it seems unlikely that it would

account solely for the observed effects.
rich foods appear to delay

gastri~

Many plant fibers and fiber

emptying thus providing carbohydrate

to the intestines for digestion and absorption more slowly than after a
low fiber meal.

The gelatinous globules presumably formed in the small

intestine by water soluble fibers may retard starch and sugar hydrolysis
by separating carbohydrate to the distal jejunum where carbohydrate is
less efficiently absorbed due to lower concentrations of disaccharidases.

In addition, fiber may inhibit digestive enzyme activities and

slow the digestion and absorption of carbohydrate, proteins and fats.
Since our study diets contained high concentrations of sucrose and
relatively standard amounts of natural fiber, the effect of sucrose content in a diet of normal composition was adequately measured.

Thus, the

differences in our results, as compared to other investigators most
probably reflect the structural components of the diet and are much more
representative of the specific effect of sucrose intake on a diabetic
population consuming disaccharide in a non-hospital, home situation.
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Restricting sucrose intake in diabetic patients is based on the
premise that sucrose might cause rapid oscillations of blood

gluco~e,

result in glucosuria and cause interference with metabolic control (2).
Our studies demonstrate no such oscillation.

The fact that urine 24

hour glucose concentrations decrease when isocaloric carbohydrate diets,
which have high sucrose content, are given is extremely interesting.
Diets which are isocalorically similar should affect urinary glucose
output in a similar fashion.

It can only be concluded from our study

that sucrose enriched diets have no effect on causing an increase in
urinary glucose output.

The decreased excretion of glucose must mean

that the carbohydrate moiety is metabolized and is not excreted by the
patient.

The decrease in gluco$uria on the low sucrose diet is ex-

pected since the total carbohydrate intake of these patients was slightly less and the refined sucrose intake was minimal (the majority of
carbohydrate being starch).

The observation that the control group also

demonstrated a slight decrease in 24 hour glucosuria suggests that hospitalization could also lower glucose excretion.

Though this could be a

factor, we feel that it could not alone lead to the significant reduction in 24 hour urine glucose excretion observed in patients consuming the study diets.

The lack of any significant increase in serum

glucose concentration or urinary glucose output while consuming the high
sucrose diet points to the possibility that the increased proportion of
calories as sucrose, may be utilized metabolically to produce triglyceride.

Examination of the data obtained on fasting triglyceride con-

centrations indicates large increases in circulating triglyceride
levels after high sucrose intake and relatively little change in these

221
levels following low sucrose intake (Figure 17).

These results are

substantiated by other reports which stress the effect of sucrose
tent in the diet on circulating blood lipid.

~on

Nikkila {465), MacDonald

{30, 34) and Kuo (23) studied normal and non-diabetic subjects finding
that increased dietary sucrose intake significantly alters the metabolism of triglyceride in human subjects.

Studies by Sunt (466), Cohen

(28), and Chlouverakis (142) have demonstrated that sucrose appeared
to be responsible for the increased levels of circulating lipids observed in some diabetic patients.

These studies suggest that the

absence of fat in the diet was being met by the synthesis of lipid due
to carbohydrate induction.

Further evidence to support this possibility

was seen in the altered fatty acjd pattern observed in patients on a
high sucrose regimen in which the observed increase in oleic acid is
consistent with the conversion of carbohydrate to fat (23).
The effect of sucrose induced carbohydrate hyperlipemia was
challenged by Albrink and Newman (38) who ascertained the effects of
high and low fiber diets on plasma lipid levels.

They gave two high

carbohydrate diets, one with high fiber, the other with low fiber and
suggested that carbohydrate induced hyperlipemia does not occur if the
carbohydrate diet is rich in dietary fiber.
findings.

Our results refute these

We demonstrated a significant sucrose induced hypertrigly-

ceridemic effect even though our diets had standard fiber contents.
Mann et al. (33) were able to reduce serum triglyceride levels an
average of 22% in non-diabetics through voluntary sucrose restriction.
Though we were able to reduce sucrose intake to 3 g/day, much lower than
possible in the self-selected diets of Mann, we observed no reduction in
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triglyceride levels with restricted sucrose intake.

Fasting trigly-

ceride levels remained virtually the same as those observed when the
120 g/day sucrose control diet was given.

Postprandial triglyceride

concentrations significantly increased from control diet values when
patients consumed the low sucrose diet, probably reflecting the slightly higher lipid content of the low sucrose diet (Figure 18).

Again, no

effect on fasting triglyceride levels were observed, either as a result
of sucrose restriction or altered postprandial lipid values.

With this

in mind, the introduction of sucrose into the diabetic diet at levels of
less than 120 gm/day might be safe.

This might allow easier compliance

with the moderate fat restriction now recommended for the population at
large which is even more compell)ng for the diabetic patient.
The changes in triglyceride concentration were not paralleled by a
rise in serum cholesterol levels in patients on either study diet
(Figure 21).

Both fasting and non-fasting cholesterol levels decreased

relative to control diet values with consumption of the high sucrose
diet.

This indicates that high carbohydrate ingestion does not increase

cholesterol levels, a principal advantage in diabetic patients when carbohydrate intake is increased (6).

The observation that high carbohy-

drate, high sucrose diets calorically similar to the control, resulted
in a lowering of cholesterol levels indicates that the sucrose content
of the diet has no effect on cholesterol levels in the blood.

This is

further illustrated by the fact that although sucrose content was reduced to an extremely low level, no improvement in serum cholesterol
concentration was realized.

Again, a dietary regime in which small

amounts of sucrose are included could be beneficial because the

,

'
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increased palatability would lead to greater dietary compliance.
Though HDL-cholesterol concentrations are often insensitive

~o

diet (467), levels increased significantly while patients consumed the
low sucrose diet.

HDL-cholesterol levels showed no change, or in some

cases, a slight decrease in patients on high sucrose diets (Figure 19).
This inverse relationship between HDL-cholesterol and plasma triglyceride concentration has been extensively documented (453-455).

Blum

et al. (457) showed that dietary substitution of carbohydrate for fat
is accompanied by an increase in VLDL, a decrease in HDL and a reduction in the ratio of HDL 2 to HOL 3 . The negative association with
total triglyceride concentration is stronger for HDL 2 than HDL 3 .
There also appears to be a sex related difference in the inverse relationships between HDL-cholesterol and VLDL triglyceride though this
difference was not tested in this study (456).

In both study groups,

HDL-cholesterol levels may be lowered since these individuals were
diabetic.

The HDL-cholesterol results obtained after low sucrose in-

take represent a small metabolic benefit.

It must be pointed out that

high sucrose diets did not result in any significant deterioration of
HDL-cholesterol plasma levels (Figure 19).
The recognition of HDL-cholesterol as a negative risk factor for
the development of premature cardiovascular disease is well known (454,
455).

Two general mechanisms have been proposed by which HDL is a

primary deterrent for the development of cardiovascular disease.

The

first mechanism involves the proposed role of HDL in cholesterol transport in which HDL facilitates removal of cholesterol from peripheral
cells to the liver for ultimate removal by the body.

The second mecha-
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nism involves the competitive inhibition of LDL binding to peripheral
cells by HDL.

Decreased plasma levels of HDL, in both cases,

cou~d

be postulated to cause an increased cholesterol build up in the body.
The ingestion of low sucrose diets did result in a significant increase in serum HDL cholesterol levels, the only benefit obtained by
sucrose restriction.

However, in contrast to Blum (457) who demon-

strated a decrease in HDL-cholesterol following increased carbohydrate
intake, this study shows that ingestion of high sucrose diets caused
minimal reductions in HDL-cholesterol levels.
Lipoprotein concentrations changed predictably in conjunction
with the changes in the lipid concentrations discussed above (Figure
27).

The greatest change occurred in the S and pre-S lipoprotein con-

centrations during consumption of the high sucrose diet.

A large

increase in pre-s lipoprotein concentration with reciprocal decrease
in

lipoprotein concentration was observed.

Since little significant

change was observed in these fasting parameters while low sucrose diets
were consumed, sand pre-s lipoprotein levels also changed little in
this study group.
The dramatic rise in fasting serum triglyceride concentration and
the decrease in urinary glucose output with consumption of the high
sucrose diet indicates that retained carbohydrate might be used to produce triglyceride in the liver de novo.

Increased triglyceride synthe-

sis may be due to a metabolic condition peculiar to the diabetic.
Normal patients, in many instances, did not demonstrate the extreme
fluctuation in triglyceride concentration seen in the type II diabetics
in this study (24, 29, 31, 23).

225
If indeed the metabolism of sucrose is different in diabetics,
then differences might be reflected in the concentration of hormones
required to metabolize the disaccharide.

Insulin and glucagon re-

sults obtained from patients consuming the different study diets confirm this speculation.

In general, the observed changes in hormone

concentrations in these patients when high and low sucrose diets were
administered were quite different.

Relatively high fasting insulins

were observed in all patients upon admission to the study.

This was

generally expected since many type II diabetics may demonstrate insulin
resistance and thus elevated fasting insulin concentrations (446).

When

high sucrose diets were administered, fasting and non-fasting insulins
increased dramatically.

This effect of hyperinsulinemia with increased

sucrose ingestion has also been observed in other reports (33, 34, 39,
40, 46).

Low sucrose diets however, resulted in relatively little

change in fasting and non-fasting levels.
Insulin increments, the difference between fasting and non-fasting
insulins, clearly increased when high sucrose diets were consumed, as
seen in Figure 25.

This significant increase in non-fasting insulins

over the control diet clearly demonstrates that dietary sucrose content
affects insulin secretion in these hyperlipemic diabetics.

As an addi-

tional consequence, Beck-Nielsen and Pederson (39) demonstrated that
high sucrose feeding can result in a 36% decrease in specific cell binding fractions for insulin.

A decrease in insulin binding is associated

with reciprocal increases in plasma insulin concentration.

This situa-

tion may contribute, along with increased insulin secretion, to the
hyperinsulinemic status of these patients.
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Another mechanism by which this hyperinsulinemia could occur is
explained by adaptive changes in the intestine in response to increased sucrose intake.

Sucrase activity was greater in humans who

consumed isocaloric diets containing sucrose as compared to glucose
(41).

The concept of specific dietary regulation of jejunal sucrase

activity has been investigated by Rosenweig and Herman (136).

Reiser

demonstrated that a high sucrose diet caused a large secretion of GIP
as compared to isocaloric diets which were composed of starch (44).
He also found the disaccharidase enzyme and GIP secreting cells were
in close approximation on the brush border of the intestinal wall.
Since disaccharidase activity has been shown to occur in proximal
areas of the small intestine, the sucrose absorbed in this part of the
small intestine has been found to be an important secretogogue for GIP
(138).

GIP is known to be an important stimulator of insulin release

(48, 139).

The more rapid absorption of glucose after a sucrose load

in these adapted individuals may lead to an enhanced secretion of GIP.
Overall, the effect of disaccharide in producing hyperinsulinism is
probably the result of increased insulin resistance due to loss of peripheral binding sites and of increased insulin secretion due to greater
stimulation of GIP hormone.
In this study, hyperinsulinism develops at precisely the same time
as the development of hypertriglyceridemia.

These results directly con-

tradict the findings of Hayford and Danney (36) who found negative
correlations between triglyceride and insulin levels.

However, our re-

sults are in agreement with the findings of Olefsky and Eaton (37, 46)
who demonstrated a positive effect of insulin upon the production of
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hypertriglyceridemia.

Evidence that insulin promotes VLDL-triglycer-

ide secretion was shown by Salans (447).

Using perfused liver slices,

Letarte and Fraser (448) demonstrated that insulin promotes the incorporation of 14 glucose into fatty acid moieties of hepatic lipid
and increases their subsequent release.

Further support for the con-

cept of increased dietary sucrose causing a hyperlipemic response,
through increased triglyceride synthesis, was demonstrated by Michaelis
(140) who found lipogenic enzymes in the rat liver were induced to a
greater extent when animals were fed sucrose than when consuming equivalent amounts of glucose.

Bruchdorfer (141) found increases in

hepatic fatty acid synthetase enzymes after high sucrose diets.

Olefsky

(37) believed, as the results of; our own study indicated, that hyperinsulinemia acts upon the liver to accelerate hepatic triglyceride synthesis and secretion resulting in elevated triglyceride levels.
The changes observed in circulating glucagon levels in response
to different sucrose content diets probably occur due to the insulin
response previously discussed.

This assumption is reasonable since the

cells of the pancreas belong to a family of cells which are sensitive
to insulin concentration (451).
tion in sensitivity of the

Unger (42) has postulated that reduc-

cells to chronic elevations of insulin re-

sulted in decreased suppressibility of glucagon release.

Our studies

do not confirm this postulate since the circulating levels of glucagon
decreased with increasing insulin concentration.
Other reports have supported the concept of increased triglyceride
synthesis causing hypertriglyceridemia in response to dietary carbohydrate type and load (50-52).

Because a removal defect of triglyceride
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from the plasma could also be responsible for this patterned lipemic
response, the possibility of the existence of a defect in removal was
determined by in vivo techniques utilizing radiolabeled glycerol.

Two

possibilities could exist to increase plasma triglyceride levels, synthesis could saturate the removal mechanism, or alterations could occur
in the removal of triglyceride from the plasma caused by a defect in
the lipase enzymes or the substrates on which the enzymes act.
Results of this study agree with those of Nikkila and Kekki (57)
who found the enzyme system (lipoprotein lipase) followed Michaelis
Menton kinetics and could be saturated.

We found that patients who

consumed the high sucrose diet showed no statistically significant
change in Km when compared to
the control diet.

t~ose

values obtained while consuming

These results do not agree with those of Adam's and

Kissebah (59) who demonstrated an increased Km but a decreased Vmax in
their patients who consumed high carbohydrate diets.

However, it must

be emphasized that the Vmax values obtained from our patient population
on both high and low sucrose diets appeared to be still lower than those
obtained from normal patient populations (59).

Patients who consumed

the low sucrose diet showed no change in Km or Vmax from the control
values and it must be assumed that sucrose restriction offered no
improvement in peripheral triglyceride removal efficiency.
The apparent inability of these patients to activate their triglyceride removal mechanisms, by lowering Km, after sucrose induced
triglyceride production is intriguing.

This possible faulty removal

mechanism, not observed in normal patients (402) could be an additional
causative factor in the hyperlipemic response observed after high
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sucrose intake.

The inability to activate the triglyceride removal

system, when high sucrose diets are consumed, could be related to a
change in VLDL apoprotein cofactors first identified by Bar-On {64).
Endogenous lipoproteins are presumed to be the natural substrates for
the lipoprotein lipase enzymes.

The results obtained in this study

could be a reflection of two possible mechanisms: the VLDL isolated
from the different groups may not be identical or the lipoprotein
lipase system may contain two different enzymes which have different
characteristics.
Experiments performed to substantiate sucrose induced changes
in the apoprotein constituents of the VLDL demonstrated that high
sucrose diets resulted in an inorease in apo CIII 1 protein, an inhibitor of lipoprotein lipase (218) (Figure 42). Furthermore, apo
CIII 1 levels were significantly correlated with triglyceride concentration in this study (Figure 44).
crease in these same patients.

Apo CIII 2 levels were found to deApo CII was slightly decreased or re-

mained the same.
Overall, the ratio of apo CII/apo CIII 1 decreased and significant correlations between this ratio and triglyceride concentrations
were observed (Figure 46).

These results corroborate the findings of

Gabor and Spain (63), and Lambert (68) and Catapano (69) who believed
the relative amounts of apo CII as compared to apo CIII 1 enhanced the
interaction between lipoprotein lipase and triglyceride within the cell
surface monolayer.

These results also substantiate the postulate put

forth by Alaupovic (154) who proposed that the type of apoprotein found
in VLDL reflected the nutritional and metabolic status of the indivi-
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dual.
We did not observe an increase in apo CII levels during the _high
carbohydrate sucrose intake as suggested by Falko (67).

The initially

low apo CII concentration observed in these patients may be best explained by the depressed HDL-cholesterol levels found in all patients
who entered the study.

Havel (271) demonstrated that chylomicron and

VLDL metabolism involve net transfers of apo CII protein from HDL to
VLDL and back to HDL.

The nascent VLDL that is released from the liver

is stabilized by apo CII from circulating HDL.

While the transfer of

apo CII back to HDL is proportional to triglyceride hydrolysis (275),
insufficient levels of HDL, and a decreased capacity to supply VLDL
with apo CII, will prevent

norm~l

triglyceride hydrolysis resulting in

increased triglyceride concentration.
Speculation on the effect of apo CIII 1 and CIII 2 on VLDL
metabolism was suggested by Shelburne and Windler (281, 282). These
investigators observed that apo CIII 1 not only inhibited lipoprotein
lipase but also demonstrated a pronounced inhibitory effect on hepatic
uptake of VLDL.

Bar-On and Roheim (64) noted that apo CIII 1 and apo
CIII 2 were different only in sialic acid content. It is possible that
this glycoprotein is similar to other sialated glycoproteins which
demonstrate correlation between sialic acid levels and hepatic receptor
affinity (283).

Apo CIII 1 may provide a mechanism for denying lipoproteins hepatic access until appropriate peripheral metabolism has

occurred.

If apo CIII 1 were not present, ineffectual recycling of the
lipoprotein by the liver would occur. The uptake of remnant VLDL will

be decreased if apo CIII 1 is not removed in the periphery and could
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result in hyperlipemia.

In contrast, apo CIII 2 does not inhibit lipoprotein lipase but can diminish the effect of apo CIII 1 by binding.to
the same active site but still allowing the lipase to be activated by
apo CII (269, 270).

It has been observed that the sialic acid content

of these two proteins is determined by their residency time in the
Golgi apparatus of hepatic cells (217).

The fact that apo CIII 1 has
less sialic acid residues indicates the amount of time spent in the

Golgi is less than that for apo CIII 2 .
Increased insulin found in patients who consumed the HSD stimulates triglyceride production. Since hepatic triglyceride synthesis is
increased, VLDL production is increased as well.
total apo CIII in the Golgi

app~ratus

The residency time of

is decreased resulting in an in-

creased proportion of apo CIII 1 in these patients. Since apo CII is
also depressed, because of lower circulating HDL levels, the decreased
ratio of CII/CIII 1 apoprotein does not stimulate increased lipoprotein
lipase activity even in the presence of increased circulating triglyceride levels.

Finally, since the triglyceride and apo CIII 1 are not
removed as rapidly as normal, the VLDL circulates for an extended period

of time.

The observations above could account for the decreased uptake

of a portion of partially hydrolyzed lipoproteins which contain relatively high levels of apo CIII 1 . Patients who consumed the low
sucrose diet exhibited little change in the triglyceride removal Km
values from control to study diet.

In these patients apo CIII 2 levels
increased while apo CIII 1 levels decreased or remained the same.
Thus, inhibition of lipoprotein lipase can not be postulated as above.
In fact, these results would point to an increased removal of VLDL by
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plasma lipase.

However, studies from several laboratories suggest

that human plasma lipoprotein lipase activity is a combination of
several lipases which have different properties (266, 458).

It has

been found that insulin levels could play a role in specific lipase
activity (266).

Certain lipoprotein lipase enzymes appear to be more

susceptible to insulin concentrations than others.

Since the low suc-

rose study group had slightly lower or unchanged insulin levels, it could
be possible that one set of enzymes remains inactive because of lower
insulin concentrations resulting in no change in Km observed in this
patient population.

Also, Persson (61) demonstrated that patients who

had normal or increased cholesterol levels with steady triglyceride
levels would have normal

lipoly~ic

activity.

Cholesterol levels re-

mained stable or increased slightly in the LSD study patients.

A

possibility exists that the kinetic data generated by low sucrose diet
individuals reflects a two enzyme system.

One enzyme is inhibited,

resulting in an increased Km, while the other is stimulated, to clear
triglyceride more rapidly, resulting in a decreased Km.

This compensa-

tory mechanism allows for little observable change to occur in both
plasma triglyceride levels and Km values in these patients.
The data on the effect of sucrose enriched diets on apo E levels
were partially corroborated by Mahley (226) who demonstrated that
dietary changes could elicit an increase in apo E concentration.

His

diets contained high amounts of cholesterol however, and to date, the
specific effect of sucrose on apo E is unreported.

This study demon-

strated no significant change in total apo E, but a significant increase in one of the isoprotein subunits, apo EIII, was observed in
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high sucrose diet patients (Figure 43).

Low sucrose diets demonstrated

no effect on isoprotein composition of apo E.

Increase in the apo_ EIII

subunit would seem plausible since Schneider (321) has demonstrated
that apo EIII is one of the main protein cofactors needed for proper
hepatic uptake of remnant VLDL.

Studies by Havel and others have

demonstrated that patients with type III hyperlipoproteinemias, characterized by a dysfunctioning apo EIII protein, generally were observed
to have decreased hepatic uptake of intermediate density lipoprotein
(223, 227-228).

The increase in apo EIII observed in our patients may

be a mechanism used by the individual to produce accelerated clearance
of these remnant VLDL lipoproteins and aid in triglyceride clearance
from the plasma.
Other experimental data corroborating the above mechanism was
obtained from four patients whose response to high sucrose consumption
differed from the others.

Their hyperlipoproteinemic pattern shifted

from type IV to type III (Figure 49).

These patients demonstrated a

complete absence of the apo EIII isoprotein subunits (Figure 50).

The

remnant VLDL have prolonged circulating half-lives due to decreased
apo EIII and are devoid of most apo C proteins due to the action of
lipoprotein lipase.
have more

s character

Therefore, the remnant VLDL of these patients
since there is more apo B as total apoprotein.

Since the charge of this lipoprotein now resembles that of the
lipoprotein, electrophoretic migration is similar or identical to the
broad

s pattern.

Loss of apo EIII inhibits the uptake of these rem-

nants by the liver and increases their circulating half-lives.

Since

these remnants still contain nominal amounts of triglyceride, this
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mechanism increases the hyperlipemic response observed in these
patients.
The above assumptions cannot be made to explain the change in
the lipoprotein pattern when high sucrose diets are consumed by this
patient subgroup.

However, it could be possible that a small amount

of apo EIII is produced by these patients.

In these study patients,

increased synthesis of triglyceride by the liver stimulates VLDL production to such an extent that apo EIII synthesis lags behind and the
VLDL produced either have extremely low concentrations of the apo EIII
protein or are totally lacking in the structural component.
Therefore, in general, the results of this series of experiments
demonstrate that sucrose causes; increased synthesis of triglyceride, but
also alters the apoprotein content of nascent VLDL released by the
liver, and possibly functions to decrease removal of peripheral VLDL by
lipoprotein lipase.
Another line of approach to study the effect of sucrose consumption on type II diabetics is to investigate platelet adhesiveness and
platelet aggregation.

Increased platelet aggregation has been ob-

served in diabetics (89-92).

Since hyperlipemia has also been demon-

strated to increase platelet function (97), a natural relationship
exists between the effects of sucrose on circulating lipids and platelet aggregation.

Renaud (387) was the first to demonstrate the effect

of dietary-induced hyperlipemia on platelet aggregation.

His results,

and the results of this study, demonstrate that increased hyperlipemia
causes increased platelet aggregation (Figure 53).

Szanto et al. (101)

found that increased insulin levels correlate well with increased
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platelet adhesiveness.

Our studies confirm these findings as well.

The low sucrose study patients, who demonstrated insignificant alterations in insulin concentration, also had unaltered platelet responses
to diet.

But patients consuming high sucrose diets had increased

insulin levels, platelet sensitivity and platelet aggregation.
Farbiszewski et al. (389) also observed a distinct effect of lipoproteins on platelet aggregation.

In our study, patients who consumed

high sucrose diets had increased circulating VLDL and increased platelet responses to aggregating agents.

It is possible that lipoproteins

interact with platelets in the circulation altering platelet membrane
components.

Bolton (98) found the 8 lipoprotein interacts with certain

receptor sites on the platelet Sijrface resulting in altered platelet
mobility.

Since VLDL contain similar apoprotein constituents, extended

circulating half lives of these lipoproteins, due to decreased clearance, might allow the platelets to incorporate these lipoproteins or
their components into their membranes.
A mechanism for the increased platelet sensitivity observed in
these patients, other than changes in membrane fluidity, was reported
by Sinha (398).

This investigation demonstrated that increased lipid

incorporation into the platelet membrane is associated with decreases
in the activity of membrane bound adenyl cyclase and depressed cAMP
levels.

Insulin, a known inhibitor of cAMP production, is elevated

in the patient who consumed high sucrose diets.

Since cAMP is a potent

inhibitor of platelet aggregation, a decrease in cAMP levels induced
by both increased lipid incorporation and increased insulin concentrations could cause increased platelet aggregation in these hyperlipemic
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patients.

Thus, the impact of the high sucrose diet through either

mechanism results in the development of increased platelet aggregation
and responsiveness of platelets to aggregating agents.
The deleterious effects of sucrose seem to occur only when extremely high levels of the disaccharide are ingested.

Our results show

that even when sucrose intake is reduced to a point which would be
impossible to obtain in an outpatient dietary regime, lipid production,
blood glucose, urinary glucose output, VLDL composition and platelet
aggregation are altered minimally or unchanged when compared to a diet
consisting of 120 g/day sucrose intake.

Fasting triglyceride levels in-

creased only with the highest sucrose levels, demonstrating that exquisite sensitivity of hypertriElyceridemics to another normally used
nutrient, alcohol (52) does not seem to apply for the more ubiquitous
disaccharide.

But the general conclusion is one that we share with

Frank Nutall that 11 Actually, there is little scientific basis for the
complete exclusion of refined sugars from a diabetic persons diet 11 (51).

A.

Conclusion and Future Directions
This study was designed to ascertain the effects of sucrose con-

sumption in a diabetic population which is predisposed to hyperlipemia.
This was a relevant problem since many studies, as alluded to previously, presented conflicting results concerning the effect of sucrose
on blood lipid levels, glucoregulatory hormones and lipid transport
mechanisms.

Diabetic dietary therapy has shown a pronounced shift

toward increased carbohydrate consumption.

Therefore, the ingestion

of refined sugars, especially sucrose, which remains unquantitated and
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hidden in certain foodstuffs, has possibly increased.

Also dietary

acceptance is an important factor in any chronic therapy.

The

pal~ta

bility that small amounts of sucrose adds to a diet lends an increased
likelihood of compliance with the dietary regime and ultimately, improved blood glucose control.

Thus, it is mandatory to know the effects

of graded amounts of sucrose in natural mixed diets and the chemical
response of these type II diabetics to such diets.
Ideally, an experimental search for a cause of hyperlipemia would
be to investigate whether the suspected factor actually produces the
disease.

But, none of the ordinary laboratory animals can be made to

develop the hyperlipemic state as seen in man, and of course, it is out
of the question that one should pttempt to do so in humans.

The alter-

native is short term experiments in man in which attempts to reproduce
some of the characteristics of hyperlipemia are made.

The experiments

designed here enabled us to answer a number of questions concerning the
effects of sucrose as an etiological factor in diabetic control and the
development of hypertriglyceridemia.

The primary goal was to see

whether sucrose produced, not simply an increase in triglyceride concentration, but as many other potential abnormalities associated with
poor diabetic control.
This study demonstrated that under controlled conditions, no
special sensitivity to variation in sucrose restriction can be observed.

Essentially, no effect of widely variable sucrose levels on

blood glucose and glucosuria was identified.

In addition, no

deleterious changes in the levels of serum HDL-cholesterol or cholesterol were seen when diets rich in sucrose were ingested.

Furthermore,
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no improvements to normal levels could be detected when sucrose restricted diets were given to this patient population.

On the other

hand, high sucrose consumption had a most significant effect resulting
in a great increase in fasting triglyceride levels.

The changes in

the plasma lipoprotein constituents reflect, predictably, changes that
occurred in the lipid constituent of the plasma.
Glucoregulatory hormones showed a pronounced increase in circulating levels of fasting insulin with significantly larger insulin increments and a reduction in fasting glucagon levels with consumption
of high sucrose diets.

This suggests that the hypertriglyceridemia

associated with increased sucrose intake is due to increased triglyceride synthesis.

Kinetic studies of the plasma triglyceride pool

demonstrated that sucrose rich diets had no effect on the affinity of
the removal system for plasma triglyceride.

Thus the lack of any

stimulated increase in peripheral triglyceride removal, while consuming (HSD) could be a contributing factor to the hyperlipemic response.
Again, complete sucrose restriction and complex starch replacement
offered little improvement in fasting insulin concentration and plasma
triglyceride removal mechanisms over those obtained by intermediate
(control) sucrose levels.
Studies of the very low-density lipoprotein (VLDL), the main
carrier of triglyceride in the fasted state, and the apoproteins that
comprise them were carried out in order to identify whether the proportions of dietary sucrose affect these transport proteins.

It was

found that high sucrose consumption alters the apoprotein content of
the VLDL.

The apo CII/CIII ratio decreased which could have resulted
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in decreased stimulation of the lipoprotein lipase system and an
altered removal of VLDL from the plasma pool.

The increase in apo

CIII may be a reflection of either a decreased residency time in the
hepatocyte Golgi apparatus of VLDL apoprotein components or an increased plasma residency time of the VLDL in the peripheral pool.

The

former is a reflection of a possible increased liver VLDL secretion
due to increased triglyceride synthesis.

The latter is a result of an

elongated plasma pool half life as demonstrated by the extremely low K
values observed in these patients.
We have also demonstrated that elevated sucrose intake associated
with hyperlipemia results in increased platelet aggregation and sensitivity of platelets to aggregating agents, never before reported in the
literature.
The minimal effects of a daily consumption of sucrose in quantities of less than 100 gm per day suggests that its cautious introduction in mixed meals might allow easier compliance with the moderate fat
restriction now recommended for the diabetic population at large.
Furthermore, by contributing to palatability, dietary sugar will ease
the life of many diabetics perhaps contributing to better adherence to
diet as part of the whole health care program in diabetic treatment.
In view of this, we strongly recommend that sucrose intake from all
sources be monitored in a valid manner.

The implementation of this

study would entail a radical new outlook in dietary therapy for the
diabetic.

Perhaps, it is reasonable to suggest that sucrose content

of packaged, frozen, and canned foods be determined and that a
campaign be launched to inform the susceptible population.
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